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The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, 
ecstasy) is a widely used recreational drug, which produces strong psychological effects 
such as increased empathy and sociability. MDMA inhibits the uptake of and releases 
serotonin, dopamine, and norepinephrine via an interaction with the respective monoamine 
transporter. While the role of serotonin in the human pharmacology of MDMA has been 
well described, the role of norepinephrine in the mediation of the effect of MDMA is 
mostly unexplored. Preclinical data indicate that norepinephrine may play a crucial role in 
the effects of MDMA. This project focused on the role of norepinephrine in the 
pharmacology of MDMA in humans. We performed five experimental clinical studies and 
analyzed data from a previously performed study investigating the role of norepinephrine 
in the mechanism of action of MDMA. All studies were pharmacological interaction 
studies with selective medications used as research tools to inhibit the effects of MDMA in 
healthy subjects. All clinical studies used placebo-controlled, double-bind cross-over 
designs and were each performed in 16 healthy subjects in the University Hospital of 
Basel. In the first study, we showed that the selective norepinephrine transporter inhibitor 
reboxetine reduced the MDMA-induced increases in circulating plasma norepinephrine, 
psychostimulant, and cardiovascular effects in healthy volunteers. Moreover, we also 
showed that the observed pharmacodynamic interaction in this study was not attributed to a 
pharmacokinetic interaction between reboxetine and MDMA, because reboxetine 
decreased the pharmacodynamics effects of MDMA although it increased MDMA plasma 
levels. The results demonstrate a critical role for transporter-mediated norephinephrine 
release in the cardiovascular and the subjective stimulant-like effects of MDMA in 
humans. Norephinephrine transporter inhibitors could therefore be useful in the clinical 
treatment of stimulant addiction. In the second study, we then demonstrated that the !2 
agonist clonidine, an inhibitor of the vesicular norepinephrine release, did not inhibit the 
response to MDMA in healthy subjects confirming that vesicular release of norepinephrine 
is not responsible for the effects of MDMA in humans. This study also confirmed 
indirectly that the monoamine transporter is the primary target of psychostimulants such as 
MDMA and that physiological impulse-dependent release of monoamines does not appear 
to be critical for the effects of MDMA in humans. In the ensuing studies we addressed the 
roles of the postsynaptic adrenergic receptors where the norepinephrine released by 
MDMA would be expected to act. We analyzed data from a previously performed study 
and showed that the non-selective " adrenergic receptor antagonist pindolol reduced 
MDMA-induced increases in heart rate but had no effect on blood pressure or body 
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temperature elevations produced by MDMA. In the third study, we assessed the effects of 
the postsynaptic !1 and " adrenergic receptor antagonist carvedilol on the cardiostimulant, 
thermogenic, and subjective response to MDMA in healthy subjects. Carvedilol reduced 
elevations in blood pressure, heart rate, and body temperature but did not affect the 
subjective effects produced by MDMA. Thus, !1 and " adrenergic receptors contribute to 
the cardiostimulant and thermogenic effects of MDMA in humans. The findings suggest 
that carvedilol would be useful in the treatment of cardiovascular and hyperthermic 
complications associated with ecstasy use. In the fourth study, we determined the effect of 
a pretreatment with the selective !1 adrenergic receptor blocker doxazosin on the response 
to MDMA. Doxazosin reduced MDMA-induced increases in blood pressure but did not 
affect heart rate responses to MDMA. Doxazosin also attenuated some of the subjective 
effects of MDMA indicating that !1 adrenergic also contribute to the psychotropic effects 
of MDMA. Taken together, the studies suggest a role for norepinephrine in particular in 
the cardio- and the psychostimulant aspects of the MDMA effect in humans. However, 
MDMA is not only a potent releaser of norepinephrine but also serotonin. Previous clinical 
studies have shown that inhibition of the serotonin transporter reduced positive 
psychotropic effects produced by MDMA. However, selective serotonin or norepinephrine 
transporter inhibitors, when used alone, only moderately affected the response to MDMA 
in humans. In fifth study we therefore tested the effects of the dual serotonin and 
norepinephrine transporter inhibitor duloxetine on the acute effects of MDMA in humans. 
We demonstrated that duloxetine almost completely prevented the pharmacodynamic 
response to MDMA despite an increase in duloxetine-associated elevation in MDMA 
plasma levels. The serotonin and norepinephrine transporters may therefore both be 
potential targets for the treatment of psychostimulant dependence.  
In an additional analysis of the Duloxetine-MDMA study, we showed that MDMA 
increased plasma copeptin, a marker for arginine vasopressin (AVP) secretion, in women 
but not in men. This sex-difference in the MDMA-induced AVP secretion may explain 
why hyponatremia is typically reported in female ecstasy users. The copeptin response to 
MDMA is likely mediated via MDMA-induced release of serotonine and/or noreinephrine 
because it was prevented by duloxetine which blocks the interaction of MDMA with the 
serotonin and norepinephrine transporter. Finally, we addressed two research questions that 
require a larger study sample in pooled analyses across several of our clinical studies. To 
study the effects of MDMA on social cognition, we investigated the effects of MDMA on 
the ability to infer mental states of others from social cues of the eye region using the 
-3++!45.
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Reading the Mind in the Eyes Task in 48 subjects. We showed that MDMA differently 
affected mind reading depending on the emotional valence of the stimuli. MDMA 
enhanced the accuracy of mental state decoding for positive stimuli (e.g., friendly), 
impaired mind reading for negative stimuli (e.g., hostile), and did not affect mind reading 
for neutral stimuli (e.g., reflective). MDMA also produced subjective prosocial effects, 
including feelings of being more open, talkative, and feeling closer to others. The shift in 
the ability to correctly read socioemotional information toward stimuli associated with 
positive emotional valence, together with the prosocial feelings elicited by MDMA, may 
enhance social approach behavior and sociability when MDMA is used recreationally and 
facilitate therapeutic relationships in MDMA-assisted psychotherapy settings. In a second 
pooled analysis, we investigated the effect of MDMA on pupillary function using infrared 
pupillometry data from 80 subjects from all our five clinical studies. We demonstrated that 
while MDMA-induced mydriasis is lasting and mirrors the plasma concentration-time 
curve of MDMA, the impairment in the reaction to a light reflex is associated with the 
subjective and other autonomic effects induced by MDMA and exhibits acute tolerance. 
Taken together, these experimental clinical studies contributed to the understanding of the 
mechanism of action of MDMA in humans.  
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The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA) 
(Fig. 1) is the main compound found in ecstasy tablets. Ecstasy use is often associated with 
recreational settings such as nightclubs and raves frequented by young people. An ecstasy 
tablet generally contains between 80 mg and 150 mg of MDMA1, although this is highly 
variable and contamination with other drugs such as methamphetamine, caffeine, and 
aspirin, is common.2,3 In 2009, the United Nations drug report estimated that up to 28 
million people had used ecstasy at least once in this particular year. A number which 
remained stable over the past few years.4 In the late 90ies ecstasy was the second most 
commonly used drug in Europe5 and a survey in 2007 in the Swiss population revealed that 
at least 1.8% of the over 15 years old had consumed ecstasy at least once in their life time.6  
 
 
As a psychotropic drug, MDMA has remarkable and relatively rare characteristics. 
When administered to healthy volunteers in a controlled setting, MDMA produces a 
mental state that is usually enjoyable to almost every subject, almost every time. Most 
psychotropic substances, like psilocybin or ketamine for example additionally induce 
feelings of unease, whereas MDMA mostly produces enjoyable drug effects (e.g. “blissful 
state”) and only minimal negative effects (Fig. 2)7. In a great majority of the subjects 
taking MDMA in a controlled setting, MDMA produces arousal, deep euphoria, closeness 
to others, and extroversion.8-10 There are also sex differences in response to MDMA, while 
women are more sensitive to the drug than men.9 The onset of the drug takes between 20 
and 60 minutes, with peak effects usually occurring 60 to 90 minutes after ingestions. 
MDMA’s main effects normally last for 3 to 5 hours.9,11,12 One of the unusual properties of 
the MDMA effect is that the substance encourages social contacts and breaks down 
emotional barriers. David Nicholas, co-author of the first publication about the 
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pharmacology of MDMA, suggested to classify the drug in a novel pharmacological class 
called “entactogens”.13 Further, MDMA increases oxytocin levels in animals14 and 
humans.15 Oxytocin is a neuro-peptide, which has received abundant attention for its role 
as a key regulator of emotional and social behavior.16,17 MDMA produces an increased 
social behavior in male rats, an effect which can be attenuated by the administration of an 
oxytocin receptor antagonist prior to MDMA.14 There might be a connection between the 
“love drug” and the “love hormone”; but the link between the two has not been fully 
elucidated.  
 
MDMA also exerts amphetamine-like stimulant effects including increased alertness 
and heightened energy level. These effects are very likely linked to the somatic 
sympathomimetic effects MDMA which include a marked increase in blood pressure, heart 
rate, pupil size, and slight elevations in body temperature. The sympathomimetic effects of 
MDMA are responsible for some of the adverse effects of MDMA. Mild adverse effects 
are common after MDMA ingestion, but-generally short lived. In addition, MDMA might 
also induce bruxism, trismus, dry mouth, loss of appetite, sweating, or headache. 
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Until the late 1980s the use of ecstasy was not controlled by legislation, but since 
then it has been considered a dangerous narcotic on both sides of the Atlantic and placed in 
the highest category of harmful drugs, along with heroin and cocaine.18 The decision of 
banning MDMA was initiated by the widespread use of ecstasy and partly by the first 
reports of ecstasy-related deaths among young people.19 20 Most deaths resulted from a 
syndrome of persistent hyperthermia, which leads to rhabdomyolysis, with subsequent 
kidney and other organ-system failure.21 22 From the 87 ecstasy-associated deaths reported 
in the literature until 2001, 30 were due to hyperthermia.22 Also, in a controlled clinical 
setting, MDMA produced a small increase in body temperature of about 0.5°C.23-25 This 
slight increase might not be enough to produce hyperthermia. However, additional factors 
such as prolonged dancing in a hot environment without rest and a lack of liquid intake 
increases the risk of hyperthermia. In an attempt to guard against hyperthermia and 
dehydration, recommendation was given that dancers at rave parties should drink plenty of 
liquid. Unfortunately, some took this advice too literally and cases of acute hyponatremia 
occurred among ecstasy users. However, the increased fluid intake seems not to be the only 
reason for this high prevalence of cases of ecstasy-related hyponatremia. MDMA 
associated hyponatremia is also possibly due to inappropriate secretion of the hormone 
arginine vasopressin (AVP) particularly in women.26-29 A large retrospective series of 
ecstasy exposures reported to the California poison center found hyponatremia in 73 of 188 
cases.28 Of the 73 cases with hyponatremia, 55 were women and only 18 men. In a small 
laboratory study MDMA also produced a significant increase in plasma concentrations of 
AVP.30,31  
A case series studied 19 366 deaths between January 1997 and July 2000 in New 
York City. Toxicological post-mortem analysis revealed that only 22 of the cases were 
considered to be ecstasy related.32,33 A total of 81 ecstasy use related deaths were reported 
in the United Kingdom between 1997 and 2000 for which also post-mortem analysis was 
available.34 Only six of the total 81 cases appeared to have died after taking ecstasy alone. 
Most of those who died had been taking other drugs at the same time as ecstasy and more 
than half had taken heroin or a related opiate.33 The rare fatalities attributed to ecstasy need 
to be considered in relation to the very large number of individuals using the drug. In 2007 
two groups of experts met to assess the harms of a range of illicit drugs (heroin, cocaine, 
alcohol, barbiturates, amphetamine, methadone, benzodiazepines, solvents, buprenorphine, 
0$,4%)3",0%$.
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tobacco, steroids, cannabis, LSD, and ecstasy) in an evidence-based fashion.35,36 The 
analysis revealed that ecstasy was on the third bottom place for all categories of harm 
whereas heroin, cocaine, barbiturates, and alcohol were on the top of all.36  
High production, availability, and consumption of ecstasy4 render appropriate a 
contemporary review of the dependence potential of the drug. However, MDMA 
dependence might be less likely than dependence upon other drugs. Some preclinical 
studies demonstrated that animals self-administer MDMA,37,38 whereas other studies failed 
to document acquisition of MDMA self-administration behavior in animals even after 
extended training periods.37 The animal model of self-administration is a widely used test 
of whether a drug is likely to produce dependence in humans.39 The mesolibmic-
frontocortical system is implicated in the development and maintenance of drug 
dependence.39 Acute and chronic use of many drugs of abuse directly or indirectly affect 
this dopaminergic pathway40 and MDMA is no exception.41,42 However, MDMA also 
releases 5-HT and this effect of MDMA attenuates its reinforcing effects compared with 
other amphetamines.41 Co-administration of MDMA also attenuates the reinforcing effects 
of cocaine43 and methamphetamine44,45 in animals, suggesting an interference of MDMA 
with the DA release actions of these drugs. Together, animal studies have shown that 
MDMA has weaker effects on the reward system than most other illicit drugs.46  
There is a large scientific literature on the fact that administration of MDMA to 
animals results in neurotoxicity, especially to the serotonin system.47-49 MDMA-induced 
alterations include serotonin (5-HT) depletion, lower levels of 5-HT metabolites, lower 
levels of 5-HT transporters, and higher levels of 5-HT2 receptors.48,50 These changes 
mostly represent neuroadaptive changes. Structureal serotonergic neuronal damage 
including gliosis in is only seen at very high doses of MDMA and in the presence of 
additional permissive factors such as hyperthermia and inconsistently across species.47,49,51 
A further issue of controversies is that in most animals studies MDMA was administered 
by injection, where fast drug absorption and high peak plasma levels are reached compared 
to the slower oral route employed by most human users.49 Nevertheless, it is clear that high 
doses of MDMA are neurotoxic to the serotonergic system of animals. The question is, 
whether the data on the neurotoxicity of MDMA in rodents or primates are relevant for 
humans. The problem with human neurotoxicity studies are that direct measures of 
serotonin concentration for example cannot be performed in the human brain. Therefore 
indirect approaches must be adopted. One approach is to use brain imaging studies. These 
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experiments assess whether the activity of specific brain regions differs in drug-users, 
performing a specific task, from the brain activity of non-drug users performing the same 
task. For example, Bauernfeind and colleagues showed different visual stimuli to MDMA 
users and matched controls while performing functional magnetic resonance imaging 
(fMRI). The study revealed that higher lifetime MDMA exposure was associated with 
increased activation in specific serotonergic areas in the brain.52 This so called increase in 
cortical excitability was then interpreted as a loss of serotonergic neurons.52 Two other 
neuro-imaging studies, that also included ex-ecstasy users as subjects found that the 
subjects who had stopped using ecstasy had no reductions in serotonin transporter 
densities, suggesting that the changes observed in current users are reversible.53,54 
A further indirect method to assess MDMA’s neurotoxicity is to test whether 
cognitive impairments are consistently found in ecstasy users and whether they persist after 
drug use. There are various reviews on studies demonstrating that ecstasy users display 
negative residual effects on various cognitive tasks, especially on lowered verbal 
memory.55-57 However, such naturalistic studies always suffer from methodological issues. 
For example the non-user controls in most studies were not members of the ‘rave’ 
subculture. Thus, unlike ecstasy users, they were not exposed to repeated sleep and liquid 
deprivation from all-night dancing, both factors which can also produce cognitive 
deficits.58,59 An additional problem of almost all studies is that the ecstasy users included in 
the studies reported an extensive life-time history of other drug use, including cocaine, 
methamphetamines, cannabis, or hallucinogens –which might themselves produce 
neurotoxic effects. In a recent study Halpern and colleagues have overcome those 
methodological issues and found that of 15 neuropsychological tasks ecstasy users 
performed as well as controls.58 Simply the Revised Strategy Application Test showed a 
clear indication of poorer performance in heavy ecstasy users, suggesting poorer strategic 
self-regulation and hence perhaps greater reflection impulsivity.58 If impulsivity is an 
effect of ecstasy use or a cause for substance abuse is a matter of considerable debate.  
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Like other amphetamines MDMA works indirectly by causing an acute and rapid 
release of presynaptic monoamine transmitters including serotonin (5-HT), dopamine 
(DA), and norepinephrine (NE).60-62 The MDMA-induced release of 5-HT, DA and NE is 
thought to be due to reverse-transport of these monoamines through the corresponding 
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uptake transporters, resulting in increased concentrations of the monoamines in the 
synaptic cleft. As in all phenethylamines of the amphetamine class, MDMA has a chiral 
center and therefore two enantiomers the (S)- and (R)-isomer.63 The (S)-MDMA isoform is 
thought to be more active than the (R)-MDMA isoform.63 MDMA also binds to the 
classical neurotransmitter receptors such as 5-HT2, !2 adrenergic, M1 muscarinic, and 
histamine H1 receptors.64 While the neurochemical effects of MDMA have been relatively 
well studied in preclinical models, it is less clear how the neurochemistry translates into 
the psychotropic and physiological effects in humans. Pretreatment with selective 
serotonin reuptake transporters (SSRIs), drugs typically used in the treatment of depression 
or anxiety disorders, decreased the MDMA-induced release of serotonin in the rat brain62,65 
and the behavioral response to MDMA in animals.66,67 In healthy volunteers, the SSRIs 
citalopram, fluoxetine, and paroxetine partially reduced the subjective and somatic 
response to MDMA.12,25,68,69 These findings confirmed that the interaction of MDMA with 
the serotonin uptake transporter is one mode of action of MDMA. Additional studies in 
healthy subjects demonstrated that the moderate hallucinogen-like perceptual changes 
produced by MDMA were reduced after pretreatment with a postsynaptic 5-HT2 
antagonist70 while blockade of 5-HT1 receptors only slightly attenuated positive mood 
effects of MDMA.71 MDMA also releases dopamine from cerebral tissue, as has been 
shown by both in vivo microdialysis72-75 and by in vitro studies using tissue slices.76,77 
However, the involvement of the dopamine uptake site in MDMA-induced dopamine 
release is controversial. Whereas some in vitro studies demonstrated an inhibition of the 
MDMA-induced dopamine release by selectively blocking the dopamine transporter,60,78 
others were not able to show this effect.65 There is also evidence that dopamine release 
might not be directly involved in the mechanism of action of MDMA but via 5-HT2 
receptor stimulation.72 This mechanism is supported by the fact that MDMA-induced 
striatal dopamine release is reduced by pretreatment with fluoxetine.74  
In a gene knock-out model, mice with a dopamine D1, D2, and D3 receptor deletion 
did not produced MDMA-induced locomotor effects. !n humans, the D2 receptor 
antagonist haloperidol attenuated positive mood effects produced by MDMA.79 However, 
haloperidol alone produced dysphoric mood effects in healthy subjects compared to 
placebo, possibly explaining the attenuation on MDMA-induced euphoric mood effects.79  
0$,4%)3",0%$.
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The mesolimbic dopamine plays an important role in the mediation of reward and 
reinforcement but to which extend the dopaminergic system is involved in the mechanism 
of action of MDMA remains unclear.  
MDMA is rapidly absorbed after oral administration.80-82 There are two main 
metabolic pathways for MDMA in humans. MDMA is mostly metabolized to 
3,4-dihydroxymethamphetamine (HHMA) that is then rapidly methylated to the main 
metabolite found in plasma and urine; 4-hydroxy-3-methoxymethamphetamine 
(HMMA).80,82 The active but minor metabolite 3,4-methylenedioxyamphetamine (MDA) is 
formed by N-demethylation of the mother substance.51,82 
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The noradrenergic system can be divided into the central and the peripheral 
noradrenergic pathways. The main chemical messenger of the noradrenergic system NE 
and serves as a transmitter to manifold brain functions including arousal, attention, mood, 
learning, memory and the stress response.83 The central noradrenergic neurons are 
localized in brainstem nuclei, such as the locus ceruleus, but noradrenergic nerves project 
diffusely to almost every part of the brain.84 In the neurons, NE is synthesized from the 
amino acid tyrosine, which is supplied by the blood and extracellular fluid.85 To date, little 
is known about the role of NE in the mediation of the effects of psychostimulants such as 
MDMA. To investigate the ability of MDMA and other drugs to bind to the presynaptic 
transporter and release the corresponding monoamines (Fig 3), nerve endings were isolated 
from rat brain and studied in vitro.60,62  These studies revealed that MDMA binds to the NE 
transporter with the highest affinity compared to 5-HT or DA. In addition MDMA also 
releases NE more potently than it releases 5-HT or DA.60 This finding was confirmed in in 
vitro models using human cells transfected with human monoamine transporters.78 Finally, 
it is also highly likely for NE to play an important role in mediating peripheral effects of 
MDMA. In animals, MDMA dramatically increased circulating plasma levels of NE, 
causing a positive chronotropic effect and vasoconstriction, both effects being blocked by 
the NE transporter inhibitor desipramine.48 In rats, the postsynaptic !1 adrenergic receptor 
antagonist prazosin reversed MDMA-associated locomotor stimulation86 or vascular 
effects.87 In addition, blockade of the effects of NE at postsynaptic !1 and " adrenergic 
receptors reversed the hyperthermic response to MDMA in rats or mice.88,89 In healthy 
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volunteers, MDMA increases heart rate, blood pressure and body temperature via 
stimulation of the sympathetic nervous system.11,25 
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Serious adverse effects of uncontrolled ecstasy use also include cardiovascular and 
hyperthermic reactions that are likely to be mediated by a MDMA-induced activation of 
the adrenergic system.90 The cardiovascular effects evoked by MDMA are only partly 
attenuated by serotonin transporter inhibition12,68 and largely unaffected by postsynaptic 
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of psychostimulants derives from the clinical findings that the NE inhibitor atomoxetine 
attenuated cocaine-induced systolic blood pressure increases91 and cardiovascular and 
subjective responses to D-amphetamine.92 Together, these preclinical and clinical findings 
suggest that NE may critically be involved in the mediation of the psychotropic and 
particularly the cardiovascular and thermogenic effects of psychostimulants including 
MDMA in humans.  
In addition, the noradrenergic system may play an important role in stimulant 
addiction.85 Pre-clinical models show that NE is critically involved in the mediation of the 
effects of psychostimulants including sensitization, drug discrimination, and reinstatement 
of drug seeking.93,94 
1:8 ->[L>H>C<LCA.
Consumption of psychostimulants including MDMA is highly prevalent in our 
society. In Switzerland, more than 1.8% of the over 15 year olds report having used ecstasy 
at least once in their life.6 Besides from being abused as an illicit drug MDMA is also used 
experimentally in clinical research. For example, a recent pilot study with patients 
suffering from post-traumatic stress disorders (PTSD) has shown that MDMA positively 
affected the outcome of psychotherapy.95 MDMA could also be useful to study mood 
disorders96,97 and the neuropharmacology of mood in humans.15,96 Recreational use of 
MDMA as ecstasy can result in adverse and potentially fatal medical complications.90,98 
Extensive ecstasy consumption has also been associated with neurotoxic effects to 
serotonergic brain neurons.48,52 Because MDMA is widely used, a better understanding of 
its pharmacology and toxicology is warranted. A better understanding of the clinical 
pharmacology and toxicology of MDMA will also help in the treatment of intoxications 
with MDMA and other amphetamine-type stimulants. Finally, selective norepinephrine 
transporter inhibitors or dual norepinephrine and serotonin transporter inhibitors, as 
suggested to be evaluated in this thesis, may provide treatments for amphetamine 
dependence. 
1:\ !>B?.].^KOG=;A?>?.
The main aim of this thesis was to investigate the role of NE in the mediation of the 
effects of MDMA in humans. As previously discussed (1:7. 4GDA. GH. LGEAO>LAO;E>LA. >L. =;A.
O;<EB<CGDG[K.GH.+)+!), preclinical and clinical studies implicate NE in the mediation of 
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the effects of psychostimulants, including MDMA. Our overall hypothesis was that an 
inhibition of noradrenergic targets would reduce the acute effects of MDMA. 
Consequently, we performed a series of experimental clinical studies to assess the effect of 
different pretreatments acting on noradrenergic binging sites on the pharmacodynamic and 
pharmacokinetic response to MDMA in humans.  
In the first study, we investigated the effects of the NE transporter inhibitor 
reboxetine on the subjective, somatic, and neuroendocrine response to MDMA and also 
studied the pharmacokinetics of both drugs. Based on the preclinical evidence we 
hypothesized that the pretreatment with reboxetine would reduce acute effects of MDMA 
to the extent that they depend on NE transporter-mediated NE release. To evaluate the role 
of impulse-dependent monoamine release in the mediation of the effects of MDMA we 
similarly evaluated the effect of the !2 agonist clonidine, an inhibitor of the vesicular NE 
release, on the response to MDMA. We postulated that clonidine would reduce the 
subjective and cardiovascular effects of MDMA to the extent that the clinical effects of 
MDMA are mediated by the exocytotic release of NE. In a further study we then tested the 
effect of the dual 5-HT and NE transporter blocker duloxetine on the response to MDMA 
using the same outcome measurements. The hypothesis of this study was that duloxetine 
would block the transporter-mediated release of 5-HT and NE and therefore significantly 
reduce the acute subjective, cardiovascular, and neuroendocrine effects induced by 
MDMA. We then similarly evaluated the effect of the !1 and " adrenergic receptor blocker 
carvedilol and of the !1 adrenergic antagonist doxazosin on the response to MDMA. We 
postulated that carvedilol would reduce the heart rate, blood pressure and subjective 
response to MDMA. The hypothesis for a pretreatment with the !1 adrenergic antagonist 
doxazosin was that doxazosin would lead to a reduction of the blood pressure elevations 
and the acute emotional effects evoked by MDMA.  
All studies used randomized double-blinded cross-over study designs and 16 healthy 
volunteers were included in each study.  
In addition, we investigated the effect of MDMA on emotion recognition or pupillary 
function using pooled study data.  
 
 .J.19.J.
 
 
 
 
 
:";%5& 9*%<& ='$%& '(& >"558%5?@%08"+%0& AB&
=%$%",%&8*&+C%&:,6)C',+824$"*+&B((%)+,&
.
.
.
.
,;A.$GEAO>LAO;E>LA.,E<L?OGE=AE.0L;>T>=GE.4ATGNA=>LA.4AMFCA?.
-=>BFD<L=.(HHAC=?.GH.+)+!.P`(C?=<?KaQ.>L.^FB<L?.
.
.
.
"+.^K?AU1I.').->BBDAE1I.+.0LA>C;AL1I.(.*EGFbB<LL2I.+".^GALAE6I.4.cEALLA>?AL7I.
d.^FXKDAE8.<LM.+(.'>AC;=>1.
.
1S?KC;GO;<EB<CGDG[K. 4A?A<EC;. *EGFOI. )>V>?>GL. GH. "D>L>C<D. S;<EB<CGDG[K. <LM. ,GN>CGDG[KI. )AO<E=BAL=. GH.
c>GBAM>C>LA.<LM.)AO<E=BAL=.GH.0L=AEL<D.+AM>C>LAI.3L>VAE?>=K.^G?O>=<D.<LM.3L>VAE?>=K.GH.c<?ADI.c<?ADI.-X>=bAED<LMe.
2)>V>?>GL. GH. "D>L>C<D. S;<EB<CGDG[K. <LM. ,GN>CGDG[KI. 3L>VAE?>=K.^G?O>=<DI. '<F?<LLAI. -X>=bAED<LMe. 6S;<EB<CAF=>C<D?.
)>V>?>GLI.$AFEG?C>ALCA.4A?A<EC;I.f:.^GHHB<LLJ'<.4GC;A.'=M:I.c<?ADI.-X>=bAED<LMe.7)AO<E=BAL=.GH."D>L>C<D.4A?A<EC;I.
3L>VAE?>=K. GH. cAELI. cAELI. -X>=bAED<LMe. 8)AO<E=BAL=. GH. S;<EB<CAF=>C<D. -C>ALCA?I. 3L>VAE?>=K. GH. c<?ADI. c<?ADI.
-X>=bAED<LM:.
.
"D>L>C<D.S;<EB<CGDG[K.].,;AE<OAF=>C?I.2R11.
CLINICAL PHARMACOLOGY & THERAPEUTICS 1
ARTICLESnature publishing group
3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is 
widely used as a recreational drug, but it is also being investi-
gated as an adjunct to psychotherapy in patients with post-trau-
matic stress disorder.1 In humans, MDMA produces euphoria, 
happiness, and cardiovascular activation.2–4 In vitro, MDMA 
induces carrier-mediated release of dopamine (DA), serotonin 
(5-HT), and norepinephrine (NE) through DA (DAT), 5-HT 
(SERT), and NE transporter (NET), respectively.5–9 However, 
it is not clear how these monoamines contribute to the acute 
psychostimulant e!ects of MDMA in humans.8,10
"e role of DA in the reinforcing e!ects of psychostimu-
lants is well established in animal models. However, deletions 
of dopamine D1, D2, and D3 receptor genes in mice had mini-
mal e!ects on MDMA-induced acute changes in locomotor 
behavior,11 and DAT inhibition did not a!ect acute responses 
to MDMA in rhesus monkeys.12 In humans, DA D2 recep-
tor antagonists reduced amphetamine-induced and MDMA-
induced euphoria only at doses that produced dysphoria.13–15 
"erefore, non-DA systems may be principally responsible for 
the acute e!ects of MDMA.
SERT inhibitors (SSRIs) decrease MDMA-induced 5-HT 
release in vitro7 and in animals16 and also attenuate behavioral 
e!ects of MDMA in animals.17 Consistent with this preclinical 
evidence for a role of SERT, SSRIs reduced the subjective and 
cardiovascular response to MDMA in humans,18–21 indicating 
that MDMA-induced, SERT-mediated 5-HT release critically 
contributes to the psychotropic and physical e!ects of MDMA 
in humans. However, the blood pressure response to MDMA 
is only partly attenuated by blockade of 5-HT release18 and is 
largely una!ected by postsynaptic 5-HT1 or 5-HT2 receptor 
antagonist pretreatment.22,23
"e role of the NET in the mechanism of action of MDMA 
in humans has not yet been explored. As compared to SERT 
and DAT, MDMA exhibits higher a#nity for human NET.5,6 
MDMA releases NE more potently than 5-HT or DA from 
monoamine-preloaded human embryonic kidney (HEK) cells 
transfected with the corresponding human monoamine trans-
porter.6 "e NET inhibitor desipramine and the SERT inhibitor 
citalopram, but not the DAT/NET inhibitor methylphenidate, 
reversed the acute cognitive e!ects of MDMA in rhesus mon-
keys.12 NE also plays a role in mediating the peripheral e!ects 
of MDMA. MDMA increases the levels of circulating NE in 
rats.24 "e adrenergic A1 receptor antagonist prazosin reversed 
MDMA-associated locomotor stimulation25 and vascular 
e!ects26 in rats. "e NET inhibitor nisoxetine abolished contrac-
tion of the rat aorta produced by 4-methylthioampethamine,27 
a compound with a pharmacology similar to that of MDMA. 
Clinically, MDMA increases plasma NE levels4 and stimulates 
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The Norepinephrine Transporter Inhibitor 
Reboxetine Reduces Stimulant Effects of MDMA 
(“Ecstasy”) in Humans
CM Hysek1, LD Simmler1, M Ineichen1, E Grouzmann2, MC Hoener3, R Brenneisen4, J Huwyler5  
and ME Liechti1
This study assessed the pharmacodynamic and pharmacokinetic effects of the interaction between the selective 
norepinephrine (NE) transporter inhibitor reboxetine and 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in 
16 healthy subjects. The study used a double-blind, placebo-controlled crossover design. Reboxetine reduced the effects 
of MDMA including elevations in plasma levels of NE, increases in blood pressure and heart rate, subjective drug high, 
stimulation, and emotional excitation. These effects were evident despite an increase in the concentrations of MDMA 
and its active metabolite 3,4-methylenedioxyamphetamine (MDA) in plasma. The results demonstrate that transporter-
mediated NE release has a critical role in the cardiovascular and stimulant-like effects of MDMA in humans.
2 www.nature.com/cpt
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the sympathetic nervous system, as evidenced by increases in 
heart rate, blood pressure, pupil size, and body temperature.18 
Serious adverse e!ects of uncontrolled ecstasy use also include 
hypertensive and hyperthermic reactions that are likely to be 
mediated by an activation of the adrenergic system by MDMA.28 
"e importance of NE in the mechanism of action of amphet-
amine-type stimulants in general is further supported by the 
observation that the subjective e!ects of these stimulants in 
humans correlate with their potency to release NE and not with 
their e!ect on DA.8 Further support for a role of the NET in the 
e!ects of psychostimulants derives from the clinical $ndings 
that the NET inhibitor atomoxetine attenuated cocaine-induced 
systolic blood pressure increases29 and cardiovascular and sub-
jective responses to d-amphetamine in humans.30 Together, the 
preclinical and clinical $ndings suggest that NE may contribute 
critically to the psychotropic and, even more importantly, the 
Table 1 Mean ± SEM values and statistics of drug effects
Placebo–placebo 
(mean p SEM)
Reboxetine–
placebo  
(mean p SEM)
Placebo–MDMA 
(mean p SEM)
Reboxetine–
MDMA  
(mean p SEM) F(3,45) = P <
Circulating catecholamines
 Epinephrine (nmol/l) At 1 h 0.11 p 0.02 0.08 p 0.02 0.35 p 0.08* 0.21 p 0.03 6.70 0.001
 Norepinephrine (nmol/l) At 1 h 1.29 p 0.16 1.18 p 0.15 2.05 p 0.20** 1.31 p 0.13†† 12.40 0.001
Physiologic effects
 SBP (mm Hg) Emax 11.1 p 2.1 8.5 p 1.5 38.7 p 2.6*** 20.7 p 2.6*,††† 33.50 0.001
 DBP (mm Hg) Emax 8.6 p 1.5 5.2 p 1.0 20.8 p 1.7*** 15.8 p 1.9* 17.40 0.001
 MAP (mm Hg) Emax 8.0 p 1.4 5.1 p 1.0 25.8 p 1.9*** 16.2 p 1.9**,†† 30.80 0.001
 Heart rate (beats/min) Emax 11.3 p 1.9 12.3 p 2.4 31.7 p 3.1*** 23.4 p 3.0**,† 17.90 0.001
 Body temperature (°C) Emax 0.41 p 0.06 0.46 p 0.07 0.74 p 0.10* 0.51 p 0.09 3.40 0.05
Visual analog scales (VAS, %max)
 Any drug effect Emax 1.9 p 1.3 8.0 p 3.4 85.4 p 4.8*** 67.7 p 6.2***,†† 120.40 0.001
 Drug high Emax 4.9 p 3.7 9.3 p 4.6 86.31 p 4.0*** 65.3 p 8.1***,† 61.10 0.001
 Stimulated Emax 2.6 p 2.6 3.4 p 2.5 71.9 p 8.0*** 51.1 p 9.4***,† 34.00 0.001
 Closeness Emax 0.25 p 0.19 0.00 p 0.00 33.9 p 5.9*** 20.8 p 4.5***,† 22.70 0.001
 Good drug effect Emax 0.06 p 0.06 6.3 p 3.4 85.6 p 4.1*** 72.6 p 7.2*** 114.60 0.001
 Liking Emax 3.1 p 3.1 15.6 p 7.0 86.6 p 4.7*** 77.9 p 5.1** 75.60 0.001
Adjective Mood Rating Scale (AMRS score)
 Activity Emax 1.56 p 0.52 1.38 p 0.45 3.81 p 0.98* 4.19 p 1.02** 4.80 0.05
 Inactivation Emax 1.88 p 0.82 3.56 p 1.03 8.19 p 2.06 6.50 p 1.73 4.80 0.05
 Extroversion Emax 1.06 p 0.31 1.25 p 0.57 4.00 p 078* 4.13 p 0.83** 10.10 0.001
 Introversion Emin −0.44 p 0.20 −1.06 p 0.35 −3.00 p 0.82*** −1.19 p 0.39†† 6.20 0.001
 Well-being Emax 1.75 p 0.37 2.56 p 0.83 6.50 p 1.28** 6.25 p 1.46* 16.60 0.001
 Emotional excitation Emax 0.44 p 0.27 1.53 p 0.69 7.50 p 1.20*** 3.94 p 1.14*,† 14.20 0.001
 Anxiety-depression Emax 0.31 p 0.18 1.25 p 0.50 2.25 p 0.71 1.38 p 0.62 2.90 0.05
 Dreaminess Emax 0.69 p 0.25 1.63 p 0.46 4.00 p 0.74*** 3.19 p 0.68** 7.30 0.001
State-Trait Anxiety Inventory Emax 1.44 p 0.58 2.19 p 0.98 10.19 p 2.36** 3.81 p 1.06† 9.40 0.001
List of complaints (total score)
 Acute adverse effects At 3 h −1.00 p 0.53 −0.19 p 1.30 10.13 p 1.90*** 1.94 p 2.80† 7.73 0.001
 Subacute adverse effects At 24 h −1.19 p 0.63 0.06 p 0.92 5.38 p 1.47** 0.44 p 1.33† 5.95 0.01
Ex vivo binding (Ki,%)
 NET 24.00 p 1.28 9.09 p 1.66*** 22.17 p 1.66 7.16 p 0.83***,††† 48.02 0.001
 SERT >25 >25 >25 >25
 DAT >25 >25 >25 >25
Values are mean p SEM of changes from baseline of 16 subjects.
DAT, dopamine transporter; DBP, diastolic blood pressure; Emax, peak effects; Emin, minimum effects; Ki, inhibition constant calculated as % of plasma sample dilution with 
undiluted plasma set as 100%; MAP, mean arterial pressure; MDMA, 3,4-methylenedioxymethamphetamine; NET, norepinephrine transporter; SBP, systolic blood pressure; SERT, 
serotonin transporter.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to placebo–placebo. †P < 0.05, ††P < 0.01, †††P < 0.001 compared to placebo–MDMA.
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cardiovascular e!ects of MDMA in humans. "is study evalu-
ated pharmacokinetic and pharmacodynamic e!ects of the 
interaction between the selective NET inhibitor reboxetine and 
MDMA in healthy subjects. We hypothesized that pretreatment 
with reboxetine would attenuate the subjective, neuroendocrine, 
cardiovascular, and adverse e!ects of MDMA to the extent that 
they depend on NET-mediated release of NE.
Pharmacokinetic interactions were evaluated to con$rm that 
the e!ects of reboxetine on the MDMA response could not be 
explained by the exposure to MDMA or its active metabolites 
being too low. MDMA is n-demethylated to the active, but minor, 
metabolite 3,4-methylenedioxyamphetamine (MDA) by cyto-
chrome P450 (CYP) 2B6 and 3A4. "e major pathway of MDMA 
degradation includes CYP2D6-mediated O-demethylation to 
3,4-dyhydroxymethamphetamine (HHMA), followed by cate-
chol-O-methyltransferase-catalyzed methylation to 4-hydroxy-
3-methoxymethamphetamine (HMMA).31
RESULTS
Pharmacodynamics
MDMA increased the levels of both circulating NE and epine-
phrine relative to placebo. Reboxetine prevented the MDMA-
induced increase in NE, an endocrine correlate of sympathetic 
activation (Table 1). It also reduced the cardiovascular and psy-
chostimulant e!ects of MDMA. Reboxetine decreased MDMA-
induced elevations in blood pressure and heart rate (Figure 1 and 
Table 1) and attenuated MDMA-induced visual analog scale (VAS) 
score increases in “any drug e!ect,” “drug high,” “stimulated,” and 
“closeness to others” (Figure 2 and Table 1). In contrast, reboxetine 
did not a!ect MDMA-induced VAS score changes with regard to 
“good drug e!ect” and “drug liking” (Figure 2 and Table 1). On 
the 5-Dimensions of Altered States of Consciousness (5D-ASC) 
Rating Scale, analysis of variance showed signi$cant main e!ects 
of the drug in the sum score and in all the dimensions of the scale 
(F(3,45) = 32.8, 32.9, 8.5, and 17.8 for ASC, oceanic boundlessness 
(OB), anxious ego dissolution (AED), and visionary restructurali-
zation (VR), respectively; all P < 0.001). MDMA robustly increased 
scores in the OB, AED, and VR dimensions relative to placebo (all 
P < 0.001) (Figure 3). Reboxetine reduced MDMA’s e!ect on the 
total ASC score (P < 0.01) in the OB dimension (P < 0.01) and in 
the VR dimension (P < 0.05), including signi$cant reductions in 
OB item clusters for “experience of unity” (P < 0.01) and “blissful 
state” (P < 0.1). With respect to the Adjective Mood Rating Scale 
(AMRS) scale, reboxetine prevented MDMA-induced increase in 
emotional excitation and decrease in introversion (Figure 4 and 
Table 1). MDMA increased a sense of well-being, extroversion, 
and dreaminess and produced inactivation at 1.25 h and activation 
at 2 h, which resulted in peak increases in both activity and inacti-
vation relative to placebo. Reboxetine had no e!ect on these sub-
jective e!ects associated with MDMA. Finally, reboxetine reduced 
MDMA-induced elevations in State-Trait Anxiety Inventory 
(STAI) anxiety scores (Figure 4 and Table 1).
Adverse effects
MDMA increased the total list of complaints adverse e!ects 
score at 3 h and again at 24 h a&er administration, relative to 
placebo (Table 1). "e most frequently reported adverse e!ects 
of placebo–MDMA and reboxetine–MDMA included lack of 
appetite (n = 12 and n = 8, respectively), di#culty in concentrat-
ing (n = 12 and n = 12, respectively), tremor (n = 9 and n = 3, 
respectively), restlessness (n = 8 and n = 4, respectively), and 
dizziness (n = 6 and n = 4, respectively). Reboxetine decreased 
the number of MDMA-induced adverse e!ects (Table 1).
Pharmacokinetics
"e decrease in the pharmacodynamic response to MDMA 
a&er reboxetine pretreatment is not attributable to a phar-
macokinetic interaction between reboxetine and MDMA 
because reboxetine was shown to increase exposure to 
MDMA. Reboxetine increased the maximum concentration 
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Figure 1 Physiologic effects. Values are mean ± SEM of changes from 
baseline in 16 subjects. Reboxetine was administered at t = −12 h and at 
t = −1 h. 3,4-Methylenedioxymethamphetamine (MDMA) was administered at 
t = 0 h. Reboxetine pretreatment reduced MDMA-induced elevations in blood 
pressure and heart rate.
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(Cmax) of MDMA by 19 p 6% (F(1,15) = 9.23; P < 0.01) and the 
area under the plasma concentration–time curve (AUC)0–24 h 
by 9 p 4% (F(1,15) = 5.53; P < 0.05) (Figure 5a and Table 2). 
Reboxetine also increased AUC0–24 h and AUC0–∞ values 
of MDA by 50 p 13% (F(1,15) = 15.98; P < 0.001) and 66 p 
16% (F(1,15) = 19.03; P < 0.001), respectively (Figure 5b and 
Table 2). Conversely, MDMA increased the Cmax of reboxetine 
by 16 p 6% (F(1,15) = 5.97; P < 0.05) (Figure 5c and Table 2). 
"e pharmacokinetic parameters of MDMA were not depen-
dent on CYP2D6 phenotype.
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Pharmacokinetic–pharmacodynamic relationship
Figure 5d,e shows MDMA’s e!ects in terms of the plasma con-
centration. MDMA-induced changes in (Figure 5d) mean arte-
rial pressure (MAP) and (Figures 5e) “any drug e!ect” returned 
to baseline within 8 h and 6 h, respectively, when MDMA con-
centrations were still high (clockwise hysteresis). Reboxetine 
pretreatment attenuated both physical and subjective responses 
to MDMA (Figure 5d,e).
Ex vivo binding studies
Plasma from subjects treated with reboxetine–placebo or rebox-
etine–MDMA inhibited ex vivo radioligand binding to NET but 
not to SERT or DAT (Table 1).
DISCUSSION
In this study, pretreatment with the selective NET inhibitor 
reboxetine prevented MDMA-induced increase in circulating 
levels of NE, which is a marker of sympathetic system activa-
tion, and signi$cantly reduced the cardiovascular response to 
MDMA. Reboxetine also attenuated some, but not all, of the 
psychotropic e!ects of MDMA and reduced MDMA-induced 
drug high, stimulation, emotional excitation, and anxiety, as 
well as the blissful state and experience of unity elicited by 
MDMA. Reboxetine also ameliorated some of the adverse 
e!ects of MDMA such as tremor and restlessness. Overall, 
blockade of NET resulted in a pronounced decrease in the car-
diovascular stimulant e!ects of MDMA and a moderate attenu-
ation of its psychostimulant properties. In contrast, good drug 
e!ects and the sense of well-being associated with MDMA 
were not signi$cantly altered by reboxetine pretreatment. "e 
$ndings are consistent with a role for NET in the mediation 
of the sympathomimetic stimulant-like aspects of the MDMA 
e!ect.
"e pharmacodynamic interaction observed in this study can-
not be explained on the basis of a pharmacokinetic interaction 
between reboxetine and MDMA because reboxetine decreased 
the pharmacodynamic e!ects of MDMA even while it increased 
the Cmax of MDMA by 20% and the AUC0–24 h of MDMA and 
its active metabolite MDA by 10% and 50%, respectively. "e 
potent CYP2D6 inhibitor paroxetine has previously been shown 
to increase the Cmax and AUC0–27 h of MDMA by 20% and 30%, 
respectively, and of MDA by 20% and 20%, respectively31 (simi-
lar to the e!ect of reboxetine in our study), whereas it decreased 
MDMA metabolism to HHMA and HMMA.31 "e e!ects of 
paroxetine and reboxetine on MDMA metabolism can there-
fore be explained by CYP2D6 inhibition32 and a shi& of the 
metabolism from the major pathway (by reducing HHMA and 
HMMA formation) to a minor pathway (including an increase 
in MDA formation). However, we did not measure HHMA 
and HMMA levels in plasma, and this may be a limitation with 
respect to the conclusion regarding pathways. Furthermore, 
MDMA is itself a mechanism-based inhibitor of CYP2D6, and 
its pharmacokinetics is nonlinear.33,34 In this study, we used an 
ex vivo binding assay to investigate whether the plasma sam-
ples taken from the subjects exhibited NET-binding properties. 
We con$rmed that plasma from reboxetine-treated subjects 
displaced 3H-nisoxetine from NET and that there was a trend 
toward this e!ect with regard to plasma from MDMA-treated 
subjects. Although both reboxetine and MDMA bind to NET in 
vitro and inhibit NE uptake,6,35 MDMA is also a NET substrate 
and releases NE.6 "e pharmacodynamic interaction between 
reboxetine and MDMA observed in this study is consistent with 
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inhibition of the MDMA-induced NET-mediated NE release by 
reboxetine.
"e role for NET in the mechanism of action of MDMA, as 
suggested by the results of this study, is in line with both pre-
clinical and clinical data from other studies, as outlined in the 
introduction. As compared to SERT and DAT, MDMA shows 
higher a#nity to NET in vitro5,6 and releases NE more potently 
than 5-HT or DA.6,8 In humans, NET inhibition reduced 
cardiostimulant responses to cocaine29 and both cardiostimulant 
and psychostimulant responses to d-amphetamine,30 similar to 
the $ndings in our study with MDMA.
"e SERT inhibitor citalopram has been shown to reduce the 
cardiovascular and subjective e!ects of MDMA in humans.18,19 
Citalopram reduced MDMA-induced increases in systolic blood 
pressure and emotional excitation by <50% and positive mood 
effects by >50%. In contrast, reboxetine reduced MDMA-
Table 2 Pharmacokinetic parameters of MDMA, MDA, and reboxetine
Cmax (ng/ml) Tmax (h) T1/2 (h) AUC0–24 h (ng/ml·h) AUC0–d (ng/ml·h)
MDMA
 Placebo–MDMA 298.0 p 12.3 2.6 p 0.2 9.6 p 0.8 3,357.1 p 159.0 4,127.2 p 229.2
 Reboxetine–MDMA 351.0 p 19.0** 2.8 p 0.4 7.0 p 0.3 3,629.1 p 167.5* 4,106.2 p 215.8
MDA
 Placebo–MDA 19.0 p 2.1 4.7 p 0.6 16.1 p 1.8 227.4 p 19.0 358.6 p 25.0
 Reboxetine–MDA 23.0 p 2.7 7.0 p 0.6 17.3 p 1.9 327.7 p 24.0** 572.2 p 48.9***
Reboxetine
 Reboxetine–placebo 371.7 p 33.9 3.3 p 0.4 13.7 p 0.7 5,704.4p599.6 8,292.5 p 1,042.2
 Reboxetine–MDMA 416.9 p 31.1† 3.6 p 0.5 13.2 p 0.9 6,176.2 p 553.2 9,103.4 p 1,099.9
Values are mean p SEM of 16 healthy subjects.
AUC, area under the plasma concentration–time curve; Cmax, maximum plasma concentration; MDA, 3,4-methylenedioxyamphetamine; MDMA, 
3,4-methylenedioxymethamphetamine; T1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to placebo–MDMA. †P < 0.05 compared to reboxetine–placebo.
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induced increases in systolic blood pressure and emotional 
excitation by >50% and positive mood e!ects by <50%. "e 
two studies indicate that SERT-mediated 5-HT release is more 
important than NET-mediated NE release for MDMA-typical 
positive mood e!ects, whereas NET-mediated NE release pri-
marily mediates the more stimulant-typical emotional excitation 
and cardiovascular response to MDMA. "e e!ect of reboxetine 
on subjective responses to MDMA is similar to changes in the 
subjective e!ects of d-amphetamine a&er pretreatment with the 
NET inhibitor atomoxetine.30 As in our study, NET inhibition 
reduced amphetamine-induced increases in subjective ratings 
of “stimulated” and “high” but not in “drug liking,”30 thereby 
reinforcing the view that NET contributes mainly to the psy-
chostimulant aspect of amphetamines.36
DA is commonly thought to mediate the reinforcing and 
rewarding e!ects of drugs of abuse. For example, the DAT/NET 
inhibitor methylphenidate has been shown to reduce intrave-
nous amphetamine use in amphetamine-dependent patients.37 
"e role of DA in the mediation of the acute subjective e!ects of 
amphetamine-type stimulants in humans is less clear. "e DAT/
NET inhibitor bupropion was shown to attenuate subjective 
responses to methamphetamine.38 However, the e!ect of DAT 
inhibition on the acute response to MDMA has not been studied 
in humans. We have previously shown that the DA D2 antago-
nist haloperidol reduces the positive mood elicited by MDMA 
and that haloperidol depresses mood also when given alone, as 
compared to the e!ect of placebo.15 Similarly, DA D2 receptor 
blockade did not a!ect subjective responses to d-amphetamine, 
according to the results of most studies.13,14 Accordingly, DA may 
primarily mediate the reinforcing properties of psychostimulants 
but might not be the primary mediator of their acute e!ects.8
"e exact mechanism by which monoamine transport inhibi-
tors interact with MDMA-induced monoamine release is not 
known. "e SERT, DAT, and NET inhibitor indatraline blocks 
MDMA-induced transmitter release according to simple com-
petitive models.7 Other inhibitors alter the e#ciency of the 
MDMA-induced transmitter release in a noncompetitive man-
ner, possibly by inducing conformational changes in the trans-
porter protein.7 A channel-like conformation of DAT, resulting 
in rapid DA e'ux, has also been described for amphetamine-
induced DA release.39
The present study adds to a better understanding of the 
mechanism of action of MDMA. Our $nding that reboxetine 
reduces the subjective e!ects of MDMA (stimulant and drug 
high) is similar to the $nding from another study that atom-
oxetine attenuates the subjective e!ects of d-amphetamine.30 
Taken together, these $ndings indicate that NET inhibitors may 
potentially be useful as treatments for stimulant addiction.36,40 
However, further clinical studies are needed to explore the thera-
peutic potential of NET inhibitors in stimulant dependence.
In summary, we showed that NE plays a critical role in the 
acute physiologic and subjective e!ects of MDMA in humans.
METHODS
Study design. We used a double-blind, placebo-controlled, randomized, 
crossover design with four experimental conditions (placebo–placebo, 
reboxetine–placebo, placebo–MDMA, and reboxetine–MDMA). The 
order of the four test sessions was counterbalanced. Washout periods 
between sessions were 10–14 days long. The study was conducted in 
accordance with the Declaration of Helsinki and the International 
Conference on Harmonisation Guidelines on Good Clinical Practice 
and was approved by the Ethics Committee of the Canton of Basel, 
Switzerland. The use of MDMA in healthy subjects was authorized by 
the Swiss Federal Office of Public Health, Bern, Switzerland. The study 
was registered at ClinicalTrials.gov (NCT00886886).
Study outline. Subjects completed a screening session, four test sessions 
with a next-day follow-up, and an end-of-study visit. Test sessions took 
place in a quiet hospital research ward with no more than two research 
subjects present per session. Prior to admission to the test sessions, the 
subjects were asked about potential health problems; drug tests and urine 
tests for pregnancy were also performed. An indwelling intravenous cath-
eter was placed in the antecubital vein for blood sampling. Reboxetine 
(8 mg orally) or placebo was administered at 20:00 h the day before the 
test session and again at 7:00 h a&er a light meal on the day of the test. 
MDMA (125 mg orally) or placebo was administered at 8:00 h, 1 and 
12 h a&er reboxetine. A standardized lunch was served at 12:00 h, and 
subjects were sent home at 18:00 h. On the day following each test session, 
the subjects returned to the research ward at 8:00 h for the assessment of 
adverse e!ects and blood sampling. During the test sessions, the subjects 
did not drink beverages containing ca!eine or alcohol. "ey were read-
ing, listening to music, or walking around in the research ward. For most 
of the time, they were sitting or lying comfortably. Outcome measures 
were assessed repeatedly before and a&er drug administration.
Subjects. Sixteen healthy subjects (eight men and eight women), 20–44 
years of age (mean p SD: 25.7 p 5.5 years), were recruited on the uni-
versity campus by word of mouth. Exclusion criteria included: age <18 
or >45 years, pregnancy (urine pregnancy test before each test session), 
abnormal body mass index (<18.5 or >25 kg/m2), personal or family 
($rst-degree relative) history of psychiatric disorder (as assessed by the 
structured clinical interview for axis I and II disorders according to the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV),41 supplemented by psychometric instruments),42 regular use 
of medications, chronic or acute physical illness (as assessed by physical 
examination, electrocardiogram, standard hematological, and chemical 
blood analyses), smoking (more than 10 cigarettes/day), lifetime history 
of illicit drug use more than $ve times (except for tetrahydrocannabi-
nol), illicit drug use within the past 2 months, and illicit drug use during 
the study (urine tests for drug use before test sessions using TRIAGE 8, 
Biosite, San Diego, CA). "e subjects were asked to abstain from exces-
sive alcohol consumption between test sessions and, in particular, to limit 
alcohol use to one glass on the day before each test session. "ree subjects 
were light smokers (fewer than 10 cigarettes/day). "ey maintained their 
usual smoking habit but were not allowed to smoke for 6 h a&er MDMA/
placebo administration. Eleven subjects had previously used cannabis. 
Six subjects had illicit drug experiences (one to four times): one subject 
had tried cocaine, one had tried ecstasy, two had tried psilocybin, one 
had tried psilocybin and ecstasy, and one had tried ecstasy, psilocybin, 
and cocaine. "e three subjects with ecstasy experience had all used the 
drug only once. All the subjects were phenotyped for CYP2D6 activity, 
using dextrometorphan as the probe drug. "ere were 10 extensive, 4 
intermediate, and 2 poor CYP2D6 metabolizers in the study. All subjects 
gave their written informed consent before participating in the study, and 
they were paid for their participation.
Study drugs. (p) MDMA hydrochloride (Lipomed AG, Arlesheim, 
Switzerland) was obtained from the Swiss Federal Office of Public 
Health and prepared as gelatin capsules (100 mg and 25 mg) by Bichsel 
Laboratories AG, Interlaken, Switzerland, in accordance with good 
manufacturing practice. Identical placebo (lactose) capsules were pre-
pared. MDMA was administered in a single absolute dose of 125 mg, 
corresponding to a dose of 1.85 p 0.24 mg/kg body weight. "is dose 
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of MDMA corresponds to a typical recreational dose of ecstasy, and 
comparable doses of MDMA have previously been used in controlled 
settings.2–4,43 Reboxetine is a potent, selective, and speci$c NE uptake 
inhibitor.35 Reboxetine (8 mg, Edronax; P$zer, Zurich, Switzerland) and 
identical-looking placebo (lactose) capsules were similarly prepared by 
Bichsel Laboratories. Reboxetine (8 mg) or placebo was administered 
twice, 12 h and 1 h before MDMA (125 mg) or placebo. Similar dosing 
regimens have previously been used to manipulate the NE system func-
tion in healthy subjects.44
Pharmacodynamics
Psychometric scales: Subjective measures included VAS,21 the AMRS,45 
the 5D-ASC,46 and the STAI.42
VAS: VASs included “any drug e!ect,” “drug high,” “stimulated,” “close-
ness to others,” “good drug e!ect,” and “liking.”3,20,21 VASs were pre-
sented as 100-mm horizontal lines marked “not at all” on the le& and 
“extremely” on the right. "e VAS for “closeness to others” was bidirec-
tional (p 50 mm). VAS tests were administered 1 h before and at 0, 0.33, 
1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 h a&er MDMA/placebo administration.
5D-ASC: "e 5D-ASC rating scale measures alterations in mood, 
perception, experience of self in relation to environment, and thought 
disorder. "e instrument comprises $ve subscales (dimensions)46 and 
eleven lower-order scales47: "e 5D-ASC dimension OB (27 items) 
measures derealization and depersonalization associated with positive 
emotional states ranging from heightened mood to euphoric exaltation. 
"e corresponding lower-order scales are “experience of unity,” “spiritual 
experience,” “blissful state,” and “insightfulness.” "e dimension AED 
(21 items) summarizes ego disintegration and loss of self-control, phe-
nomena associated with anxiety. "e corresponding lower-order scales 
are “disembodiment,” “impaired control of cognition,” and “anxiety.” "e 
dimension “VR (18 items) consists of the lower-order scales “complex 
imagery,” “elementary imagery,” “audiovisual synesthesia,” and “changed 
meaning of percepts.” Two other dimensions of the scale were not used in 
our study. "e global ASC score was constructed by adding the OB, AED, 
and VR scores. "e 5D-ASC scale was administered 4 h a&er administra-
tion of MDMA or placebo.
AMRS: "e 60-item Likert-scale short version of the AMRS45 was 
administered 1 h before and at 1.25, 2, 3, and 24 h a&er MDMA or pla-
cebo. "e AMRS contains subscales for activity, inactivation, extroversion 
and introversion, well-being, emotional excitation, anxiety–depression, 
and dreaminess.
STAI: "e STAI state-anxiety scale42 test was administered 1 h before 
and at 1.25, 2, and 3 h a&er MDMA or placebo.
Physiologic measures. Physiologic measures were assessed repeatedly, at 
−1, 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, and 10 h a&er administration 
of MDMA or placebo. Heart rate, systolic blood pressure, and diastolic 
blood pressure were measured using an OMRON M7 blood pressure 
monitor (OMRON Healthcare Europe, Hoofddorp, "e Netherlands) in 
the dominant arm a&er a resting time of 5–10 min, with the volunteer sit-
ting in bed with the back supported. Measures were taken twice per time 
point with an interval of 1 min, and the average was used for analysis. 
Between measurements, subjects were allowed to engage in nonstrenuous 
activities. Core (tympanic) temperature was assessed using a GENIUS 
2 ear thermometer (Tyco Healthcare Group, Watertown, NY). "e tem-
perature of the room was maintained at 22.5 p 0.5 °C.
Adverse effects. Adverse e!ects were assessed at 0, 3, and 24 h a&er 
administration of MDMA or placebo by using the List of Complaints.2,48 
"e scale consists of 66 items, yielding a total adverse e!ects score (non-
weighted sum of the item answers), reliably measuring physical and gen-
eral discomfort. "e scale has previously been shown to be sensitive to 
the adverse e!ects of MDMA.2,22
Blood collection for endocrine and pharmacokinetic measurements. 
Samples of whole blood for the determination of MDMA, MDA, and 
reboxetine levels were collected into lithium heparin monovettes at −1, 
0, 0.33, 0.66, 1, 1.5, 2,3.5, 3, 3.5, 4, 6, 8, 10, and 24 h a&er administration 
of MDMA or placebo. Blood samples to determine concentrations of NE 
and epinephrine were taken 60 min a&er administration of MDMA or 
placebo. All blood samples were collected on ice and centrifuged within 
10 min at 4 ºC. Plasma was then stored at −70 ºC until analysis.
Laboratory analyses
Catecholamines: "e levels of free catecholamines (NE and epinephrine) 
were determined using a modi$ed method of the RECIPE kit (ClinRep; 
RECIPE Chemicals and Instruments, Munich, Germany) (see Sup-
plementary Methods online). "e lower limit of quanti$cation was 
20 pmol/l, and interassay precisions (coe#cient of variation (CV)) were 
<15%.
MDMA and MDA: Plasma concentrations of MDMA and its active 
metabolite, 3,4-methylenedioxyamphetamine (MDA), were determined 
using high-performance liquid chromatography with diode-array detec-
tion49 (see Supplementary Methods online). "e limit of quanti$cation 
was 5 ng/ml for MDMA and 2 ng/ml for MDA. Interday precision values 
(CV) were 7 and 4%, and interday accuracy values were 96–106% and 
100–103% for MDMA and MDA, respectively.
Reboxetine: Plasma reboxetine concentrations were analyzed using liq-
uid chromatography–mass spectrometry (see Supplementary Methods 
online). "e limit of quanti$cation was 34.5 ng/ml. Interday precision 
(CV) values were 5.7 and 3.2%, and interday accuracy values were 98.5 
and 101.8%, at 92 ng/ml and at 344 ng/ml, respectively.
Ex vivo binding: Plasma samples for investigating ex vivo binding were 
collected 60 min a&er administration of MDMA or placebo. We deter-
mined the potencies of plasma to inhibit 3H-nisoxetine, 3H-citalopram, 
and 3H-WIN35, 428 binding to NET, SERT, and DAT, respectively (see 
Supplementary Methods online). Ki values were calculated as percent-
ages of plasma sample dilutions required for obtaining 50% of maximum 
e!ect (10 µmol/l indatraline in human plasma was used to achieve 100% 
inhibition). Undiluted plasma samples were set as 100%. "erefore, a Ki 
of 10% indicates that a plasma sample diluted 10-fold displaced 50% of 
the radioligand.
Pharmacokinetics. Data for plasma concentrations of MDMA, MDA, 
and reboxetine were analyzed using noncompartmental methods 
(WinNonlin; Pharsight, Mountain View, CA). Cmax and time to maxi-
mum concentration (Tmax) were obtained directly from the concen-
tration–time curves of observed values. "e terminal elimination rate 
constant (Lz) was estimated by log-linear regression a&er semilogarithmic 
transformation of the data, using at least three data points of the termi-
nal linear phase of the concentration–time curve. Terminal elimination 
half-life (t1/2) was calculated using Lz and the equation t1/2 = ln2/Lz. "e 
AUC0–24 h was calculated using the linear trapezoidal rule. "e AUC0–d 
was determined by extrapolation of the AUC0–24 h, using Lz.
Statistical analysis. Values were transformed to di!erences from base-
line. Peak e!ects (Emax) were determined for repeated measures. Emax 
values were compared by one-way General Linear Models repeated meas-
ures analysis of variance with drug as a factor, using STATISTICA 6.0 
(StatSo&, Tulsa, OK). Tukey post hoc comparisons were performed based 
on signi$cant main e!ects of treatment. Additional analyses of variance 
were performed with drug order as an additional factor so as to exclude 
carryover e!ects. "e criterion for signi$cance was P < 0.05. MAP was 
calculated from diastolic blood pressure and systolic blood pressure using 
the formula MAP = DBP + (SBP−DBP)/3.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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ABSTRACT
The mechanism of action of 3,4-methylenedioxymethamphet-
amine (MDMA; ecstasy) involves the carrier-mediated and po-
tentially vesicular release of monoamines. We assessed the
effects of the sympatholytic !2-adrenergic receptor agonist
clonidine (150 "g p.o.), which inhibits the neuronal vesicular
release of norepinephrine, on the cardiovascular and psycho-
tropic response to MDMA (125 mg p.o.) in 16 healthy subjects.
The study used a randomized, double-blind, placebo-con-
trolled crossover design with four experimental sessions. The
administration of clonidine 1 h before MDMA reduced the
MDMA-induced increases in plasma norepinephrine concen-
trations and blood pressure but only to the extent that clonidine
lowered norepinephrine levels and blood pressure compared
with placebo. Thus, no interaction was found between the
cardiovascular effects of the two drugs. Clonidine did not affect
the psychotropic effects or pharmacokinetics of MDMA. The
lack of an interaction of the effects of clonidine and MDMA
indicates that vesicular release of norepinephrine, which is
inhibited by clonidine, does not critically contribute to the ef-
fects of MDMA in humans. Although clonidine may be used in
the treatment of stimulant-induced hypertensive reactions, the
present findings do not support a role for !2-adrenergic recep-
tor agonists in the prevention of psychostimulant dependence.
Introduction
The sympathomimetic amphetamine derivative 3,4-methyl-
enedioxymethamphetamine (MDMA; ecstasy; C11H15NO2) re-
leases norepinephrine (NE), serotonin [5-hydroxytryptamine
(5-HT)], and dopamine from nerve terminals via their corre-
sponding presynaptic monoamine transporters (Rudnick and
Wall, 1992; Rothman et al., 2001; Verrico et al., 2007). The
psychotropic and cardiostimulant effects of MDMA in humans
seem to depend on the transporter-mediated release of NE and
5-HT. Both the subjective and cardiovascular responses to
MDMA can be reduced by blocking the NE or 5-HT transporter
by using selective transporter inhibitors (Liechti et al., 2000;
Farre´ et al., 2007; Tancer and Johanson, 2007; Hysek et al.,
2011). The release of NE has been shown to critically mediate
the effects of psychostimulants (Rothman et al., 2001; Sofuoglu
et al., 2009), including MDMA (Hysek et al., 2011; Newton,
2011). However, MDMA-induced increases in extracellular
monoamines may also result from impulse-dependent vesicu-
lar/exocytotic release or transmitter uptake inhibition (Seiden
et al., 1993; Florin et al., 1994; Hondebrink et al., 2011). The
vesicular release of NE is under negative feedback control me-
diated by presynaptic !2-adrenergic receptors (Buccafusco,
1992; Starke, 2001), and !2 receptors are thereby involved in
noradrenergic function, including vascular contraction, blood
pressure control, body temperature regulation, arousal, and
memory (Starke, 2001). Clonidine is an !2-adrenergic receptor
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agonist and sympatholytic drug that reduces noradrenergic ac-
tivity by decreasing the impulse-mediated vesicular release of
NE (Buccafusco, 1992; Philipp et al., 2002). In healthy subjects,
clonidine dose-dependently suppressed plasma levels of NE
(Veith et al., 1984), blood pressure (Mitchell et al., 2005), and
cardiac output, lowered body temperature (Bexis and Docherty,
2005), and had sedative effects (Hall et al., 2001). These sym-
patholytic effects of clonidine are opposite to the clinical effects
of sympathomimetic drugs, including MDMA. Therefore, cloni-
dine has been recommended in the treatment of MDMA intox-
ication (Green et al., 1995; Liechti, 2003), and it is routinely
used to control sympathetic activation during withdrawal from
drugs of abuse.
In rats, clonidine blocked the behavioral response and hip-
pocampal and prefrontal NE release after treatment with
cocaine or low doses of amphetamine (Florin et al., 1994;
Carey et al., 2008). Clonidine may therefore reduce stimu-
lant-induced NE release and the associated behavioral ef-
fects of psychostimulants and may even be used in the treat-
ment of stimulant addiction. In fact, clonidine prevented
amphetamine-induced psychomotor stimulation (Vander-
schuren et al., 2003), cue-induced cocaine seeking in rats
(Smith and Aston-Jones, 2011), and drug craving in cocaine
users (Jobes et al., 2011).
The effects of clonidine on the acute response to psycho-
stimulants have not yet been evaluated in humans. In the
present study, we assessed the interactive pharmacodynamic
effects of clonidine and MDMA in healthy subjects. We ex-
pected that clonidine would reduce the effects of MDMA in
humans to the extent that the clinical effects of MDMA are
mediated by the exocytotic release of NE.
Materials and Methods
Study Design. We used a double-blind, placebo-controlled, ran-
domized, crossover design with four experiential conditions (placebo-
placebo, clonidine-placebo, placebo-MDMA, and clonidine-MDMA) in
a balanced order. The washout periods between sessions were 10 to
14 days long. The study was conducted in accordance with the
Declaration of Helsinki and the International Conference on Harmo-
nization Guidelines on Good Clinical Practice and approved by the
Ethics Committee of the Canton of Basel, Switzerland. The use of
MDMA in healthy subjects was authorized by the Swiss Federal
Office of Public Health, Bern, Switzerland. The study was registered
at http://clinicaltrials.gov (NCT01136278).
Study Procedures. The subjects completed a screening session,
four test sessions, and an end-of-study visit. The test sessions were
conducted in a quiet hospital research ward with no more than two
research subjects present per session. Before undergoing the test
sessions, the subjects were asked about potential health problems.
Drug tests and urine tests to determine pregnancy were also per-
formed. An indwelling intravenous catheter was placed in the ante-
cubital vein for blood sampling. Clonidine (150 "g p.o.) or placebo
was administered at 8:00 AM. MDMA (125 mg p.o.) or placebo was
administered at 9:00 AM. A standardized lunch was served at 12:00
PM, and the subjects were sent home at 3:00 PM. Outcome measures
were assessed repeatedly before and after drug administration.
Subjects. Sixteen healthy subjects (eight men and eight women)
with a mean # S.D. age of 25.4 # 4.9 years were recruited on the
University of Basel campus. The exclusion criteria included the
following; 1) age$18 or%45 years, pregnancy determined by a urine
test before each test session; 2) body mass index $18.5 kg/m2 or %25
kg/m2; 3) personal or family (first-degree relative) history of psychi-
atric disorder (determined by the structured clinical interview for
Axis I and Axis II disorders according to the Diagnostic and Statis-
tical Manual of Mental Disorders, 4th edition (Wittchen et al., 1997)
supplemented by the SCL-90-R Symptom Checklist (Derogatis et al.,
1976; Schmitz et al., 2000), Freiburg Personality Inventory (Fahren-
berg et al., 1984), and Trait Scale of the State-Trait Anxiety Inven-
tory (STAI; Spielberger et al., 1970); 4) the regular use of medica-
tions; 5) chronic or acute physical illness assessed by physical
examination, electrocardiogram, standard hematology, and chemical
blood analyses; 6) smoking more than 10 cigarettes per day; 7) a
lifetime history of using illicit drugs more than five times, with the
exception of cannabis; 8) illicit drug use within the last 2 months;
and 9) illicit drug use during the study determined by urine tests
conducted before the test sessions by using TRIAGE 8 (Biosite, San
Diego, CA). The subjects were asked to abstain from excessive alco-
hol consumption between test sessions and limit alcohol use to one
glass on the day before each test session. All of the subjects were
nonsmokers. Twelve subjects had previously used cannabis. Five
subjects reported using illicit drugs once, in which one subject had
tried lysergic acid diethylamide, ecstasy, and psilocybin, two had
Fig. 1. Plasma concentration changes in norepinephrine (a) and epinephrine (b). Values are expressed as mean # S.E.M. changes from baseline in 16
subjects. a, MDMA increased the plasma level of norepinephrine. Clonidine prevented the MDMA-induced increase in norepinephrine but also reduced
the concentration of norepinephrine compared with placebo. b, the drug effects on plasma epinephrine levels were not significant.
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tried cocaine and psilocybin, one had tried ecstasy, and one had tried
psilocybin. All of the subjects were phenotyped for CYP2D6 activity
by using dextromethorphan as the probe drug. Eight extensive,
seven intermediate, and one poor CYP2D6 metabolizer were identi-
fied in the study. The female subjects were investigated during the
follicular phase (days 2–14) of their menstrual cycle when the reactivity to
amphetamines is expected to be similar to men (White et al., 2002). All of
the subjects provided theirwritten informed consentbeforeparticipating in
the study, and they were paid for their participation.
Drugs. (#)MDMA hydrochloride (C11H15NO2; Lipomed AG, Ar-
lesheim, Switzerland) was obtained from the Swiss Federal Office of
Public Health and prepared as gelatin capsules (100 and 25 mg).
Identical placebo (lactose) capsules were prepared. MDMA was ad-
ministered in a single absolute oral dose of 125 mg, corresponding to
a dose of 1.88 # 0.28 mg/kg body weight. Clonidine tablets (150 "g;
Catapresan; Boehringer Ingelheim GmbH, Basel, Switzerland) were
encapsulated within opaque gelatin capsules, and identical placebo
(lactose) capsules were prepared. Clonidine (150 "g) or placebo was
administered 1 h before MDMA (125 mg) or placebo administration.
Oral medication administration was supervised by study personnel.
Pharmacodynamic Measurements. Psychometric scales. Sub-
jective measures were assessed by using Visual Analog Scales (VAS)
(Hysek et al., 2011), the Adjective Mood Rating Scale (AMRS) (Janke
and Debus, 1978), the 5-Dimensions of Altered States of Conscious-
ness (5D-ASC) (Dittrich, 1998; Studerus et al., 2010), and the STAI
(Spielberger et al., 1970). VAS included any drug effect, good drug
effect, bad drug effect, drug liking, drug high, stimulated, tiredness,
closeness to others, and open (Farre´ et al., 2007; Tancer and Johan-
son, 2007; Kolbrich et al., 2008; Hysek et al., 2011). The VAS were
presented as 100-mm horizontal lines marked “not at all” on the left
and “extremely” on the right. The VAS for closeness to others and
open were bidirectional (# 50 mm). The VAS were administered 1 h
before and 0, 0.33, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 5 h after MDMA or
placebo administration. The 60-item Likert-type scale short version
of the AMRS (Janke and Debus, 1978) was administered 1 h before
and 1.25, 2, and 5 h after MDMA or placebo administration. The
AMRS contains subscales for activity, inactivation, extroversion and
introversion, well being, emotional excitation, anxiety-depression,
and dreaminess. The 5D-ASC rating scale measures alterations in
mood, perception, experience of self in relation to environment, and
thought disorder (Studerus et al., 2010). The 5D-ASC rating scale
comprises five subscales or dimensions (Dittrich, 1998) and 11 lower-
order scales (Studerus et al., 2010). The 5D-ASC dimension oceanic
boundlessness (27 items) measures derealization and depersonaliza-
tion associated with positive emotional states ranging from height-
ened mood to euphoric exaltation. The dimension anxious ego disso-
lution (21 items) summarizes ego disintegration and loss of self-
control, two phenomena associated with anxiety. The corresponding
lower-order scales included: disembodiment, impaired control of cog-
nition, and anxiety. The dimension visionary restructuralization (18
items) consists of the lower-order scales complex imagery, elemen-
tary imagery, audiovisual synaesthesia, and changed meaning of
percepts. The dimension auditory alterations (16 items) subsumes
auditory (pseudo) hallucinations, and the dimension vigilance reduc-
tion (12 items) describes states of drowsiness and impaired alertness
and cognitive performance. The global ASC score was determined by
adding the oceanic boundlessness, anxious ego dissolution, and vi-
sionary restructuralization scores. The 5D-ASC scale was adminis-
tered 4 h after MDMA or placebo administration. The STAI state-
anxiety subscale (Spielberger et al., 1970) was administered 1 h
before and 1.25, 2, and 5 h after MDMA or placebo administration.
Physiologic measures. Physiologic measures were assessed repeat-
edly 1 h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after
MDMA or placebo administration. Heart rate, systolic blood pressure
(SBP), and diastolic blood pressure (DBP) were measured by using
an OMRON M7 blood pressure monitor (OMRON Healthcare Eu-
rope, Hoofddorp, The Netherlands) in the dominant arm after a
resting time of 5 min. Measures were taken twice per time point with
an interval of 1 min, and the average was used for analysis. Core
(tympanic) temperature was assessed by using a GENIUS 2 ear
thermometer (Tyco Healthcare Group, Watertown, NY).
Adverse Effects. Adverse effects were assessed 1 h before and 3
and 24 h after MDMA or placebo administration by using the List of
Complaints (Zerssen, 1976; Hysek et al., 2011). The scale consists of
66 items that yield a total adverse effects score, reliably measuring
physical and general discomfort.
Laboratory Analyses. Samples of whole blood for the determina-
tion of MDMA and 3,4-methylenedioxyamphetamine (MDA;
C10H13NO2), the active metabolite of MDMA, were collected 1 h before
and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, and 6 h after MDMA or placebo
administration. Blood samples to determine concentrations of NE and
Fig. 2. Physiologic effects. Values are expressed as mean # S.E.M.
changes from baseline in 16 subjects. Clonidine was administered at t &
'1 h. MDMA was administered at t & 0 h. a, clonidine reduced the
MDMA-induced elevation in blood pressure to the same extent as it
reduced blood pressure compared with placebo. b and c, clonidine had no
significant effects on MDMA-induced elevations in heart rate (b) and
body temperature (c).
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epinephrine were taken at 1 h before and 1 and 2 h after MDMA or
placebo administration. All blood samples were collected on ice and
centrifugedwithin 10min at 4°C. The plasmawas then stored at'20°C
until analysis. The plasma levels of free catecholamines (NE and epi-
nephrine) were determined by high-performance liquid chromatogra-
phy (HPLC) with an electrochemical detector as described previously
(Hysek et al., 2011). The plasma concentrations of MDMA and MDA
were determined by usingHPLC coupled to tandemmass spectrometry.
The analytes were extracted by protein precipitation using methanol
(CH4O) that contained 0.1 "g/ml MDMA-d5 (C11H10D5NO2), MDA-d4
(C10H9D4,NO2) (both from Lipomed, Arlesheim, Switzerland), dulox-
etine-d7 (C18H12D7NOS; Toronto Research Chemicals Inc., North York,
ON, Canada), and pholedrine (C10H15NO) (Sigma, Buchs, Switzerland).
Chromatographic separation was performed on a Shimadzu HPLC sys-
tem (Shimadzu, Reinach, Switzerland) that consisted of a HTS PAL
autosampler (CTC Analytics, Zwingen, Switzerland), two Shimadzu
LC-20 AD pumps controlled by a Shimadzu CBM-20A unit, a Shimadzu
CTO-20AD column oven, and a six-port VICI valve (VICI, Schenkon,
Switzerland). A Chromolith SpeedROD RP-18e column (50 ( 4.6 mm;
VWR, Dietikon, Switzerland) was used for the separation of the ana-
lytes. Eluent A (0.1% formic acid in water) and eluent B (0.1% formic
acid in methanol) were used in the following gradient: 100% A for 0 to
1 min, 20 to 95% B for 1 to 4 min, 95% B for 4 to 5 min, and 100% A for
5 to 6 min. The mobile phases were delivered at a constant flow rate of
0.8 ml/min. The total run time was 6.0 min. The column oven was set at
35°C. The injection volumewas 10"l. Mass spectrometric detectionwas
performed by using a triple quadrupole mass spectrometer (API4000;
Applied Biosystems, Rotkreuz, Switzerland) operated in electrospray-
ionization positive-ion mode. The samples were quantified by using
peak area ratios. The assays were linear in the concentration range of
1 to 1000 ng/ml for MDMA and MDA. The performance of the method
was monitored by using quality-control samples at the lower limit of
quantification and at two or three concentrations. The interassay accu-
racy for the quality-control samples ranged from 97.5 to 100% for
MDMA and from 95.3 to 103% for MDA. Interassay precision values
ranged from 2.8 to 8.0% for MDMA and from 3.8 to 10.5% for MDA.
Pharmacokinetics and Pharmacokinetic-Pharmacodynamic
Modeling. Pharmacokinetics. The data for the plasma concentra-
tions of MDMA andMDAwere analyzed by using noncompartmental
methods. Maximal plasma concentration (Cmax) and time to Cmax
were obtained directly from the concentration-time curves of the
observed values. The terminal elimination rate constant ()z) for
MDMA was estimated by log-linear regression after semilogarithmic
transformation of the data, using the last two to three data points of
the terminal linear phase of the concentration-time curve of MDMA.
The terminal elimination half-life (t1/2) was calculated by using )z
and the equation t1/2 & ln2/)z. The area under the plasma concen-
tration-time curve (0–6 h) was calculated by using the linear trap-
ezoidal rule. Plasma concentrations were determined only up to 6 h
after MDMA administration, because the aim of the study was to
assess potential changes in plasma levels of MDMA during the time
of the pharmacodynamic effects of MDMA. Determining the t1/2 for
MDA was not possible, because of its long t1/2, which would require
an extended sampling time.
PK-PD modeling. We evaluated the in vivo relationship between
the MDMA concentration and the effect of MDMA on mean arterial
TABLE 1
Mean # S.E.M. values and statistics of pharmacodynamic effects
Values are expressed as mean # S.E.M. changes from baseline of 16 subjects.
Placebo-Placebo Clonidine-Placebo Placebo-MDMA Clonidine-MDMA F3,45 p
Mean # S.E.M.
Circulating catecholamines
Epinephrine, nM Emax 0.01 # 0.02 '0.02 # 0.03† 0.17 # 0.05 0.12 # 0.03 4.16 $0.05
Norepinephrine, nM Emax '0.24 # 0.10 '0.52 # 0.10**†† 0.41 # 0.06** '0.04 # 0.08†† 22.72 $0.001
Physiologic effect
SBP, mm Hg Emax 5.4 # 3.1 '5.8 # 2.2**††† 36.6 # 2.48*** 27.5 # 3.3*** 52.87 $0.001
AUEC0–6 736.8 # 16.0 654.2 # 21.5***††† 840.3 # 17.1*** 807.5 # 18.4***† 98.25 $0.001
DPB, mm Hg Emax 3.0 # 1.8 '4.5 # 2.5††† 20.8 # 2.2*** 15.3 # 2.4*** 26.48 $0.001
AUEC0–6 438.2 # 9.7 371.9 # 12.3***††† 505.8 # 9.9*** 479.7 # 10.8***† 93.35 $0.001
MAP, mm Hg Emax 2.2 # 1.7 '6.4 # 1.9*††† 25.0 # 2.2*** 18.2 # 2.5*** 49.97 $0.001
AUEC0–6 537.7 # 10.5 466.0 # 14.7***††† 616.9 # 11.0*** 589.0 # 12.0***† 104.89 $0.001
Heart rate, beats/min Emax 2.8 # 2.5 5.9 # 2.9 26.0 # 3.2*** 25.0 # 5.6*** 15.03 $0.001
AUEC0–6 402.3 # 13.9 389.6 # 12.4††† 472.3 # 15.7*** 460.0 # 17.5*** 22.16 $0.001
Body temperature, °C Emax 0.7 # 0.1 0.4 # 0.1† 0.9 # 0.1 0.9 # 0.2 3.50 $0.05
AUEC0–6 222.3 # 0.7 221.7 # 0.6 223.0 # 0.6 223.2 # 0.6 3.61 $0.05
Visual Analog Scale (%max)
Any drug effect Emax 0.9 # 0.9 16.8 # 6.2††† 89.6 # 4.0*** 81.56 # 6.9*** 87.55 $0.001
Good drug effect Emax 0.0 # 0.0 3.2 # 1.7††† 91.8 # 4.4*** 79.94 # 7.2*** 160.10 $0.001
Bad drug effect Emax 0.0 # 0.0 2.6 # 2.2† 21.6 # 5.8** 25.56 # 6.6** 8.36 $0.001
Drug liking Emax 0.0 # 0.0 2.4 # 2.1††† 91.1 # 4.6*** 80.94 # 6.8*** 154.30 $0.001
Drug high Emax 0.0 # 0.0 0.6 # 0.4††† 85.6 # 6.7*** 75.38 # 8.0*** 95.74 $0.001
Stimulated Emax 0.0 # 0.0 0.4 # 0.4††† 70.7 # 7.9*** 64.38 # 9.3*** 46.76 $0.001
Tiredness Emax 24.7 # 6.7 62.8 # 8.1††† 55.4 # 7.2** 53.81 # 7.4* 7.16 $0.001
Closeness to others Emax 0.4 # 0.4 0.0 # 0.0††† 23.4 # 4.6*** 24.06 # 4.7*** 20.35 $0.001
Open Emax 0.0 # 0.0 0.0 # 0.0††† 30.3 # 4.4*** 30.2 # 4.9*** 33.71 $0.001
Adjective Mood Rating Scale (score)
Emotional excitation Emax '1.0 # 0.7 -0.3 # 0.5††† 4.5 # 1.1*** 4.6 # 0.9*** 15.98 $0.001
Well being Emax 0.8 # 0.9 '0.4 # 1.0††† 6.4 # 1.5** 6.5 # 1.1** 13.69 $0.001
Extroversion Emax 1.6 # 0.5 '0.8 # 0.4*††† 3.3 # 0.7 3.9 # 0.8* 13.59 $0.001
Dreaminess Emax 0.6 # 0.5 1.9 # 0.6†† 4.5 # 0.6*** 3.4 # 0.7** 13.64 $0.001
Activity Emax 0.4 # 0.6 '0.9 # 1.0 2.1 # 1.5 3.4 # 1.0 4.68 $0.01
Inactivation Emax 1.9 # 1.4 10.7 # 2.0** 8.8 # 2.3* 7.9 # 1.8* 6.07 $0.01
Anxiety-depression Emax '0.4 # 0.4 0.4 # 1.6 0.8 # 0.4 2.1 # 0.7** 4.98 $0.01
State-Trait Anxiety Inventory (state scale score)
Emax 0.1 # 1.4 0.6 # 1.2 3.7 # 1.7 4.8 # 2.1 3.23 $0.05
List of Complaints (total score)
Acute adverse effects at 3 h 0.6 # 0.8 1.2 # 0.6††† 10.3 # 1.7*** 12.7 # 1.9*** 24.48 $0.001
Subacute adverse effects at 24 h '1.1 # 0.6 0.1 # 0.6 2.1 # 1.2* 3.9 # 1.3*** 7.08 $0.001
* P $ 0.05; ** P $ 0.01; *** P $ 0.001, compared with placebo-placebo.
† P $ 0.05; †† P $ 0.01; ††† P $ 0.001, compared with placebo-MDMA.
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pressure (MAP) by using a soft-link PK-PD model (Meibohm and
Derendorf, 1997). Blood pressure and plasma concentrations were
assessed at the same time points. Because we observed clockwise
hysteresis in the effect-concentration relationship over time, we used
PK-PD data pairs within the ascending part of the individual curves
up to the maximal effect (Emax) or Cmax. Our estimation of Emax,
which should represent the maximal response portion of the dose-
response curve, may already have been affected by acute tolerance.
However, Emax values of 100% (scale maximum) or stable high values
were reached by most subjects despite possible tolerance. Based on
the good brain penetration of MDMA and absence of a time lag, we
assumed rapid equilibration between the plasma and central com-
partment (brain). A sigmoidal dose-response (variable slope) model
was fitted to the pooled data of all individuals: E & Emax/(1 *
10
(logEC50'Cp) ( h
) in which E is the observed effect, Cp is the plasma
MDMA concentration, EC50 is the plasma concentration at which
50% of the maximal effect is reached, Emax is the maximal effect, and
h is the Hill slope. The sigmoidal dose-response model provided the
best fit to the data and a better fit than a simple Emax or linear
model. Data pooling was used because only a few data pairs were
available for each subject. Nonlinear regression was used to obtain
parameter estimates.
Statistical Analyses. Values were transformed to differences
from baseline. The Emax and AUEC values were determined for
repeated measures and compared by one-way General Linear Models
repeated-measures analysis of variance (ANOVA) with drug treat-
ment as a factor, using STATISTICA 6.0 software (StatSoft, Tulsa,
OK). Tukey post hoc comparisons were performed based on signifi-
cant main effects of treatment. Additional two-way ANOVAs with
the two drug factors, MDMA (MDMA versus placebo) and clonidine
(clonidine versus placebo), were used to test for interactive versus
additive effects of the two drugs on physiological measures or blood
levels of catecholamines. Additional ANOVAs were performed, with
drug order as an additional factor, to exclude carryover effects. The
criterion for significance was p $ 0.05. Mean arterial pressure was
calculated from DBP and SBP by using the formula MAP & DBP *
(SBP ' DBP)/3.
Results
Neuroendocrine and Cardiovascular Effects. MDMA
increased the level of circulating NE, an endocrine marker of
sympathetic nervous system activation, and elevated blood
pressure and heart rate compared with placebo (Figs. 1a and 2,
a and b; Table 1). Clonidine prevented the MDMA-induced
increase in plasma NE (Fig. 1a; Table 1). It also attenuated the
blood pressure response to MDMA, although reflected only by
the AUEC and not Emax (Fig. 2a; Table 1). Clonidine also
decreased the level of circulating NE and blood pressure com-
pared with placebo to a similar extent as the reduction in NE
and pressure elevations induced by MDMA (Figs. 1a and 2;
Table 1). Additional ANOVAswith the two drug factors,MDMA
and clonidine, yielded significant main effects of MDMA and
clonidine on Emax values of MAP (F1,15 & 106.1 and 18.1, re-
spectively; both p $ 0.001) but no MDMA ( clonidine interac-
tion (F1,15 & 0.2; p & 0.7), which is consistent with an additive
effect of the two drugs. Likewise, the ANOVA of NE levels
showed significantmain effects ofMDMAand clonidine (F1,15&
Fig. 3. Time course of subjective VAS ratings. Values are expressed as mean # S.E.M. of percentage of maximal values in 16 subjects. MDMA
increased scores on all scales. Although clonidine produced tiredness, it only weakly and nonsignificantly affected the pronounced subjective responses
to MDMA.
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41.5 and 34.2, respectively; both p $ 0.001) but no MDMA (
clonidine interaction (F1,15 & 0.0; p & 1). The circulating levels
of epinephrine were not significantly altered by the drugs, and
clonidine did not affect the increase in heart rate produced by
MDMA (Fig. 2b; Table 1).
Psychotropic Effects. Overall, clonidine had no effect on
the psychotropic response to MDMA. It did not significantly
affect the MDMA-induced increases in VAS ratings of sub-
jective effects or AMRS scores (Figs. 3 and 4; Table 1), al-
though it weakly but nonsignificantly attenuated good drug
effect, drug liking, and drug high produced by MDMA (Fig.
3). Clonidine alone increased the VAS score for tiredness and
the AMRS score for inactivation compared with placebo
(Figs. 3 and 4; Table 1). Clonidine had no effect on the robust
changes produced by MDMA on the 5D-ASC rating scale
(Fig. 5). Neither clonidine nor MDMA altered the state anx-
iety scale scores on the STAI (Table 1).
Adverse Effects. MDMA increased the total adverse ef-
fects score on the List of Complaints both 3 and 24 h after
administration compared with placebo (Table 1). The adverse
effects of clonidine and MDMA were additive (Table 1). Thus,
clonidine did not affect the untoward effects of MDMA. The
frequently reported adverse effects of MDMA included a lack
of appetite (n & 11), restlessness (n & 11), thirst (n & 10),
sweating (n & 8), and bruxism (n & 8). Tiredness was typi-
cally reported after administration of clonidine-placebo and
clonidine-MDMA (n & 11 and 10, respectively). No severe
adverse effects were reported.
Pharmacokinetics and PK-PD Relationship. Cloni-
dine did not affect the plasma concentration-time curves of
MDMA or MDA (Fig. 6, a and b; Table 2). The pharmacoki-
netic parameters of MDMA did not depend on CYP2D6 phe-
notype. However, the sample was small, and only one subject
was a poor metabolizer. Figure 6, c and d shows the effects of
MDMA on blood pressure in terms of plasma concentration.
The hysteresis loop shows that the MDMA-induced changes
in MAP returned to baseline within 6 h when MDMA con-
centrations were still high (clockwise hysteresis), which is
consistent with acute pharmacodynamic tolerance (Fig. 6c).
Clonidine reduced the MDMA-induced blood pressure re-
sponse for all MDMA plasma concentrations, which is re-
flected by a downward shift in the concentration-pressure
effect curve of MDMA (Fig. 6c). This shift was similar to the
blood pressure-lowering effect of clonidine alone compared
with placebo. Thus, the effects of the drugs were additive.
Clonidine did not affect the EC50 value of the concentration-
pressure effect curve of MDMA (Fig. 6d).
Discussion
In the present study, the !2-adrenergic receptor agonist
clonidine reduced the elevations in the plasma concentration
of NE and increases in blood pressure in response to MDMA.
However, clonidine decreased plasma NE levels and blood
pressure to a similar extent as the decreases in the response
to MDMAwhen its effects were compared with placebo. Thus,
the sympatholytic effects of clonidine and the sympathomimetic
effects of MDMAwere additive with no interaction between the
effects of MDMA and clonidine on the noradrenergic system. In
addition, clonidine did not affect the psychotropic effects of
MDMA, although clonidine was used in this study in a rela-
tively high single dose that produced sympatholytic effects,
including lower plasma NE levels, decreased blood pressure,
and sedation on all psychometric scales compared with placebo,
Fig. 4. Mood effects in the AMRS. Values are expressed as mean # S.E.M. of AMRS score changes from baseline in 16 subjects. MDMA produced emotional
excitation, well being, extroversion, and dreaminess. It increased activity at the beginning of the session and inactivation toward the end of the session. Clonidine
produced inactivation but did not affect responses to MDMA on any of the scales.
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which are findings consistent with previous studies (Kera¨nen et
al., 1978; Anavekar et al., 1982).
We used the sympatholytic drug clonidine to block the
MDMA-induced impulse-dependent vesicular release of NE
(Florin et al., 1994). The fact that clonidine did not interact
with the clinical effects of MDMA in the present study indi-
cates that the vesicular release of NE is not involved in the
mediation of the effects of MDMA in humans. The finding
indirectly supports the view that the effects of MDMA in
humans primarily depend on the transporter-mediated re-
lease of NE, 5-HT, and possibly dopamine (Liechti et al.,
2000; Hysek et al., 2011). A preclinical study that used
microdialysis in rats showed that clonidine reduced the NE
response only to a low dose of amphetamine, but clonidine
became less effective as the dose of amphetamine in-
creased (Florin et al., 1994). This result suggests that
amphetamine acts primarily as a transporter-mediated
NE releaser at higher doses (Florin et al., 1994). In con-
trast to our study, clonidine prevented behavior relevant to
stimulant addiction, including amphetamine-induced psy-
chomotor stimulation (Vanderschuren et al., 2003), cue-
induced cocaine seeking in rats (Smith and Aston-Jones,
2011), and drug craving in cocaine users (Jobes et al.,
2011). Altogether, the previous preclinical studies and our
clinical findings indicate that amphetamines, including
MDMA, do not increase NE impulse flow and their action
in humans depends on transporter-mediated monoamine
release that is not altered by clonidine.
The pharmacokinetic and other pharmacodynamic interac-
tions between clonidine and MDMA need to be considered
in the interpretation of the present findings. First, MDMA
metabolism involves CYP2D6-mediated O-demethylation to
3,4-dihydroxymethamphetamine and N-demethylation to MDA
by CYP2B6 and CYP3A4 (Segura et al., 2005). Clonidine is
not known to affect cytochrome P450 function. As expected,
clonidine did not alter the plasma-concentration time curves
for MDMA or MDA in the present study. Second, both cloni-
dine andMDMA bind to !2-adrenergic receptors (Battaglia et
al., 1988; Lavelle et al., 1999), and some !2 agonistic actions
in the peripheral NE system have been documented for
MDMA in vitro (Lavelle et al., 1999). However, in contrast to
clonidine, MDMA increased plasma NE levels and blood
pressure in the present and previous studies (Dumont et al.,
2009; Hysek et al., 2011), indicating that the !2 agonistic
effects of MDMA are not relevant for its main action in
humans or are outweighed by the transporter-mediated re-
lease of NE and other monoamines.
Our study has a few limitations. First, only single doses of
MDMA and clonidine were used. A dose-response study was
not feasible because we did not want to expose our subjects to
more than two doses of MDMA in a crossover design. The
doses of both drugs were selected in the upper dose range,
and both drugs produced marked effects. Unknown is
whether clonidine affects the response to low doses of
MDMA. Second, the clinical effects of clonidine may be at-
tributable to actions at other binding sites. For example,
clonidine binds to the imidazoline binding site with very high
affinity (Buccafusco et al., 1995), and this binding site is also
involved in the mediation of the pressure-lowering effects of
clonidine (Ernsberger et al., 1990).
Fig. 5. 5D-ASC scale. Values are expressed as mean # S.E.M. in 16 subjects. MDMA markedly increased scores on the oceanic boundlessness (OB),
anxious ego dissolution (AED), visionary restructuralization (VR), and vigilance reduction (VIR) dimensions and on most subscales compared with
placebo (!, p $ 0.05; !!, p $ 0.01; !!!, p $ 0.001). Clonidine did not change MDMA’s effect on any of the ASC dimensions and reduced MDMA’s effect
on only one of the subscales (#, p $ 0.05). The main effects of the drug in the analysis of variance were significant for the sum score and all dimensions
of the scale [F3,45 & 26.96, 25.52, 9.70, 20.49, 5.20, and 13.70 for the ASC sum score, OB, AED, VR, auditory alterations (AA), and VIR, respectively;
all p $ 0.001 with the exception of VIR, p $ 0.01].
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The present study further characterized the pharmacody-
namic and pharmacokinetic effects of a single dose of 125 mg
of MDMA in healthy male and female subjects with no or only
single previous MDMA use. MDMA produced cardiovascular-
stimulant effects, positive mood, emotional stimulation, and
extroversion, confirming previous studies in healthy subjects
(Liechti et al., 2000; Dumont and Verkes, 2006; Hysek et al.,
2010, 2011) and MDMA users (Farre´ et al., 2007; Tancer and
Johanson, 2007; Kolbrich et al., 2008). The study documented
the phenomenon of rapid acute tolerance to the effects of
MDMA. The Emax in blood pressure was observed within 60
to 120 min, and Cmax was reached within 120 to 180 min after
MDMA administration. In addition, the plasma levels ofMDMA
remained close to Cmax for several hours, whereas the pharmaco-
dynamic effects returned to baseline more rapidly. Furthermore,
half-maximal effects (EC50) of MDMA on blood pressure were
observed at plasma concentrations of MDMA of approximately 50
ng/ml, which was 4-fold lower than the Cmax of MDMA. Acute
tolerance to the effects of psychostimulant drugs, including
MDMA, cocaine, and nicotine, has been described previously (Van
Dyke et al., 1978; Porchet et al., 1987; Hysek et al., 2011). This
pharmacodynamic tolerance could be attributable to receptor or
transporter down-regulation or desensitization (Meibohm and
Derendorf, 1997; Robertson et al., 2009), the more rapid distribu-
tion of drug to the brain than to venous blood (Porchet et al., 1987),
or the functional depletion of presynaptic monoamine stores so
that no more transmitter can be released despite high concentra-
tions of MDMA.
In summary, our findings support the hypothesis that the
Fig. 6. a and b, pharmacokinetics of MDMA (a) and MDA (b). The values are expressed as mean # S.E.M. in 16 subjects. Clonidine was administered
at t & '1 h, and MDMA was administered at t & 0 h. c, MDMA effects on blood pressure plotted against simultaneous plasma MDMA concentrations.
The values are expressed as the means of the changes from baseline in 16 subjects, with S.E.M. values omitted for clarity. The time of sampling is noted
next to each point in minutes or hours after MDMA administration. Clonidine produced a downward shift in the pressure response-concentration curve
of MDMA. The magnitude of the shift was similar to the pressure-lowering effect of clonidine alone compared with placebo. d, PK-PD relationship.
Values are expressed as individual MDMA concentration-effect data pairs for ascending concentrations for placebo-MDMA (black squares) and
clonidine-MDMA (gray circles). Notice the large interindividual variance in the response to MDMA. The solid lines show the fit of a sigmoid Emax model
to the pooled observed data. Dashed lines indicate 95% confidence intervals of the estimation error. Clonidine produced a downward shift of the
concentration-pressure effect curve of MDMA, indicating that it reduced the effect of MDMA at all concentrations. The magnitude of the downward
shift was similar to the blood pressure-lowering effect of clonidine compared with placebo. Thus no interaction effect was found between clonidine and
MDMA on blood pressure, and the effects of the two drugs were additive. Clonidine did not affect the EC50 value of the concentration-pressure effect
curve of MDMA. The EC50 values (mean 95% confidence interval) were 44 ng/ml (14–74 ng/ml) and 66 ng/ml (41–91 ng/ml) for placebo-MDMA and
clonidine-MDMA, respectively.
TABLE 2
Pharmacokinetic parameters of MDMA and MDA
Values are expressed as mean # S.E.M. of 16 healthy subjects.
Cmax tmax t1/2 AUC0–6
ng/ml h ng/ml ! h
MDMA
Placebo-MDMA 238 # 10 2.5 # 0.2 7.7 # 0.7 1021 # 35
Clonidine-MDMA 231 # 11 2.5 # 0.1 9.4 # 0.9 1032 # 51
MDA
Placebo-MDMA 10.9 # 0.7 5.2 # 0.3 N.A. 42.3 # 3.1
Clonidine-MDMA 11.2 # 0.8 5.1 # 0.4 N.A. 44.3 # 3.4
tmax, time to maximum plasma concentration; t1/2, terminal elimination half-life;
AUC, area under the plasma concentration-time curve; N.A., not assessed.
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effects of MDMA in humans do not depend on the vesicular
release of NE but on transporter-mediated monoamine re-
lease. The clinical implications of the present study are that
clonidine could be of limited use in the treatment of hyper-
tensive reactions in psychostimulant users. In contrast, the
lack of an effect of clonidine on the euphoria produced by
MDMA does not indicate a role for !2-adrenergic receptor
agonists in the prevention of psychostimulant dependence,
despite their utility in the treatment of withdrawal from
drugs of abuse.
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BACKGROUND AND PURPOSE
The use of !3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is associated with cardiovascular complications and
hyperthermia.
EXPERIMENTAL APPROACH
We assessed the effects of the a1- and b-adrenoceptor antagonist carvedilol on the cardiostimulant, thermogenic and
subjective responses to MDMA in 16 healthy subjects. Carvedilol (50 mg) or placebo was administered 1 h before MDMA
(125 mg) or placebo using a randomized, double-blind, placebo-controlled, four-period crossover design.
KEY RESULTS
Carvedilol reduced MDMA-induced elevations in blood pressure, heart rate and body temperature. Carvedilol did not affect
the subjective effects of MDMA including MDMA-induced good drug effects, drug high, drug liking, stimulation or adverse
effects. Carvedilol did not alter the plasma exposure to MDMA.
CONCLUSIONS AND IMPLICATIONS
a1- and b-Adrenoceptors contribute to the cardiostimulant and thermogenic effects of MDMA in humans but not to its
psychotropic effects. Carvedilol could be useful in the treatment of cardiovascular and hyperthermic complications associated
with ecstasy use.
Abbreviations
AUC, area under the concentration–time curve; Cmax, maximal plasma concentration; CYP, cytochrome P450; 5D-ASC,
5-Dimensions of Altered States of Consciousness; Emax, maximal effect; MDA, !3,4-methylenedioxyamphetamine;
MDMA, !3,4-methylenedioxymethamphetamine; VAS, Visual Analogue Scale
Introduction
!3,4-Methylenedioxymethamphetamine (MDMA, ‘ecstasy’)
is widely abused for its euphoric effects. The use of ecstasy is
associated with hyperthermia (Henry et al., 1992; Liechti
et al., 2005; Halpern et al., 2011). MDMA-induced hyperther-
mia is a life-threatening disorder that may lead to rhabdomy-
olysis, disseminated intravascular coagulation, acute hepatic
and renal failure and death (Henry et al., 1992; Liechti et al.,
2005). Severe hyperthermia has typically been observed when
ecstasy is used in crowded clubs, at high ambient tempera-
tures or during physical activity (Henry et al., 1992; Parrott,
2012). In laboratory animals, crowding, high ambient tem-
perature, reduced water consumption and repeated dosing
similarly enhanced MDMA-induced hyperthermia (Dafters,
1995; Docherty and Green, 2010). However, MDMA also
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elevates body temperature under controlled laboratory con-
ditions in humans in the absence of permissive factors
(Liechti et al., 2001; Freedman et al., 2005; Dumont and
Verkes, 2006; Parrott, 2012). The clinical treatment of sym-
pathomimetic amphetamine toxicity is mainly supportive
and includes volume repletion and sedation with benzodi-
azepines (Liechti et al., 2005; Halpern et al., 2011). The man-
agement of severe MDMA-related hyperpyrexia includes
cooling and ventilation (Hall and Henry, 2006). Dantrolene,
which acts peripherally at skeletal muscles to inhibit release
of calcium from the sarcoplasmic reticulum, has also been
used (Green et al., 1995; Hall and Henry, 2006; Grunau et al.,
2010). However, dantrolene does not inhibit the thermogenic
effects of MDMA (Rusyniak et al., 2004) and the drug does not
specifically interfere with the presumed mechanism of
MDMA-induced hyperthermia. MDMA mainly releases 5-HT,
NA and dopamine (Rudnick and Wall, 1992; Liechti and
Vollenweider, 2001; Verrico et al., 2007). Stimulation of both
a1- and b3-adrenoceptors has been implicated in the ther-
mogenic effects of MDMA (Sprague et al., 2004a; 2005). Spe-
cifically, increasing NA levels through the inhibition of
phenylethanolamine N-methyltransferase potentiated the
hyperthermic effects of MDMA in rats (Sprague et al., 2007).
Combined pretreatment with the a1-adrenoceptor antagonist
prazosin plus the b3-adrenoceptor antagonist SR59230A
attenuated MDMA-induced elevations in core body tempera-
ture and creatine kinase levels in rats (Sprague et al., 2004a).
The a1 and b1,2,3 antagonist carvedilol similarly prevented the
hyperthermic response to MDMA in rats (Sprague et al.,
2005). Moreover, carvedilol reversed established hyperther-
mia when it was administered 1 h after MDMA (Sprague et al.,
2005). Selective inhibition of b3 receptors with low concen-
trations of SR59230A attenuated the slowly developing late
hyperthermic response to MDMA, suggesting a role for b3
receptors in this late response in mice (Bexis and Docherty,
2008). In contrast, a1 blockade with prazosin induced an
early hypothermic reaction to MDMA, consistent with a role
for a1-receptors in this early response to MDMA in mice
(Bexis and Docherty, 2008). Finally, mice deficient in uncou-
pling protein 3, which is regulated by NA, were protected
against the hyperthermic effects of MDMA (Mills et al., 2003)
and methamphetamine (Sprague et al., 2004b). Altogether,
the preclinical data suggest that MDMA-induced hyperther-
mia results from noradrenergic activation of mitochondrial
uncoupling that involves both a1- and b3-adrenoceptors
(Mills et al., 2004; Rusyniak et al., 2005). Additionally,
a1-receptors contribute to the vasoconstriction of skin blood
vessels, impairing heat dissipation, which enhances hyper-
thermia induced by MDMA (Pedersen and Blessing, 2001).
Psychostimulants, including MDMA, also produce hyper-
tension and tachycardia. Myocardial ischaemia and stroke are
complications of the sympathomimetic action of cocaine and
ecstasy (Brody et al., 1990; Liechti et al., 2005; Bruggisser
et al., 2010; Halpern et al., 2011). Selective b-adrenoceptor
blockers are commonly used in the treatment of myocardial
infarction or acute hypertension but are not recommended if
psychostimulants are involved because of the risk of unop-
posed a1-receptor stimulation (Hoffman, 2008). Indeed,
propranolol potentiated cocaine-induced coronary vasocon-
striction (Lange et al., 1990) and worsened cocaine-associated
hypertension (Ramoska and Sacchetti, 1985). b blockade also
did not affect the blood pressure response to MDMA (Hysek
et al., 2010). In contrast, a- and b-adrenoceptor blockade with
labetalol (Boehrer et al., 1993; Sofuoglu et al., 2000b) and
carvedilol (Sofuoglu et al., 2000a) dose-dependently pre-
vented the haemodynamic response to cocaine in humans.
Labetalol also had no negative effect on cocaine-induced
coronary vasoconstriction (Boehrer et al., 1993). Combined
a- and b-blockers may therefore be the treatment of choice
for stimulant-associated hypertension and myocardial ischae-
mia.
Because carvedilol has been shown to prevent MDMA-
induced hyperthermia and rhabdomyolysis in rats (Sprague
et al., 2005) and the cardiostimulant response to cocaine in
humans (Sofuoglu et al., 2000a), we evaluated the effects of
carvedilol on the cardiovascular and hyperthermic response
to MDMA in healthy subjects.
Methods
Study design
We used a double-blind, double-dummy placebo-controlled,
randomized, crossover study design with four experiential
conditions (placebo-placebo, carvedilol-placebo, placebo-
MDMA and carvedilol-MDMA) in a balanced order. The
washout periods between the sessions were at least 10 days.
The study was conducted at the University Hospital of Basel
in accordance with the Declaration of Helsinki and Interna-
tional Conference on Harmonization Guidelines on Good
Clinical Practice and approved by the Ethics Committee of
the Canton of Basel, Switzerland, and Swiss Agency for Thera-
peutic Products (Swissmedic). The use of MDMA in healthy
subjects was authorized by the Swiss Federal Office of Public
Health. The study was registered at ClinicalTrials.gov
(NCT01270672). The reduction in the MDMA-induced
increase in blood pressure by carvedilol was the predefined
primary outcome of this clinical trial.
Study procedures
The subjects completed a screening visit, four test sessions
and an end-of-study visit. The test sessions were conducted in
a quiet hospital research ward with no more than two
research subjects present per session. The mean (SD) room
temperature was 23.3°C (0.7°C). At the beginning of each test
session, an indwelling i.v. catheter was placed in the antecu-
bital vein for blood sampling. Carvedilol (50 mg) or placebo
was administered at 8 h 00 min. MDMA (125 mg) or placebo
was administered at 9 h 00 min. A standardized lunch was
served at 12 h 00 min, and the subjects were sent home at 15
h 00 min.
Subjects
Sixteen healthy subjects (eight men, eight women) with a
mean (SD) age of 24.2 (2.2) years and a mean body weight of
67 (13) kg were recruited from the university campus. The
allocation to treatment order was performed by drawing from
blocks of eight different balanced drug treatment sequences
by two pharmacists not involved in the study. Each code was
stored in a sealed envelope until the termination of the study.
Data from all 16 subjects were available for the final analysis.
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The exclusion criteria included the following: (i) age <18 or
>45 years; (ii) pregnancy determined by a urine test before
each test session; (iii) body mass index <18.5 kg·m-2 or
>25 kg·m-2; (iv) personal or family (first-degree relative)
history of psychiatric disorder [determined by the structured
clinical interview for Axis I and Axis II disorders according to
the Diagnostic and Statistical Manual of Mental Disorders, 4th
edition (Wittchen et al., 1997) supplemented by the SCL-90-R
Symptom Checklist (Derogatis et al., 1976; Schmitz et al.,
2000)]; (v) regular use of medications; (vi) chronic or acute
physical illness assessed by physical examination, electrocar-
diogram, standard haematology and chemical blood analy-
ses; (vii) smoking more than seven cigarettes per day; (viii) a
lifetime history of using illicit drugs more than five times,
with the exception of cannabis; (ix) illicit drug use within the
last 2 months; and (x) illicit drug use during the study, deter-
mined by urine tests conducted before the test sessions using
TRIAGE 8 (Biosite, San Diego, CA, USA). The subjects were
asked to abstain from excessive alcohol consumption
between test sessions and limit alcohol use to one glass on the
day before each test session. All of the subjects were non-
smokers. All of the subjects, with the exception of one, had
previously used cannabis. Four subjects reported using illicit
drugs, in which three subjects had tried amphetamine once
and one had tried ecstasy once and amphetamine three
times. All of the subjects were phenotyped for cytochrome
P450 (CYP) 2D6 activity using dextromethorphan as the
probe drug. Nine extensive, six intermediate and one poor
CYP2D6 metabolizer were identified in the study. The female
subjects were investigated during the follicular phase (day
2–14) of their menstrual cycle when the reactivity to
amphetamines is expected to be similar to men (White et al.,
2002). All of the subjects provided their written informed
consent before participating in the study, and they were paid
for their participation.
Drugs
!MDMA hydrochloride (Lipomed AG, Arlesheim, Switzer-
land) was prepared as gelatine capsules (100 and 25 mg of the
salt). Identical placebo (lactose) capsules were prepared.
MDMA was administered in a single oral dose of 125 mg,
corresponding to a dose of 1.93 ! 0.36 mg·kg-1 body weight.
Carvedilol tablets (50 mg, Dilatrend, Roche Pharma AG,
Basel, Switzerland) were encapsulated within opaque gelatine
capsules, and identical placebo (lactose) capsules were pre-
pared. An oral dose of carvedilol (50 mg) was used that has
previously been shown to attenuate the smoked cocaine-
induced increases in heart rate and blood pressure in humans
(Sofuoglu et al., 2000a). At this dose, carvedilol is expected to
inhibit both a1- and b-adrenoceptors (Tham et al., 1995;
Sofuoglu et al., 2000a). Carvedilol or placebo was adminis-
tered 1 h before MDMA or placebo administration so that the
maximal plasma concentration (Cmax) of carvedilol was
reached (Morgan, 1994) shortly before the Cmax of MDMA
occurred. Oral medication administration was supervised by
study personnel.
Pharmacodynamic measurements
Vital signs. Vital signs were assessed repeatedly 1 h before
and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5 and 6 h after MDMA or
placebo administration. Heart rate, systolic blood pressure
and diastolic blood pressure were measured using an OMRON
M7 blood pressure monitor (Omron Healthcare Europe,
Hoofddorp, The Netherlands) in the dominant arm after a
resting time of 5 min. Measures were taken twice per time
point with an interval of 1 min, and the average was used for
analysis. Core (tympanic) temperature was assessed using a
GENIUS 2 ear thermometer (Tyco Healthcare Group, Water-
town, NY, USA).
Plasma catecholamines. Blood samples to determine the con-
centrations of NA and adrenaline were taken 1 h before and 1
and 2 h after MDMA or placebo administration. All of the
blood samples were collected on ice and centrifuged within
10 min at 4°C. The plasma was then stored at -20°C until
analysis. The plasma levels of free catecholamines (NA and
adrenaline) were determined by HPLC with an electrochemi-
cal detector as described previously (Hysek et al., 2011).
Psychometric scales. Subjective measures were repeatedly
assessed using Visual Analogue Scales (VASs; (Hysek et al.,
2011) 1 h before and 0, 0.33, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5 and 6 h
after MDMA or placebo administration. The VASs included
‘any drug effect’, ‘good drug effect’, ‘bad drug effect’, ‘drug
liking’, ‘drug high’ and ‘stimulated’ (Farre et al., 2007; Kol-
brich et al., 2008; Hysek et al., 2011). The VASs were presented
as 100-mm horizontal lines marked ‘not at all’ on the left and
‘extremely’ on the right. Additionally, the 5-Dimensions of
Altered States of Consciousness Scale [5D-ASC; (Dittrich,
1998; Studerus et al., 2010)] was applied 4 h after MDMA or
placebo administration. The 5D-ASC rating scale measures
alterations in mood, perception and experience of self in
relation to the environment and thought disorder (Studerus
et al., 2010). The 5D-ASC dimension ‘oceanic boundlessness’
(27 items) measures derealization and depersonalization asso-
ciated with positive mood. The dimension ‘anxious ego dis-
solution’ (21 items) summarizes ego disintegration and loss of
self-control, phenomena associated with anxiety. The dimen-
sion ‘visionary restructuralization’ (18 items) describes per-
ceptual alterations. Two other dimensions of the scale were
not used in our study. The total ASC score was determined by
adding the scores of the three dimensions.
Adverse effects. Adverse effects were assessed 1 h before and 3
and 24 h after MDMA or placebo administration using the
List of Complaints (Zerssen, 1976; Hysek et al., 2011). The
scale consists of 66 items that yield a total adverse effects
score, reliably measuring physical and general discomfort.
Pharmacokinetic measurements
Samples of plasma for the determination of MDMA and!3,4-
methylenedioxyamphetamine (MDA), the active metabolite
of MDMA, were collected 1 h before and 0 (just before), 0.33,
0.66, 1, 1.5, 2, 2.5, 3, 4 and 6 h after MDMA or placebo
administration. The plasma concentrations of MDMA and
MDA were determined using HPLC coupled to tandem MS as
described previously (Hysek et al., 2012).
Data analysis
Pharmacokinetic analysis. The data for the plasma concentra-
tions of MDMA and MDA were analysed using non-
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compartmental methods. Cmax and time to Cmax were obtained
directly from the concentration–time curves of the observed
values. The area under the plasma concentration–time curve
(AUC)0–6 h was calculated using the linear trapezoidal rule.
Plasma concentrations were only determined up to 6 h after
MDMA administration because the aim of the study was to
assess potential changes in plasma levels of MDMA during
the time of the pharmacodynamic effects of MDMA.
Statistical analysis. Values were transformed to differences
from baseline. The maximal effect (Emax) values were deter-
mined for repeated measures and analysed by two-way
General Linear Models repeated-measures ANOVA with the
two drug factors MDMA (MDMA vs. placebo) and carvedilol
(carvedilol vs. placebo) using STATISTICA 6.0 software
(StatSoft, Tulsa, OK, USA). Tukey’s post hoc comparisons were
performed based on significant main effects or interactions.
Additional ANOVAs were performed, with drug order as an
additional factor, to exclude carry-over effects. The criterion
for significance was P < 0.05. A sample-size estimation based
on previous data (Hysek et al., 2011; 2012) showed that eight
subjects would be needed to detect a relevant change in the
primary study outcome with 80% power using a within-
subjects study design.
Results
Vital signs and circulating catecholamines
MDMA significantly increased blood pressure, heart rate and
body temperature compared with placebo (Table 1 and
Figure 1). Carvedilol significantly inhibited the MDMA-
induced increases in blood pressure, heart rate and body
temperature (Table 1 and Figure 1). Carvedilol alone also
moderately lowered blood pressure and heart rate compared
with placebo. The effect of carvedilol on the pressure and
hyperthermic response to MDMA was more pronounced than
the effect of carvedilol alone compared with placebo, cor-
roborated by the significant carvedilol ¥ MDMA interaction
in the two-way ANOVA. Carvedilol alone increased the plasma
concentration of NA compared with placebo. MDMA also
tended to increase circulating NA compared with placebo, but
the effect was not significant. The co-administration of
carvedilol and MDMA significantly increased both circulating
adrenaline and NA (Table 1 and Figure 2).
Subjective effects
Carvedilol did not affect the psychotropic response to
MDMA. It did not alter the pronounced MDMA-induced
increases in the VAS (Table 1 and Figure 3) or 5D-ASC ratings
of subjective drug effects (Table 1). Carvedilol alone had no
subjective effects.
Adverse effects
MDMA increased the total adverse effect score on the List of
Complaints, both 3 and 24 h after drug administration com-
pared with placebo (Table 1). Carvedilol had no effect on the
MDMA-induced increase in the total score. However, fewer
subjects reported palpitations and hot flushes after carvedilol
and MDMA co-treatment (n = 2 and n = 2, respectively)
compared with MDMA treatment alone (n = 6 and n = 5,
respectively). Frequent adverse effects of MDMA and
carvedilol-MDMA were thirst (n = 10 and n = 11, respectively),
lack of appetite (n = 9 and n = 7, respectively), sweating (n =
8 and n = 7, respectively), restlessness (n = 7 and n = 5,
respectively) and bruxism (n = 7 and n = 7, respectively). No
severe adverse effects were reported.
Pharmacokinetics and pharmacokinetic–
pharmacodynamic relationship
The decrease in the cardiovascular and thermogenic response
to MDMA after carvedilol pretreatment was not attributable
to a pharmacokinetic interaction between carvedilol and
MDMA. Carvedilol did not affect the Cmax or AUC0–6 h of
MDMA or MDA (Table 2 and Figure 4A). The effect of MDMA
on blood pressure in relation to the plasma concentration of
MDMA is illustrated by the hysteresis curves in Figure 4B.
Carvedilol produced a pronounced downward shift in the
Emax of the systolic pressure response to MDMA and a right-
ward shift in the Cmax of MDMA in the concentration-effect
curve (Figure 4B). The pharmacokinetic parameters of MDMA
did not depend on CYP2D6 phenotype or the dextromethor-
phan : dextrorphan ratio in our small study sample.
Discussion
The a1- and b1,2,3-adrenoceptor antagonist carvedilol reduced
the cardiostimulant and hyperthermic response to MDMA in
healthy subjects. Carvedilol similarly reduced MDMA-
induced hyperthermia in rats (Sprague et al., 2004a; 2005).
Additional studies in rats and mice showed that the transient
and early hypothermic effect of MDMA are enhanced by
blocking a1-receptors (Bexis and Docherty, 2008), whereas
the late hyperthermic response to MDMA is blunted by block-
ing b3-receptors (Sprague et al., 2004a; Bexis and Docherty,
2008). Moreover, a1-receptors mediate peripheral vasocon-
striction and heat dissipation, which are impaired by MDMA
(Pedersen and Blessing, 2001). Administration of b1,2-receptor
antagonists had no effect on the thermogenic response to
MDMA in rats (Sprague et al., 2005) or humans (Hysek et al.,
2010). These data suggest a role for both a1- and b3-receptors
in MDMA-induced hyperthermia. Carvedilol should be con-
sidered for the treatment of hyperthermia associated with
ecstasy use because it effectively reduced MDMA-induced
hyperthermia in both animals and humans and reversed
established hyperthermia in rats (Sprague et al., 2005).
In addition to adrenoceptors, other sites have been impli-
cated in stimulant-induced hyperthermia. MDMA primarily
induces the release of 5-HT, NA and dopamine through their
respective presynaptic monoamine transporters (Rudnick and
Wall, 1992; Rothman et al., 2001; Verrico et al., 2007). MDMA
binds to a2-adrenoceptors, 5-HT2A-receptors, H1-histamine
and trace amine-1 receptors (Battaglia et al., 1988; Bunzow
et al., 2001). The 5-HT2A-receptor antagonist ketanserin inhib-
ited the thermogenic effects of MDMA in rats (Shioda et al.,
2008), mice (Di Cara et al., 2011) and humans (Liechti et al.,
2000). In both mice and humans, ketanserin administered
alone lowered body temperature compared with vehicle and
placebo, respectively (Liechti et al., 2000; Di Cara et al., 2011).
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2280 British Journal of Pharmacology (2012) 166 2277–2288
Ta
bl
e
1
Va
lu
es
an
d
st
at
ist
ic
s
of
ph
ar
m
ac
od
yn
am
ic
ch
an
ge
s
P
la
ce
b
o
-p
la
ce
b
o
C
ar
ve
d
il
o
l-
p
la
ce
b
o
P
la
ce
b
o
-M
D
M
A
C
ar
ve
d
il
o
l-
M
D
M
A
M
D
M
A
C
ar
ve
d
il
o
l
C
ar
ve
d
il
o
l
¥
M
D
M
A
M
ea
n
(S
EM
)
F 1
,1
5
P
F 1
,1
5
P
F 1
,1
5
P
Ph
ys
io
lo
gi
ca
le
ffe
ct
s
Sy
st
ol
ic
bl
oo
d
pr
es
su
re
(m
m
H
g)
4.
7
(1
.8
)
-8
.1
(2
.0
)*
**
##
#
28
.1
(3
.2
)*
**
6.
5
(2
.2
)#
##
59
.3
0
<
0.
00
1
72
.3
3
<
0.
00
1
5.
02
<
0.
05
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
(m
m
H
g)
-1
.0
(1
.4
)
-8
.1
(1
.6
)*
##
#
15
.3
(1
.6
)*
**
9.
3
(1
.9
)*
**
#
15
1.
10
<
0.
00
1
16
.4
0
<
0.
00
1
1.
70
N
S
H
ea
rt
ra
te
(b
ea
ts
m
in
-1
)
5.
8
(3
.0
)
-5
.0
(2
.5
)*
##
#
26
.2
(3
.9
)*
**
5.
5
(3
.0
)#
##
15
.4
4
<
0.
00
1
38
.8
4
<
0.
00
1
18
.6
4
<
0.
00
1
Bo
dy
te
m
pe
ra
tu
re
(°
C
)
0.
24
(0
.0
6)
0.
32
(0
.0
6)
##
0.
69
(0
.1
0)
**
*
0.
40
(0
.0
6)
#
13
.7
8
<
0.
01
3.
29
N
S
7.
65
<
0.
05
C
irc
ul
at
in
g
ca
te
ch
ol
am
in
es
Ad
re
na
lin
e
(n
M
)
-0
.0
3
(0
.0
3)
0.
08
(0
.0
5)
0.
23
(0
.0
6)
0.
70
(0
.1
5)
**
*#
##
19
.6
3
<
0.
00
1
14
.0
4
<
0.
01
14
.2
0
<
0.
01
N
or
ad
re
na
lin
e
(n
M
)
-0
.3
4
(0
.1
4)
1.
85
(0
.3
6)
**
*#
#
0.
29
(0
.1
4)
2.
58
(0
.4
0)
**
*#
##
4.
33
0.
05
5
59
.8
6
<
0.
00
1
0.
04
N
S
Vi
su
al
An
al
og
ue
Sc
al
e
(%
m
ax
)
An
y
dr
ug
ef
fe
ct
2.
4
(1
.4
)
7.
1
(3
.4
)#
##
64
.8
(7
.5
)*
**
69
.6
(7
.6
)*
**
94
.6
7
<
0.
00
1
1.
50
N
S
0.
00
N
S
G
oo
d
dr
ug
ef
fe
ct
1.
4
(1
.4
)
0.
0
(0
.0
)#
##
71
.1
(7
.6
)*
**
76
.8
(7
.2
)*
**
11
2.
69
<
0.
00
1
0.
40
N
S
1.
01
N
S
Ba
d
dr
ug
ef
fe
ct
0.
3
(0
.3
)
2.
5
(1
.1
)
13
.6
(5
.1
)
25
.3
(9
.1
)*
*
13
.7
0
<
0.
01
1.
51
N
S
0.
92
N
S
D
ru
g
lik
in
g
1.
6
(1
.4
)
0.
0
(0
.0
)#
##
74
.8
(7
.1
)*
**
75
.9
(7
.9
)*
**
10
6.
20
<
0.
00
1
0.
01
N
S
0.
20
N
S
D
ru
g
hi
gh
1.
7
(1
.7
)
0.
0
(0
.0
)#
##
59
.4
(9
.0
)*
**
66
.3
(8
.7
)*
**
56
.4
6
<
0.
00
1
0.
49
N
S
1.
15
N
S
St
im
ul
at
ed
2.
0
(2
.0
)
0.
4
(0
.4
)#
##
57
.8
(9
.2
)*
**
61
.7
(8
.9
)*
**
47
.7
8
<
0.
00
1
0.
10
N
S
0.
38
N
S
5D
-A
SC
Sc
al
e
To
ta
lA
SC
sc
or
e
8.
7
(8
.7
)
0.
0
(0
.0
)#
#
74
7
(1
77
)*
*
89
4
(2
27
)*
**
20
.0
6
<
0.
00
1
0.
55
N
S
0.
68
N
S
O
ce
an
ic
bo
un
dl
es
sn
es
s
7.
6
(7
.6
)
0.
0
(0
.0
)#
##
43
6
(1
19
)*
*
53
1
(1
52
)*
**
13
.9
1
<
0.
01
0.
86
N
S
1.
12
N
S
An
xi
ou
s
eg
o
di
ss
ol
ut
io
n
0.
7
(0
.7
)
0.
0
(0
.0
)#
19
2
(7
5)
*
16
1
(5
5)
13
.5
3
<
0.
01
0.
12
N
S
0.
11
N
S
Vi
sio
na
ry
re
st
ru
ct
ur
al
iz
at
io
n
0.
4
(0
.4
)
0.
0
(0
.0
)#
11
9
(3
3)
*
20
2
(5
4)
**
*
16
.3
9
<
0.
00
1
3.
88
N
S
3.
94
0.
07
Li
st
of
co
m
pl
ai
nt
s
(t
ot
al
sc
or
e)
Ac
ut
e
ad
ve
rs
e
ef
fe
ct
s
(a
t
3
h)
-0
.2
(0
.3
)
0.
9
(0
.4
)#
##
8.
4
(1
.5
)*
**
9.
9
(2
.0
)*
**
46
.9
6
<
0.
00
1
0.
37
N
S
0.
08
N
S
Su
ba
cu
te
ad
ve
rs
e
ef
fe
ct
s
(a
t
24
h)
0.
1
(0
.3
)
1.
1
(0
.8
)
5.
3
(1
.6
)*
4.
9
(1
.5
)*
25
.9
6
<
0.
00
1
0.
08
N
S
0.
47
N
S
Va
lu
es
ar
e
ex
pr
es
se
d
as
m
ea
n
(S
EM
)
ch
an
ge
s
fr
om
ba
se
lin
e
of
16
su
bj
ec
ts
.
AS
C
,
Al
te
re
d
St
at
es
of
C
on
sc
io
us
ne
ss
;
N
S,
no
t
sig
ni
fic
an
t.
*P
<
0.
05
,
**
P
<
0.
01
,
**
*P
<
0.
00
1,
co
m
pa
re
d
w
ith
pl
ac
eb
o-
pl
ac
eb
o.
# P
<
0.
05
,
##
P
<
0.
01
,
##
# P
<
0.
00
1,
co
m
pa
re
d
w
ith
pl
ac
eb
o-
M
D
M
A.
BJPCarvedilol and MDMA
British Journal of Pharmacology (2012) 166 2277–2288 2281
Thus, no interactive effect of ketanserin and MDMA on body
temperature was observed, in contrast to carvedilol and
MDMA in the present study. Furthermore, ketanserin has
a1-adrenoceptor-blocking properties (Brogden and Sorkin,
1990), and its ability to reduce MDMA-associated hyperther-
mia may be explained, at least partially, by a1-receptor
antagonism. A recent study showed that mice that lack trace
amine-1 receptors did not exhibit the early hypothermic
response to MDMA, indicating a role for this receptor in the
early hypothermic effects of MDMA (Di Cara et al., 2011). D1-
and D2-dopamine receptors, a2-adrenoceptors and 5-HT1-
receptors do not appear to be involved in the effects of
MDMA on body temperature, demonstrated by preclinical
(Docherty and Green, 2010; Di Cara et al., 2011) and clinical
(Liechti and Vollenweider, 2000; Hysek et al., 2010; 2012)
studies.
Recreational users of ecstasy report subjective increases in
body temperature, sweating and hot flushes (Parrott et al.,
2008). Hot flushes and sweating were also reported after
administration of MDMA in the present and in previous
studies (Liechti et al., 2001; Freedman et al., 2005). Carvedilol
did not reduce the number of subjects who reported MDMA-
induced subjective sweating but reduced the number of sub-
jects reporting flushes. Interestingly, in another laboratory
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Figure 1
Physiological effects of carvedilol and MDMA. Carvedilol reduced MDMA-induced elevations in systolic (A) and diastolic (B) blood pressure, heart
rate (C) and body temperature (D). Carvedilol was administered at t = -1 h. MDMA was administered at t = 0 h. The values are expressed as mean
! SEM changes from baseline in 16 subjects.
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Figure 2
Effects of carvedilol and MDMA on circulating catecholamines. Carvedilol alone increased the plasma levels of noradrenaline (A) compared with
placebo. MDMA alone produced a similar non-significant increase in noradrenaline. Co-administration of carvedilol and MDMA increased the
concentrations of circulating noradrenaline (A) and adrenaline (B) compared with placebo. The values are expressed as mean! SEM changes from
baseline in 16 subjects.
Figure 3
Time course of subjective drug effects on Visual Analogue Scale ratings. MDMA increased scores on all scales. Carvedilol did not affect any of the
MDMA-induced increases in Visual Analogue Scale ratings. Carvedilol was administered at t = -1 h. MDMA was administered at t = 0 h. The values
are expressed as mean ! SEM percentage of maximal values in 16 subjects.
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study, MDMA did not influence the perceptions of warmth
and cold but delayed the onset of sweating at a warm ambient
temperature along with an MDMA-induced increase in body
temperature (Freedman et al., 2005).
Carvedilol also reduced the cardiostimulant response to
MDMA, including blood pressure and heart rate. The a- and
b-blockers carvedilol and labetalol have similarly been shown
to inhibit the blood pressure response to cocaine in humans
(Boehrer et al., 1993; Sofuoglu et al., 2000a,b). Blockade of
b-receptors alone did not reduce the pressure response to
cocaine (Ramoska and Sacchetti, 1985) or MDMA (Hysek
et al., 2010) in humans and enhanced cocaine-induced coro-
nary vasoconstriction (Lange et al., 1990). In rats, the block-
ade of a1-receptors inhibited both the pressure response and
vasoconstriction in isolated vessels in response to cocaine
(Mo et al., 1999). The data indicate that dual a,b-blockers, but
not selective b-blockers, should be used in the treatment of
psychostimulant-associated hypertension and myocardial
ischaemia. The data indicate that carvedilol could be useful in
the treatment of both psychostimulant-induced hyperten-
sion and hyperthermia.
Circulating catecholamine levels were increased by both
MDMA and carvedilol. Plasma adrenaline is mainly derived
from the adrenals, whereas plasma NA stems largely from
transmitters released by sympathetic nerves and the escape of
NA into the circulation (Esler et al., 1990; Eisenhofer et al.,
1995). Circulating NA is therefore considered an indicator
of sympathetic system activation. We observed a marked
increase in plasma NA concentrations after carvedilol admin-
istration. This compensatory sympathoadrenal response with
enhanced levels of catecholamines has previously been docu-
mented after a1- or a- and b-adrenoceptor blockade (Omvik
et al., 1992; Mazzeo et al., 2001). The MDMA-induced
increase in circulating NA in the present study did not
reach statistical significance compared with previous work
(Dumont et al., 2009; Hysek et al., 2011; 2012). It is possible
that the peak effect was missed because we took only two
samples. The catecholamine response was enhanced when
MDMA was administered following carvedilol. A similar
potentiation of the exercise-induced increases in plasma
catecholamines has been shown following blockade of
a1-adrenoceptors or a- and b-adrenoceptors (Berlin et al.,
1993).
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Figure 4
Pharmacokinetics (A) and pharmacokinetic–pharmacodynamic relationship (B). Carvedilol non-significantly increased the exposure to MDMA and
MDA (A). The values are expressed as mean ! SEM in 16 subjects. Carvedilol was administered at t = -1 h. MDMA was administered at t = 0 h.
MDMA effects on systolic blood pressure plotted against MDMA plasma concentration (B). The values are expressed as means of the changes from
baseline in 16 subjects. The time of sampling is noted next to each point in min or h after MDMA administration. Carvedilol produced a downward
and rightward shift of the concentration-blood pressure response curve of MDMA (B).
Table 2
Pharmacokinetic parameters of MDMA and MDA
Cmax
(ng·mL-1) Tmax (h)
AUC0–6 h
(h·ng·mL-1)
MDMA
Placebo-MDMA 214 (12) 2.9 (0.3) 866 (47)
Carvedilol-MDMA 224 (12) 2.8 (0.2) 921 (45)
MDA
Placebo-MDMA 12.3 (1.0) 5.5 (0.2) 46.3 (3.5)
Carvedilol-MDMA 12.5 (0.9) 5.0 (0.4) 49.3 (2.8)
Values are mean (SEM) of 16 healthy subjects. AUC, area under
concentration–time curve; Cmax, maximum plasma concentra-
tion; Tmax, time to maximum plasma concentration.
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Preclinical and clinical studies suggest that NA contrib-
utes to the mediation of the subjective effects of MDMA and
other psychostimulants (Sofuoglu and Sewell, 2009; Hysek
et al., 2011; Newton, 2011). For example, MDMA is more
potent in releasing NA than 5-HT or dopamine from
monoamine-preloaded human embryonic kidney cells trans-
fected with the corresponding human monoamine transport-
ers (Verrico et al., 2007). Additionally, doses of stimulants
that produce amphetamine-type subjective effects in humans
correlated with their potency to release NA (Rothman et al.,
2001). Furthermore, the NA transporter inhibitor reboxetine
attenuated the cardiovascular and subjective response to
MDMA in humans, indicating a role for MDMA-induced
transporter-mediated NA release in the psychostimulant
effects of MDMA (Hysek et al., 2011). Similarly, atomoxetine
attenuated the effects of amphetamine in humans (Sofuoglu
et al., 2009). Clonidine, which blocks the vesicular release of
NA, did not affect the psychological effects of MDMA in
humans (Hysek et al., 2012). Although these data suggest a
role for transporter-mediated NA release in the psychotropic
effects of psychostimulants, how and which postsynaptic
adrenoceptors are involved are still unclear. Carvedilol did
not alter the subjective effects of MDMA in the present study.
Similar to our results, carvedilol and labetalol did not affect
the subjective responses to cocaine in humans at doses of
cocaine that effectively inhibited the cardiostimulant effects
of the drug (Sofuoglu et al., 2000a,b). The available clinical
data do not support a critical role for a1- and b1,2,3-receptors in
the subjective effects of psychostimulants. Alternatively, the
carvedilol concentrations in humans may not have been high
enough to produce sufficient adrenoceptor occupancy in the
brain. Carvedilol is lipophilic and enters the brain (Elsinga
et al., 2005). However, carvedilol is a substrate of the efflux
transporter P-glycoprotein in the blood-brain barrier (Elsinga
et al., 2005; Bachmakov et al., 2006), and P-glycoprotein
activity is known to limit brain exposure to carvedilol
(Elsinga et al., 2005).
Preclinical studies indicate that a1-receptors are involved
in the mechanism of action of psychostimulants, including
MDMA. For example, pretreatment with the a1-receptor
antagonist prazosin inhibited locomotor stimulation induced
by cocaine (Wellman et al., 2002), amphetamine (Vander-
schuren et al., 2003) and MDMA (Fantegrossi et al., 2004;
Selken and Nichols, 2007) in rats and mice. Additionally,
a1-receptor activation in the ventral tegmental area contrib-
uted to the amphetamine-induced release of dopamine in the
nucleus accumbens (Pan et al., 1996). Injection of prazosin
directly into the ventral tegmental area also blocked the loco-
motor response to MDMA in rats (Selken and Nichols, 2007).
Furthermore, administration of prazosin in the rat prefrontal
cortex also blocked amphetamine-induced dopamine release
in the nucleus accumbens and hyperactivity (Forget et al.,
2011). Finally, a1-adrenoceptor knockout mice do not show
increased amphetamine-induced dopamine release in the
nucleus accumbens (Auclair et al., 2002) or behavioural sen-
sitization to amphetamine or cocaine (Drouin et al., 2002).
In contrast to a1-antagonism, the b-blocker propranolol
enhanced both cocaine-induced locomotion and the cocaine-
induced increase in dopamine in the nucleus accumbens
(Harris et al., 1996). Altogether, the preclinical studies indi-
cate that a1-adrenoceptors, but not b-receptors, play a role in
the hyperlocomotion and dopaminergic neurochemical
response to psychostimulants. However, the role of adreno-
ceptors in the reinforcing effects of psychostimulants
is unclear. For example, prazosin reduced the self-
administration of cocaine (Wee et al., 2008) and nicotine
(Forget et al., 2011) in rats. In contrast, prazosin had no effect
on cocaine self-administration in rhesus monkeys (Woolver-
ton, 1987). The b-blocker propranolol also inhibited cocaine
self-administration in rats (Harris et al., 1996). Carvedilol
lowered the number of cocaine self-administrations in
humans at a low but not high dose (Sofuoglu et al., 2000a). At
low doses, carvedilol preferentially blocks b-receptors (Tham
et al., 1995; Sofuoglu et al., 2000a) and active metabolites
of carvedilol may contribute to the b- but not the
a-adrenoceptor blocking effects of the drug (Spahn-Langguth
and Schloos, 1996). The antagonism of a1-adrenoceptors by
carvedilol may not have been sufficient in the brain to
attenuate the subjective effects of MDMA and we cannot
exclude a role for these receptors. The efficacy of carvedilol to
reduce cocaine use or abstinence in addicted patients is cur-
rently being investigated in ongoing clinical trials [(Sofuoglu
and Sewell, 2009) clinicaltrials.gov identifier: NCT00566969
and NCT01171183]. Further trials have investigated the
effects of selective a1-blockers on the acute response to
MDMA (NCT01386177) and cocaine (NCT01062945) and
abstinence from cocaine use (NCT00880997).
Pharmacokinetic interactions between carvedilol and
MDMA need to be considered in the interpretation of the
present findings, because both drugs are metabolized by
CYP2D6 (Graff et al., 2001; O’Mathuna et al., 2008). We
therefore assessed the potential effects of carvedilol on the
pharmacokinetics of MDMA. We found that carvedilol non-
significantly increased the plasma exposure to MDMA or
MDA. Thus, the reduced haemodynamic and thermogenic
effects of MDMA after carvedilol pretreatment did not result
from lower plasma levels of MDMA or MDA. We did not
assess the plasma concentrations of carvedilol. MDMA inhib-
its CYP2D6 (O’Mathuna et al., 2008). CYP2D6 inhibition has
been shown to increase the exposure to carvedilol but not its
pharmacodynamic or adverse effects in humans (Graff et al.,
2001).
Our laboratory study has a few limitations. The study
design is limited by the use of single doses. We did not use a
dose–response study because we did not want to expose the
subjects to more than two doses of MDMA in a within-subject
design. However, moderate to highly effective doses of both
drugs were selected. The primary goal of the study was to
investigate the role of adrenoceptors in the mechanism of
action of MDMA in humans. Therefore, the study provides
only indirect support for the use of carvedilol in the treat-
ment of stimulant toxicity, in which carvedilol would be
administered following the ingestion of ecstasy or other
stimulants. Furthermore, the MDMA-induced increase in
body temperature in our study was moderate, and we do not
know whether carvedilol would also be effective in cases of
severe hyperthermia following ecstasy use. Finally, thyroid
function may modulate the thermogenic effects of MDMA
(Martin et al., 2007; Sprague et al., 2007) and thyroid func-
tion parameters were not assessed in this study.
In conclusion, carvedilol inhibited the MDMA-induced
increase in blood pressure and body temperature under con-
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trolled laboratory conditions. The results demonstrate that
a1- and/or b1,2,3-adrenoceptors contribute to the cardiostimu-
lant and thermogenic effects of MDMA in humans. The
absence of an effect of carvedilol on the psychotropic
response to MDMA does not support a role for a- and
b-adrenoceptors in the mediation of the subjective effects of
MDMA in humans. Combined a- and b-blockers could be
useful in the treatment of intoxications with MDMA or other
psychostimulants including other amphetamine derivatives
or cocaine.
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Effects of a b-blocker on the cardiovascular response
to MDMA (Ecstasy)
C M Hysek,1 F X Vollenweider,2 M E Liechti1
ABSTRACT
Background MDMA (3,4-methylenedioxymethamph-
etamine, ‘Ecstasy’) produces tachycardia and
hypertension and is rarely associated with cardiovascular
and cerebrovascular complications. In clinical practice,
b-blockers are often withheld in patients with stimulant
intoxication because they may increase hypertension and
coronary artery vasospasm due to loss of b2-mediated
vasodilation and unopposed a-receptor activation.
However, it is unknown whether b-blockers affect the
cardiovascular response to MDMA.
Methods The effects of the non-selective b-blocker
pindolol (20 mg) on the cardiovascular effects of
MDMA (1.6 mg/kg) were investigated in a double-blind
placebo-controlled crossover study in 16 healthy
subjects.
Results Pindolol prevented MDMA-induced increases in
heart rate. Peak values (mean6SD) for heart rate
were 84613 beats/min after MDMA vs 6967 beats/min
after pindolol-MDMA. In contrast, pindolol pretreatment
had no effect on increases in mean arterial blood pressure
(MAP) after MDMA. Peak MAP values were
115611 mm Hg after MDMA vs 114611 mm Hg after
pindolol-MDMA. Pindolol did not change adverse effects
of MDMA.
Conclusion The results of this study indicate that
b-blockers may prevent increases in heart rate but not
hypertensive and adverse effects of MDMA.
INTRODUCTION
MDMA (3,4-Methylenedioxymethamphetamine)
is the main compound contained in ‘Ecstasy ’ pills.
Acute adverse effects of MDMA include hyper-
thermia leading to rhabdomyolysis and multiorgan
failure, hyponatraemic cerebral oedema, acute liver
failure, serotonin syndrome and acute panic reac-
tions.1 2 Rarely, MDMA has been associated with
vascular events such as myocardial infarction,
subarachnoid and intracranial haemorrhage and
cerebral infarction.3 4 These vascular complications
may arise from cardiostimulant and hypertensive
effects of MDMA.5 b-Adrenergic antagonists are
commonly used in the treatment of myocardial
ischaemia and hypertension. However, in the case
of intoxications with cocaine or other stimulants,
the use of b-blockers is controversial because
b-blockade is thought to worsen hypertension and
coronary artery vasospasm through unopposed
a-receptor activation.6e8 It is unknown
whetherdand, if so, howdb-blockers affect
cardiovascular responses to MDMA. We assessed
the effects of the non-selective b-blocker pindolol
on the haemodynamic effects of MDMA in healthy
subjects.
METHODS
Participants
The use of MDMA in healthy subjects was
authorised by the Swiss Federal Health Ofﬁce.
Sixteen male volunteers (age 2564 years, range
20e36) were included in the study. Subjects were
recruited from University Hospital staff or were
students at the Medical School of the University of
Zurich. All volunteers provided written consent
after being informed about the aims and design of
the study and potential risks associated with
MDMA and pindolol use. Subjects were screened to
be physically and mentally healthy according to
medical history, physical examination, ECG and
blood analyses, and were screened by a structured
psychiatric interview based on a computerised
diagnostic expert system.9 Exclusion criteria were
personal or family histories of mental diagnostic
and statistical manual of mental disorders (DSM IV)
axis I disorders, hypertension, cardiovascular or
neurological disorders, use of medications and prior
illicit drug use (except tetrahydrocannabinol-
containing products) on more than ﬁve occasions.
All subjects engaged in regular physical exercise.
Apart from sporadic use of cannabis, one subject
reported a single previous experience with a hallu-
cinogenic drug (psilocybin), two subjects had
previously used both MDMA and a hallucinogen,
and seven subjects were drug-naïve. Subjective
(primary outcome) and neurocognitive results from
the present study have previously been reported.10
Here we present the previously unpublished
cardiovascular and adverse effects (secondary
outcomes) of the same study subjects10 with one
additional subject.
Study design and setting
A double-blind placebo-controlled single-dose
crossover design was used with four treatment
conditions (placeboeplacebo, pindololeplacebo,
placeboeMDMA or pindololeMDMA) and
a 2-week washout time between sessions. This
design has the main advantage that subjects act as
their own control. Treatment order was pseudo-
random and counterbalanced to avoid time order
effects. The duration of the trial for an individual
subject was 6e10 weeks. Placebo or pindolol was
given to the subjects at 09.00 h on each of the four
study days. Sixty minutes later MDMA or placebo
was administered. Blood pressure, heart rate and
body temperature were measured at 0, 30, 60, 90,
120, 150, 180, and 210 min after pindololeplacebo
administration (!60, !30, 0, 30, 60, 90, 120 and
150 min after MDMAeplacebo administration).
Blood pressure and heart rate were registered by an
ERKA ambulatory blood pressure measuring system
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(ERKA.OS 90-2, Kallmeyer Medizintechnik GmbH, Bad Tölz,
Germany) in the non-dominant arm after a resting time of 5 min
with the volunteer sitting in an arm chair with the back
supported. Measures were taken once per time point. Between
measurements, subjects were allowed to engage in non-strenuous
activities such as reading, listening to music or walking around in
the testing room. Most of the time subjects were sitting in an
armchair or lying on a couch. Body temperature was measured
with an axillary thermometer (Terumo C202 Terumo Corp,
Tokyo, Japan). Acute adverse effects were assessed 135 min after
pindololeplacebo (75 min after MDMAeplacebo) administra-
tion by the List of Complaints.5 11 This scale consists of 66 items
yielding a total adverse effects score (non-weighted sum of the
item answers) reliably measuring physical and general discom-
fort. The scale has previously been shown to be sensitive to the
effects of pharmacological pretreatments on the adverse effects
of MDMA.12 13 Subjective and cognitive drug effects were
measured as reported elsewhere.10
Substances
(6)-MDMA hydrochloride (Lipomed, Arlesheim) was obtained
from the Swiss Federal Health Ofﬁce. Subjects received MDMA
at a dose of 1.6 mg/kg (mean6SD dose 122614 mg). This dose of
MDMA corresponds to a typical recreational dose of Ecstasy and
produces robust psychological and physiological effects.5
Pindolol (Visken, Novartis Pharma, Basel, Switzerland) was used
in a dose of 20 mg. Pindolol is a non-selective b-blocker with
intrinsic activity and additional serotonergic 5HT1-receptor-
blocking properties. We selected pindolol for this study and a dose
of 20 mg because this dose produces approximately 40% brain
5-HT1A receptor occupancy,14 and we were also interested in the
role of 5-HT1 receptors in the mediation of the subjective effects
of MDMA based on behavioural studies in rats.15e17 Pindolol is
commonly used in doses of 5e30 mg per day divided into two
daily doses in the treatment of arterial hypertension. Thus,
a single dose of 20 mg of pindolol corresponds to a moderate to
high therapeutic dose. Pindolol pretreatment slightly attenuated
positive derealisation associated with MDMA and did not alter
MDMA-induced impairment of cognitive performance as
described in detail elsewhere.10
Data analysis
All analyses were performed with STATISTICA Version 6.0
(StatSoft Inc, Tulsa, USA). We determined the peak effect in the
150 min after MDMAeplacebo administration (time points
60e210 min) and the area under the curve (AUC) of the effects
versus time curve calculated by the trapezoidal rule for each
value (time points 60e210 min). These individual peak effects
and AUC values for each outcome variable were analysed by
one-way repeated measures analysis of variance (ANOVA)
with treatment condition (placeboeplacebo, pindololeplacebo,
placeboeMDMA and pindololeMDMA) as within-subject
factor. Post hoc comparisons were performed using Tukey tests
based on signiﬁcant main effects of treatment condition in the
omnibus ANOVA. The absence of treatment order and carryover
effects was conﬁrmed by ANOVAwith treatment order (1e4) as
within-subject factor. Treatment effects were also analysed over
time with two-way repeated measures ANOVA with treatment
condition and time as within-subject factors followed by Tukey
tests based on signiﬁcant treatment by time interactions in the
omnibus ANOVA. We controlled for deviations from multivar-
iate normality using Mauchley tests of sphericity. Greenhouse
and Geisser corrections were used where necessary to adjust for
deviations from multivariate normality. These analyses yielded
similar results to those using peak and AUC values. The criterion
for signiﬁcance was set at p<0.05. Mean arterial blood pressure
(MAP) was calculated from diastolic blood pressure (DBP) and
systolic blood pressure (SBP) using the following formula:
MAP¼DBP+(SBP!DBP)/3. A decrease in MAP of 5 mm Hg was
considered clinically relevant and similar to the previously
reported one for the effects of citalopram on MDMA-induced
increases in blood pressure.12 A sample size of 15 achieves 97%
power to detect a difference of 5 between the null hypothesis
mean of !5 and the alternative hypothesis mean of 0 with
a known SD of the difference of 512 and with a signiﬁcance level
(a) of 0.05 using a two-sided one-sample t test.
RESULTS
Cardiovascular effects and body temperature
The results are shown in ﬁgure 1. All 16 subjects completed all
four study sessions. ANOVA showed that the four treatment
conditions overall resulted in signiﬁcantly different peak levels of
heart rate and MAP across sessions (main effects: F(3,45)¼28.7,
p<0.001; F(3,45)¼47.9, p<0.001; respectively). MDMA signiﬁ-
cantly increased peak values for heart rate by (mean6SD)
15610 beats/min (p<0.01) compared with placebo. Pindolol
prevented the MDMA-induced increase in heart rate (p<0.001
for placeboeMDMA vs pindololeMDMA) but had no effect on
heart rate when given alone compared with placebo. MDMA
signiﬁcantly increased peak MAP by 1668 compared with
placebo (p<0.001). Pindolol had no effect on the peak MAP
response to MDMA. The MDMA-induced increase in peak body
temperature (0.260.38C compared with placebo) was not
signiﬁcant. Pindolol had no effect on MDMA-induced elevations
in body temperature.
Adverse effects
MDMA signiﬁcantly increased acute adverse effects scores (main
effectof treatment:F(3,45)¼10.3, p<0.001, post hoc test: p<0.001
for MDMA vs placebo). The most frequently reported acute side
effects of MDMAwere impaired balance, lack of appetite, thirst,
feelings of restlessness or restless legs, difﬁculty concentrating and
feeling cold or warm. None of the subjects reported chest pain.
Pindolol did not change the adverse effects of MDMA.
DISCUSSION
The b-blocker pindolol prevented MDMA-induced tachycardia
but not hypertension or other adverse effects associated with
MDMA. Pindolol is an antagonist at central serotonin 5-HT1
receptors.14 As described in detail elsewhere,10 pindolol moder-
ately attenuated MDMA-induced increases in positive mood,
dreaminess, derealisation and mania-like experience, indicating
a possible role for serotonergic 5-HT1 receptors in the mediation
of these mood effects of MDMA. In contrast, pindolol had no
effect on MDMA-induced cognitive performance impairment.10
In addition, the effect of pindolol pretreatment on the subjective
response to MDMA was weak compared with that of the sero-
tonin uptake transporter blocker citalopram,12 18 which is
thought to block the interaction of MDMA with the serotonin
transporter so inhibits the release of serotonin from presynaptic
nerve terminals.
We are not aware of reports on the effects of b-blockers on the
haemodynamic effects of amphetamines including MDMA. The
b-blocker propranolol decreases heart rate19 20 and decreases20 or
increases19 blood pressure in patients with acute cocaine intoxi-
cation. In a placebo-controlled study, the a-b-blocker carvedilol
increased both heart rate and blood pressure in response to
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smoked cocaine when carvedilol was used at a low dose which
preferentially blocks b-receptors.21 At a higher dose, which blocks
both a- and b-receptors, carvedilol decreased all haemodynamic
effects of cocaine.21 The a-b-blocker labetolol, which has a
higher relative afﬁnity for the a-receptor than carvedilol, dose-
dependently prevented all haemodynamic effects of smoked or
Figure 1 Graphs from left to right show
drug effects over time, peak values
(60e210 min) and area under the curve
values (AUC from 60 to 210 min310!3).
(A) Pindolol pretreatment prevented the
MDMA-induced increase in heart rate.
(B) Pindolol had no effect on MDMA-
induced increases in mean arterial blood
pressure. (C) Pindolol had no effect on
the non-significant increase in body
temperature associated with MDMA.
(D) Pindolol did not change adverse
effects associated with MDMA. *p<0.05
and ***p<0.001 placebo-MDMA vs
placebo-placebo, yp<0.05 and
yyyp<0.001 placebo-MDMA vs
pindolol-MDMA. Values represent
mean6SE of 16 subjects.
588 Emerg Med J 2010;27:586e589. doi:10.1136/emj.2009.079905
Original article
 group.bmj.com on May 30, 2012 - Published by emj.bmj.comDownloaded from 
intranasal cocaine.6 22 Furthermore, propranolol, but not labe-
talol, potentiated cocaine-induced coronary vasoconstriction.6 7
Together these studies indicate that b-blockade without
a-blockade has no effect or may even increase cocaine-induced
hypertension, possibly due to unopposed a-receptor stimulation
and increased vasoconstriction. Our results extend these ﬁndings
and suggest that b-blockade affects MDMA-induced tachycardia
but does not inﬂuence the blood pressure and adverse effects of
MDMA. Severe MDMA toxicity such as multiorgan failure
results from hyperthermia and not solely from tachycardia.1
Heart rate is an easily determined marker of the severity of
MDMA poisoning and b-blockade may mask this MDMA effect,
during which time serious MDMA toxicity develops.
The present study has several limitations. Pindolol is
a non-selective b-receptor blocker with intrinsic activity, unlike
the b1-selective b-blockers that are mostly used today and that
may interact differently withMDMA. Pindolol was used because
this compound also blocks serotonergic 5-HT1 receptors and the
primary aim of this study was to investigate the role of 5-HT1 in
the subjective effects of MDMA in humans. This focus was also
the reason why pindolol was given before MDMA. Treatment
after MDMA would have more closely mirrored the clinical
situation where treatment for cardiovascular stimulation asso-
ciated with intoxication with Ecstasy would be initiated
following ingestion of MDMA. Treatment with a b-blocker after
MDMA administration may result in less effective blockade of
the effects of MDMA due to the delayed availability of the
blocker at the site of action, but is unlikely to result in a quali-
tatively different pharmacodynamic interaction. Only single
doses of pindolol and MDMA were used in the present study.
However, the signiﬁcant interactive effects of pindolol and
MDMA on heart rate indicate that effective doses of both
compounds were used. Nevertheless, different doses could
interact differently. We do not know how the haemodynamic
changes observed in our study would translate into actual risk
changes for vascular complications. For example, the beneﬁcial
effects of b-blockers on heart rate and cardiac oxygen consump-
tion may outweigh the potential harm of theoretically unop-
posed a-stimulation.23 Finally, the present study was performed
using pure MDMA in healthy subjects who were not engaged in
physical activities and were seated in a quiet research environ-
ment. In contrast, recreational users of MDMA may be dancing
and are likely to ingest other substances in addition to MDMA
including cocaine or other amphetamines and may also show
signiﬁcant co-morbidity.2 The ﬁndings from this study can
therefore not be generalised to the treatment of patients with
cardiovascular complications associated with recreational
MDMA use. Nevertheless, our results indicate that b-blockers
would not be expected to worsen the cardiovascular and adverse
effects of MDMA. In addition, subjects on b-blocker medication
are likely to show similar blood pressure responses to MDMA as
those without medication.
In conclusion, b-blockers may prevent tachycardia but not
blood pressure responses or adverse effects associated with
MDMA. The role of a-b-blockade in the treatment of MDMA
intoxications needs further evaluation. Furthermore, MDMA
stimulates the sympathetic nervous system centrally rather than
peripherally,1 24 25 so centrally-acting sedative agents (eg,
benzodiazepines) should be used as ﬁrst-line treatments in cases
of MDMA or other stimulant intoxication.1 26 27
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Duloxetine Inhibits Effects of MDMA (‘‘Ecstasy’’) In Vitro
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Abstract
This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the
effects of 3,4–methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study
used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release
of both 5-HT and NE by MDMA or by its metabolite 3,4-methylenedioxyamphetamine from transmitter-loaded human cells
expressing the 5-HT or NE transporter. In humans, duloxetine inhibited the effects of MDMA including elevations in
circulating NE, increases in blood pressure and heart rate, and the subjective drug effects. Duloxetine inhibited the
pharmacodynamic response to MDMA despite an increase in duloxetine-associated elevations in plasma MDMA levels. The
findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA. Duloxetine
may be useful in the treatment of psychostimulant dependence.
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Introduction
Amphetamine derivatives, including 3,4-methylenedioxy-
methamphetamine (MDMA, ‘‘ecstasy’’) bind to monoamine
transporters and potently release serotonin (5-hydroxytryptamine
[5-HT]), norepinephrine (NE), and dopamine (DA) through the 5-
HT (SERT), NE (NET), and DA (DAT) transporters, respectively
[1,2,3,4]. The pharmacological effect of MDMA can be blocked
by monoamine transporter inhibitors. In vitro, the MDMA-induced
release of NE, DA, or 5-HT from rat brain synaptosomes
preloaded with monoamines is competitively inhibited by the
monoamine transporter inhibitor indatraline [5,6]. In humans,
SERT inhibition reduced the psychotropic response to MDMA
[7,8,9]. NET inhibition also attenuated the acute effects of
MDMA [10] and amphetamine [11] in humans. In contrast,
clonidine, which inhibits the vesicular release of NE, did not
inhibit the effects of MDMA in humans [12]. Thus, the available
evidence indicates that the MDMA-induced transporter-mediated
release of 5-HT and NE appears to be involved in aspects of the
acute subjective and cardiovascular responses to psychostimulants
[2,7,10,11]. However, the response to MDMA in humans was
only moderately affected when either the SERT or NET was
pharmacologically blocked [7,10]. Therefore, we evaluated the
effects of dual SERT and NET inhibition with duloxetine on the
pharmacokinetics (PK) and pharmacodynamics (PD) of MDMA in
humans. Duloxetine was used because it is the most potent and
selective dual SERT and NET inhibitor, although it also inhibits
the DAT with 10- to 100-fold lower potency compared with the
SERT and NET [13,14]. MDMA is mainly metabolized to 3,4-
dihydroxymethamphetamine (HHMA) by cytochrome P450
(CYP) 2D6-mediated O-demethylation, followed by catechol-O-
methyltransferase-catalyzed methylation to 4-hydroxy-3-methox-
ymethamphetamine (HMMA) [15]. Because duloxetine inhibits
CYP 2D6 [16], we expected an increase in plasma MDMA
concentrations after duloxetine pretreatment. MDMA is also N-
demethylated to the active metabolite 3,4-mehthylenedioxyam-
phetamine (MDA). Whether the effects of MDA on 5-HT and NE
release are inhibited by transporter inhibitors is unknown.
Additionally, the inhibition of MDMA’s effect on 5-HT and NE
release by duloxetine has not been studied. Therefore, we also
assessed the effects of duloxetine on 5-HT and NE release induced
by MDMA or MDA in vitro using cells that express the respective
human transporters. We also sought to link the in vitro and in vivo
data to provide additional insights into the differential modulatory
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role of 5-HT and NE in the effects of MDMA in humans. Because
the data on monoamine transporter affinity and inhibition have
mostly been derived from studies that used rat transporters [17],
we investigated the binding and inhibition characteristics of the
human monoamine transporters for MDMA, MDA, and dulox-
etine and the transporter inhibitors used in previous clinical studies
[7,8,9,10] and in vitro studies [5,6]. Finally, we used an ex vivo
binding assay to assess whether plasma samples taken from the
drug-treated participants in the clinical study exhibit SERT, NET,
and DAT-binding properties ex vivo.
The overall hypothesis of the present study was that duloxetine
would potently bind to SERT and NET and block theMDMA- and
MDA-induced transporter-mediated release of 5-HT and NE in vitro
and markedly reduce the acute effects of MDMA in vivo in humans.
Methods
Clinical Study
The protocol for the clinical trial, the CONSORT checklist,
and the CONSORT flowchart are available as supporting
information; see Protocol S1, Checklist S1, and Figure 1. There
were no changes to the protocol during the study.
Ethics
The study was conducted in accordance with the Declaration of
Helsinki and approved by the Ethics Committee of the Canton of
Basel, Switzerland. All of the subjects provided written informed
consent before participating in the study, and they were paid for
their participation.
Design
We used a double-blind, placebo-controlled, randomized,
crossover design with four experiential conditions (placebo-placebo,
duloxetine-placebo, placebo-MDMA, and duloxetine-MDMA) in a
balanced order. The washout periods between the sessions were at
least 10 days long.
Participants
Sixteen healthy subjects (eight men, eight women) with a
mean6SD age of 26.166.0 years participated in the study. The
allocation to treatment order was performed by drawing from
blocks of eight different balanced drug treatment sequences by a
pharmacist not involved in the study. Each code was stored in a
sealed envelope until the termination of the study. Data from all 16
subjects were available for the final analysis (Figure 1). The
sample-size estimation showed that 13 subjects would be needed to
detect a meaningful reduction of 20% of the MDMA drug effect
by duloxetine with more than 80% power using a within-subjects
study design. The exclusion criteria included the following; (i) age
,18 or.45 years, (ii) pregnancy determined by a urine test before
each session, (iii) body mass index ,18.5 kg/m2 or .25 kg/m2,
(iv) personal or family (first-degree relative) history of psychiatric
disorder (determined by the structured clinical interview of Axis I
and Axis II disorders according the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition [18] supplemented by the SCL-90-R
Symptom Checklist [19,20] (v) regular use of medications, (vi)
chronic or acute physical illness assessed by physical examination,
electrocardiogram, standard hematological, and chemical blood
analyses, (vii) smoking more than 10 cigarettes per day, (viii) a
lifetime history of using illicit drugs more than five times with the
exception of cannabis, (ix) illicit drug use within the last 2 months,
and (x) illicit drug use during the study determined by urine tests
conducted before the test sessions. None of the 16 subjects had
used ecstasy previously. The subjects were asked to abstain from
excessive alcohol consumption between the test sessions and limit
their alcohol use to one glass on the day before the test session. All
of the subjects were phenotyped for cytochrome P450 (CYP) 2D6
Figure 1. CONSORT flowchart.
doi:10.1371/journal.pone.0036476.g001
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activity using dextromethorphan. Thirteen extensive, two inter-
mediate, and one poor CYP 2D6 metabolizer were identified in
the study. The female subjects were investigated during the
follicular phase (day 2–14) of their menstrual cycle.
Drugs
(6 )MDMA hydrochloride (C11H15NO2, Lipomed, Arlesheim,
Switzerland) was obtained from the Swiss Federal Office of Public
Health and prepared as gelatin capsules (100 mg and 25 mg).
Identical placebo (lactose) capsules were prepared. MDMA was
administered in a single absolute dose of 125 mg that
corresponded to an average dose of 1.8760.36 mg/kg body
weight. This dose of MDMA corresponds to a typical recreational
dose of ecstasy, and comparable doses of MDMA have previously
been used in controlled settings. Duloxetine (Cymbalta, Eli Lilly,
Vernier, Switzerland) was prepared as 60 mg gelatine capsules,
and identically looking placebo (lactose) capsules were similarly
prepared. Duloxetine (120 mg) or placebo was administered twice
16 and 4 h before MDMA or placebo administration, respectively.
The dose of the two administrations of duloxetine (120 mg/day on
two separate days) was in the upper range of the chronic doses
used clinically (60–120 mg/day). This dosing schedule was used to
obtain high plasma concentrations of duloxetine similar to those
reached with chronic administration of 60 mg/day. Drugs were
administered without food.
Assessments
Psychometric measures. The psychometric measures in-
cluded Visual Analog Scales (VAS) [8,10], the Adjective Mood
Rating Scale (AMRS) [21], and 5-Dimensions of Altered States of
Consciousness (5D-ASC) [22,23]. The VASs included ‘‘any drug
effect,’’ ‘‘good drug effect,’’ ‘‘bad drug effect,’’ ‘‘drug liking,’’
‘‘drug high,’’ ‘‘stimulated,’’ ‘‘fear,’’ ‘‘closeness to others,’’ ‘‘talka-
tive,’’ and ‘‘open’’ [8,10,12,24,25]. The VASs were pre-
sented as 100 mm horizontal lines marked ‘‘not at all’’ on the
left and ‘‘extremely’’ on the right. The VASs for ‘‘closeness to
others,’’ ‘‘open,’’ and ‘‘talkative’’ were bidirectional (650 mm).
The VASs were administered 4 h before and 0, 0.33, 1, 1.5, 2, 2.5,
3, 3.5, 4, and 5 h after MDMA or placebo administration. The 60-
item Likert-type scale of the short version of the AMRS [21] was
administered 4 h before and 1.25, 2, and 5 h after MDMA or
placebo administration. The AMRS contains subscales for activity,
extroversion and introversion, well-being, emotional excitation,
anxiety-depression, and dreaminess. The 5D-ASC rating scale
measures alterations in mood, perception, experience of self in
relation to the environment, and thought disorder. The 5D-ASC
rating scale comprises five subscales or dimensions [22] and 11
lower-order scales [23]. The 5D-ASC dimension ‘‘oceanic
boundlessness’’ (OB, 27 items) measures derealization and
depersonalization associated with positive emotional states, rang-
ing from heightened mood to euphoric exaltation. The corre-
sponding lower-order scales include ‘‘experience of unity,’’
‘‘spiritual experience,’’ ‘‘blissful state,’’ and ‘‘insightfulness.’’ The
5D-ASC dimension ‘‘anxious ego dissolution’’ (AED, 21 items)
summarizes ego disintegration and loss of self-control phenomena,
two phenomena associated with anxiety. The corresponding
lower-order scales include ‘‘disembodiment,’’ ‘‘impaired control
of cognition,’’ and ‘‘anxiety.’’ The dimension ‘‘visionary restruc-
turalization’’ (VR, 18 items) consists of the lower-order scales
‘‘complex imagery,’’ ‘‘elementary imagery,’’ ‘‘audiovisual synes-
thesia,’’ and ‘‘changed meaning of percepts.’’ Two other
dimensions of the scale were not used in our study. The global
ASC score was determined by adding the OB, AED, and VR
scores. The 5D-ASC scale was administered 4 h after MDMA or
placebo administration.
Physiologic measures. Physiologic measures were assessed
repeatedly 4, 3, 2, and 1 h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5,
3, 4, 5, and 6 h after MDMA or placebo administration. Heart
rate, systolic blood pressure, and diastolic blood pressure were
measured using an OMRON M7 blood pressure monitor
(OMRON Healthcare Europe, Hoofddorp, The Netherlands).
Measures were taken twice per time point with an interval of
1 min, and the average was used for the analysis. Core (tympanic)
temperature was assessed using a GENIUS 2 ear thermometer
(Tyco Healthcare Group, Watertown, NY). The temperature of
the room was maintained at 23.260.5uC. Adverse effects were
assessed using the List of Complaints (LC) [26], which consists of
66 items that yield a total adverse effects score and reliably
measure physical and general discomfort.
Plasma catecholamines and Pharmacokinetics (PK).
Blood samples to determine the concentrations of NE and
epinephrine were collected 4 h before and 1 and 2 h after
MDMA or placebo administration. The levels of free cate-
cholamines (NE and epinephrine) were determined using high-
performance liquid chromatography (HPLC) with an elec-
trochemical detector as described previously [10]. Plasma
concentrations of copeptin were also determined in this study as
reported elsewhere [27]. Samples of whole blood for the
determination of MDMA, MDA, HMMA, and duloxetine were
collected into lithium heparin monovettes -4, 0, 0.33, 0.66, 1, 1.5,
2, 2.5, 3, 4, and 6 h after administration of MDMA or placebo.
Plasma concentrations of MDMA, MDA, HMMA, and duloxetine
were analyzed by HPLC coupled to a tandem mass spectrometer
as described previously [12]. The assays were linear in the
concentration ranges of 1–1000 ng/ml for MDMA and MDA, 1–
500 ng/ml for HMMA, and 2.5–1000 ng/ml for duloxetine. The
performance of the method was monitored using quality control
(QC) samples at the lower limit of quantification (LLOQ) and at
two or three QC concentrations. The interassay accuracy values
for the QC samples ranged from 97.5% to 100% for MDMA,
from 95.3% to 103% for MDA, from 91.1% to 106% for HMMA,
and from 93.2% to 96.4% for duloxetine. The interassay precision
values ranged from 2.8% to 8.0% for MDMA, from 3.8% to
10.5% for MDA, from 3.1% to 8.8% for HMMA, and from 4.7%
to 9.3% for duloxetine. No hydrolysis was performed. Thus, the
values for HMMA represent the drug concentrations of the non-
conjugated metabolite. All blood samples were collected on ice
and centrifuged within 10 min at 4uC. The plasma was then stored
at –20uC until the analysis.
In vitro Studies
Binding to monoamine transporters in vitro. Human
embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland)
stably transfected with the human NET, SERT, or DAT as
previously described [28] were cultured. The cells were collected
and washed three times with phosphate-buffered saline (PBS). The
pellets were frozen at –80uC. The pellets were then resuspended in
400 ml of 20 mMHEPES-NaOH, pH 7.4, that contained 10 mM
EDTA at 4uC. After homogenization with a Polytron (Kinematica,
Lucerne, Switzerland) at 10000 rotations per minute (rpm) for
15 s, the homogenates were centrifuged at 480006g for 30 min at
4uC. Aliquots of the membrane stocks were frozen at –80uC. All
assays were performed at least three times. The test compounds
were diluted in 20 ml of binding buffer (252 mM NaCl, 5.4 mM
KCl, 20 mM Na2HPO4, 3.52 mM KH2PO4, pH 7.4) and 10
point dilution curves were made and transferred to 96-well white
polystyrene assay plates (Sigma-Aldrich, Buchs, Switzerland). N-
Duloxetine and MDMA
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methyl-3H-nisoxetine (,87 Ci/mmol, Perkin-Elmer) was the
radioligand for the NET assay and had a dissociation constant
(Kd) of 9 nM. Fifty microliters of 12 nM [
3H]-nisoxetine was
added to each well of the assay plates, targeting a final [3H]-
nisoxetine concentration of 3 nM. [3H]-citalopram (,72 Ci/
mmol; Perkin-Elmer) was the radioligand for the SERT assay
and had a Kd of 2.2 nM. Fifty microliters of 8 nM [
3H]-
citalopram was added to each well of the SERT assay plates,
targeting a final [3H]-citalopram concentration of 2 nM. [3H]-
WIN35,428 (,86 Ci/mmol; Perkin-Elmer) was the radioligand
for the DAT assay and had a Kd of 12 nM. Fifty microliters of
[3H]-WIN35,428 (,40 nM concentration) was added to each well
of the hDAT assay plates, targeting a final [3H]-WIN35428
concentration of 10 nM. Twenty microliters of binding buffer
alone in the assay plate defined the total binding, whereas binding
in the presence of 10 mM indatraline defined nonspecific binding.
Frozen NET, SERT, or DAT membrane stocks were thawed and
resuspended to a concentration of approximately 0.04 mg
protein/ml binding buffer (1:1 diluted in H2O) using a polytron
tissue homogenizer. The membrane homogenates (40 mg/ml)
were then lightly mixed for 5–30 min with polyvinyl toluene (PCT)
wheat germ agglutinin-coated scintillation proximity assay (WGA-
SPA; Amersham Biosciences) beads at 7.7 mg beads/ml homog-
enate. One hundred thirty microliters of the membrane/bead
mixture were added to each well of the assay plate that contained
radioligand and test compounds (final volume in each well, 200 ml)
to start the assay, which was incubated for approximately 2 h at
room temperature with agitation. The assay plates were then
counted in the PVT SPA counting mode of a Packard Topcount.
Fifty microliters of the [3H]-nisoxetine, [3H]-citalopram, or [3H]-
WIN35428 stocks were counted in 5 ml of ReadySafe scintillation
cocktail (Beckman Industries) on a Packard 1900CA liquid
scintillation counter to determine the total counts added to the
respective assays. Non-linear regression was used to fit the data to
sigmoid curves and determine IC50 values for binding and uptake.
Ki values for binding and uptake were calculated using the
following Cheng-Prusoff equation: Ki = IC50/(1+ [S]/Km).[29].
Monoamine uptake in vitro. Two different methodological
approaches were used to assess the effects of the drug on
monoamine uptake. Method A used centrifugation through silicon
oil, and method B used buffer to stop the reaction and wash the
cells. Method A: The SERT, NET, and DAT functions were
evaluated in human HEK 293 cells that stably expressed human
SERT, NET, and DAT. The cells were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen, Zug, Switzerland) with 10%
fetal bovine serum and 250 mg/ml geneticine. The cells (100 ml,
46106 cells/ml) were incubated for 10 min with 25 ml uptake
buffer (9.99 mM L-glucose, 0.492 mM MgCl2, 4.56 mM KCl,
119.7 mM NaCl, 0.7 mM NaH2PO4, 1.295 mM NaH2PO4,
0.015 mM sodium bicarbonate, and 1 mg/ml ascorbic acid for
[3H]-DA uptake) that contained various concentrations of
inhibitor at 25uC. Fifty microliters of 5 nM (final concentration)
[3H]-5-HT (80 Ci/mmol; Anawa), [
3H]-NE (14.8 Ci/mmol;
Perkin-Elmer), or [3H]-DA (13.8 Ci/mmol; Perkin-Elmer) was
added to start uptake. Uptake was stopped after 10 min, and
radioactivity was measured as described below for 5-HT and NE
release. Cell integrity after MDMA treatment was confirmed by
the Toxilight toxicity assay (Lonza, Basel, Switzerland). The data
were fit by non-linear regression, and Km, EC50, and Emax values
were calculated using Prism (GraphPad, San Diego, CA).
Preliminary experiments showed that the accumulation of 5-HT
and NE by the cells was time-dependent and complete after 5 min
for both 5-HT and NE, respectively. The 5-HT and NE transport
velocity was concentration-dependent and could be described by
Michaelis-Menten kinetics. The Km values were 4896147 nM,
4506125 nM, and 17076297 nM for 5-HT, NE, and DA,
respectively. Nonspecific uptake was determined for each exper-
iment in the presence of 10 mM fluoxetine for SERT cells, 10 mM
nisoxetine for NET cells, and 10 mM mazindol for DAT cells and
subtracted from the total counts to yield specific uptake.
Nonspecific uptake was ,10% of total uptake. Method B: Ligand
potencies to inhibit [3H]-DA, [3H]-5-HT, and [3H]-NE uptake via
the human DAT, SERT and NET recombinantly expressed in
HEK 293 cells were determined. The cells were grown in
Dulbecco’s modified Eagle’s medium (Invitrogen, Zug, Switzer-
land) with 10% fetal bovine serum and 250 mg/ml geneticine in
cell culture flasks. One day before the experiment, the cells were
seeded in a volume of 110 ml at a density of 0.3 million cells/ml in
96-well plates (Packard) and incubated at 37uC and 5% CO2
overnight. On the day of the uptake experiment, the 96-well plates
that contained the cells were washed with Krebs Ringer
bicarbonate buffer (Sigma-Aldrich, Buchs, Switzerland). Test
compounds (100 ml, diluted in Krebs Ringer bicarbonate buffer)
were added to the microtiter plates and incubated at 37uC for
30 min. Afterward, 50 ml [3H]-DA (35–54 Ci/mmol; Perkin-
Elmer; final concentration, 100 nM), [3H]-5-HT (28–100 Ci/
mmol; Perkin-Elmer; final concentration, 10 nM), or [3H]-NE
(5.3–14 Ci/mmol; Perkin-Elmer; final concentration, 100 nM)
were added to DAT-, SERT-, and NET-containing cells,
respectively, and incubated for 10 min at 37uC. Extracellular
[3H]-DA, [3H]-5-HT, and [3H]-NE were removed, and the plates
were washed twice with Krebs Ringer bicarbonate buffer.
Nonspecific uptake was determined in the presence of 10 mM
indatraline. Scintillant (Microscint 40, 250 ml) was dispensed to
every well, and radioactivity was determined at least 1 h later on
the Packard Topcount plate reader. The data were fit by non-
linear regression, and the IC50 was calculated using Excel
(Microsoft, Redmont, CA, USA). The compounds were tested at
least three times. The Km values were 1082 nM for [
3H]-5-HT
and .10000 nM for [3H]-DA and [3H]-NE.
5-HT and NE release in vitro. Transporter-mediated
MDMA- and MDA-induced 5-HT and NE release was evaluated
using [3H]-5-HT- and [3H]-NE-preloaded HEK 293 cells that
stably expressed human SERT and NET, respectively. The
procedures were adapted from previous studies [2,3]. SERT- or
NET-expressing cells (100 ml, 46106 cells/ml) were incubated at
25uC for 10 min with 50 ml of 5 nM (final concentration) [3H]-5-
HT or 10 nM [3H]-NE solutions, respectively. Steady-state load
with radiolabeled substrate was reached within 5 min and
remained stable for 60 min for both cell lines. Duloxetine or
other transporter inhibitors (5 ml) were added after 10 min, and
the release of [3H]-5-HT and [3H]-NE was then initiated after
another 2 min by the addition of MDMA, MDA, or buffer (25 ml).
The release reaction was stopped after 10 and 30 min for [3H]-5-
HT and [3H]-NE, respectively. The release times were based on
the evaluation of the release-over-time curves for MDMA and
MDA. The release of [3H]-5-HT and [3H]-NE was complete
within 5 and 25 min, respectively, when a new steady state was
reached and maintained for 30 min. To stop the release reaction
and wash the cells, 100 ml of the cell suspension was transferred to
0.5 ml microcentrifuge tubes that contained 50 ml of 3 M KOH
and 200 ml silicon oil (1:1 mixture of silicon oil types Ar20 and
Ar200; Wacker Chemie, Munich, Germany) and centrifuged in a
tabletop microfuge (Eppendorf, Basel, Switzerland) for 3 min at
13,200 rpm. This transports the cells through the silicon oil layer
to the KOH layer, thereby separating the cells from the buffer,
which remains on top of the silicon oil layer [30]. The centrifuge
tubes were then transferred to liquid nitrogen. The amount of
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tracer that remained in the cells was quantified by cutting the
frozen centrifuge tube above the KOH/oil interface and putting
the tip of the tube with the cell pellet in a scintillation vial that
contained 500 ml lysis buffer (0.05 M TRIS-HCl, 50 mM NaCl,
5 mM EDTA, and 1% Nonidet P-40 substitute in water). The
samples were then shaken for 1 h on a rotary shaker, and 7 ml of
scintillation fluid (Ultimagold, Perkin Elmer, Schwerzenbach,
Switzerland) was added. Cell-associated radioactivity was then
counted. The silicon oil assay allowed for the precise termination
of the transport/release process and an effective cell wash. The
experimental control condition (100% retained) was defined as the
[3H]-5HT or [3H]-NE that remained in the cells when buffer and
duloxetine were added without MDMA or MDA. A second
control condition (100% release) was defined as the [3H]-5-HT or
[3H]-NE released by 100 mM tyramine [6]. Data analysis using
either of the two control conditions yielded similar results, and the
data are presented as release expressed as the percentage of
monoamine retained. Dose-response curves were generated using
9–11 concentrations of MDMA/MDA. Nonspecific binding/
uptake was determined using preincubation with 10 mM fluoxetine
for SERT cells and 10 mM nisoxetine for NET cells before
incubation with radioligands and was ,3% of total activity. All
data points were derived from at least three independent
experiments, each assayed in triplicate. The data were fit by
non-linear regression, and EC50 and Emax values were calculated
using Prism (GraphPad, San Diego, CA).
Ex vivo Binding to Monoamine Transporters
Plasma samples for assessing ex vivo binding to monoamine
transporters were collected 120 min after MDMA/placebo
administration. We determined the potencies of the plasma to
inhibit [3H]-nisoxetine, [3H]-citalopram, and [3H]-WIN35,428
binding to NET, SERT, and DAT, respectively, according to the
method described previously [10]. IC50 values were calculated as a
percentage of the plasma sample dilutions required to obtain 50%
of the maximum effect. Indatraline (10 mM) in human plasma was
used to achieve 100% inhibition. Undiluted plasma samples were
set at 100%. Thus, an IC50 of 10% indicates that a 10-fold diluted
plasma sample displaced 50% of the radioligand.
Statistical Analyses
Pharmacodynamics. Clinical data values were transformed
to differences from baseline. Peak effects (Emax) were determined
for repeated measures. Emax values were compared using General
Linear Models repeated-measures analysis of variance, with drug
as within-subject factor, using Statistica 6.0 software (StatSoft,
Tulsa, OK). Tukey post hoc comparisons were performed based on
significant main effects of treatment. Additional analyses of
variance were performed, with period as factor to exclude period
effects. Correlation analyses were performed using Pearson’s
correlations. The criterion for significance was p,0.05. Mean
arterial pressure (MAP) was calculated from diastolic blood
pressure and systolic blood pressure using the following formula:
MAP=DBP+(SBP - DBP)/3.
Pharmacokinetics. The plasma concentration data for
MDMA, MDA, HMMA, and duloxetine were analyzed using
non-compartmental methods. Cmax and tmax were obtained
directly from the observed concentration-time curves. The
terminal elimination rate constant (lz) was estimated by log-linear
regression after semilogarithmic transformation of the data, using
the last two to three data points of the terminal linear phase of the
concentration-time curve of MDMA or duloxetine. Terminal
elimination half-life (t1/2) was calculated using lz and the equation
t1/2 = ln2/lz. The area under the plasma concentration-time curve
up to 6 h (AUC0-6h) was calculated using the linear trapezoidal
rule. The AUC0–‘ was determined by extrapolation of AUC0–6h
using lz. The PK parameters were determined using the PK
functions for Excel (Microsoft, Redmont, CA, USA). Plasma
concentrations were only determined up to 6 h after MDMA
administration because the aim of the study was to assess potential
changes in MDMA plasma levels while relevant pharmacody-
namic effects or MDMA were present. It was therefore not
possible to determine t1/2 for HMMA and MDA because of their
long t1/2, which would require sampling for an extended time.
PK-PD modeling: First, a soft-link PK-PD model was used to
evaluate the in vivo relationship between the concentration of
MDMA and subjective effect of the drug. The change in the VAS
for any drug effect was used as the pharmacodynamic measure in
each individual. Because we observed clockwise hysteresis in the
effect-concentration relationship over time, we used PK-PD data
pairs within the ascending part of the individual curves up to Emax
or Cmax. Our estimate of Emax, which should represent the
maximal response portion of the dose-response curve, may already
have been affected by tolerance. However, Emax values of 100%
(scale maximum) or stable high values were reached by most
subjects, indicating that tolerance was not an issue early in the
effect-time curve. Based on the good brain penetration of MDMA
and absence of a time lag, we assumed rapid equilibration between
plasma and the central compartment (brain). A sigmoid Emax
model was then fitted to the pooled data of all individuals: E=Emax
6Cp
h/(EC50
h+Cph), in which E is the observed effect, Cp indicates
the MDMA plasma concentration, EC50 indicates the plasma
concentration at which 50% of the maximal effect is reached, Emax
is the maximal effect, and h is the Hill slope. The sigmoid Emax
model provided a better fit than a simple Emax or linear model.
Data pooling was used because only few data pairs were available
per subject. Non-linear regression was used to obtain parameter
estimates. Second, we also used a hard-link PK-PD model to
predict in vivo PD effects based on the in vitro concentration-
response data linked to the observed individual in vivo PK. The in
vitro concentration-response relationship was described by a
sigmoidal dose-response variable slope model fitted to the effects
of MDMA on 5-HT or NE release using non-linear regression
(Prism, GraphPad, San Diego, CA). The equation was the
following: E=Emax/(1+10(LogEC50-C)6h), in which C denotes the
concentration of MDMA in the assay, and h denotes the Hill slope.
The in vitro effect-concentration relationship was determined for
MDMA-induced 5-HT and NE release separately, and separate
PD predictions were derived for each model. Similar to the soft-
link PK-PD model, a single compartment PK model (plasma=
brain concentration) was used, and only ascending PK or PD
values were included. The in vivo data were linked to the PK of
each individual, and a mean predicted effect-time curve was
established.
Results
Pharmacodynamics (PD)
Duloxetine markedly reduced the psychotropic and cardiosti-
mulant responses to MDMA in humans. Duloxetine decreased all
aspects of MDMA’s subjective effects in the VASs [8,10],
including psychostimulant effects such as feelings of ‘‘good drug
effects,’’ ‘‘drug liking,’’ ‘‘drug high,’’ and ‘‘stimulation’’ (Table 1;
Fig. 2b-d) but also so-called ‘‘entactogenic’’ or ‘‘empathogenic’’
MDMA-typical effects [31,32] such as feelings of being ‘‘open,’’
‘‘closer to others,’’ and more ‘‘talkative’’ (Table 1; Fig. 2e and f). In
the AMRS [21], duloxetine prevented MDMA-induced increases
in ‘‘well-being,’’ ‘‘emotional excitation,’’ and ‘‘extroversion’’
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(Fig. 3). In the 5D-ASC [22,23], duloxetine robustly reduced
MDMA’s effects on the total ASC score (p,0.001) and in all three
main dimensions of the scale (main effect of drug: F3,45 = 26.2,
32.6, 5.67, and 26.6 for ASC, OB, AED, and VR, respectively; all
p,0.001; Fig. 4). Duloxetine prevented the MDMA-induced
increase in circulating plasma NE levels, an endocrine marker for
sympathetic system activation (Table 1), and reduced the blood
pressure and heart rate response to MDMA (Table 1; Fig. 5).
MDMA-induced increases in plasma NE at 60 min correlated
with elevations in MAP (r =0.57, p,0.05) and increases in VAS
scores for ‘‘good drug effects,’’ ‘‘liking,’’ ‘‘open’’ (r = 0.65, 0.69,
0.77 and 0.63, respectively; all p,0.01), supporting the modula-
tory role of NE in these effects of MDMA. ANOVAs with period
as factor showed no effect of treatment order, confirming the
absence of period effects.
Pharmacokinetics
The robust decrease in the PD response to MDMA after
duloxetine was not the result of a pharmacokinetic interaction
between duloxetine and MDMA because duloxetine increased
exposure to MDMA. MDMA and duloxetine are both substrates
and inhibitors of CYP 2D6 [16]. The moderate CYP 2D6
inhibitor duloxetine increased both the Cmax and AUC0-6h of the
CYP 2D6 substrate MDMA by 1664% (mean 6 SEM;
F1,15 = 12.64, p,0.01) and 1865% (F1,15 = 8.95, p,0.01), respec-
tively (Fig. 6 and Table 2). Duloxetine had no effect on exposure to
MDA, the active metabolite of MDMA. Duloxetine decreased the
Cmax and AUC0-6h of the inactive CYP 2D6-formed MDMA
metabolite HMMA by 4666% (F1,15 = 70.03, p,0.001) and
4866% (F1,15 = 166.10, p,.001), respectively. Plasma duloxetine
concentrations nonsignificantly increased beginning 1 h after
Table 1. Pharmacodynamic peak drug effects.
Placebo-
placebo
Duloxetine-
placebo
Placebo-
MDMA
Duloxetine-
MDMA F3,45 = p,
Visual Analog Scales
Any drug effect Emax 3.8163.62 6.0062.52
### 86.6963.57*** 33.1967.74*** ### 74.47 0.001
Good drug effect Emax 4.5664.37 8.7565.01
### 89.3864.67*** 40.5669.50*** ### 42.89 0.001
Drug liking Emax 4.1364.06 7.5664.43
### 90.6964.82*** 38.3868.91*** ### 52.60 0.001
Drug high Emax 1.9461.94 4.8162.93
### 87.8164.85*** 28.9469.35** ### 55.45 0.001
Stimulated Emax 4.1361.94 5.1362.45
### 76.3166.84*** 22.2567.65### 46.25 0.001
Open Emax 1.3860.94 0.3860.38
### 32.1664.29*** 6.0063.26### 36.88 0.001
Closeness Emax 0.0060.00 0.0060.00
### 27.3163.87*** 4.6362.49### 37.32 0.001
Talkative Emax 1.1960.81 0.3160.31
### 28.8165.12*** 10.6963.73### 21.13 0.001
Adjective Mood Rating Scale
Well-being Emax 1.6660.49 0.3860.16
### 7.0661.01*** 3.5661.08## 18.0 0.001
Emotional excitation Emax 0.6960.35 0.6960.27
### 4.9460.97*** 1.3160.37### 14.7 0.001
Extroversion Emax 0.6360.24 0.3860.16
### 3.5060.61*** 1.4460.43### 17.5 0.001
Introversion Emax 0.3861.56 1.1360.30 2.6260.65** 1.6960.59 5.4 0.01
Dreaminess Emax 0.6360.33 1.3560.35 2.9460.66** 1.8160.48 4.1 0.05
Activity Emin 21,8860.50 22.6960.69 24.6961.04* 22.8160.78 2.6 0.06
Circulating catecholamines
Epinephrine (nM) Emax 0.4260.12 0.4660.10 0.5060.12 0.2660.10 ns
Norepinephrine (nM) Emax 20.2260.13 20.1860.07
### 0.4460.12*** 20.1960.10### 14.7 0.001
Physiologic effect
SBP (mm Hg) Emax 8.5661.75 6.1961.42
### 29.9463.41*** 10.9461.58### 24.6 0.001
DPB (mm Hg) Emax 6.2561.25 6.0060.97
### 22.1362.08*** 9.2261.57### 23.3 0.001
MAP (mm Hg) Emax 5.8061.27 5.1161.01
### 21.7662.73*** 8.5461.46### 20.3 0.001
Heart rate (beats/min) Emax 9.1961.29 5.0661.27
### 26.0662.77*** 11.0961.55### 25.5 0.001
Body temperature (uC) Emax 0.2360.04 0.1960.04### 0.5460.07** 0.3960.08 7.3 0.001
List of Complaints (total score)
Acute adverse effects at 3 h 20.0660.52 21.8161.09### 5.5661.72** 21.2561.49## 29.5 0.001
Sub-acute adverse effects at 24 h 21.0060.58 22.8861.35## 3.8861.09* 20.3861.32# 24.6 0.001
Ex vivo binding (IC50%)
NET .25 14.360.6*** ## 23.460.7 13.760.7*** ### 20.4 0.001
SERT .25 1.560.2 *** ### .25 1.460.2 *** ### 243.1 0.001
DAT .25 .25 .25 .25
Values are mean6SEM of changes from baseline of 16 subjects. *p,.05, **p,.01, and ***p,.001 vs. Placebo-placebo. #p,.05, ##p,.01, ###p,.001 vs. Placebo-
MDMA. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure. IC50%, inhibition constant calculated as % of plasma sample dilution
with undiluted plasma set as 100%; NET, norepinephrine transporter; SERT, SERT, serotonin transporter; DAT, dopamine transporter; ns, nonsignificant.
doi:10.1371/journal.pone.0036476.t001
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Figure 2. Duloxetine inhibited the psychotropic effects of MDMA. MDMA produced stimulant-like (b–d) and ‘‘entactogenic’’ (e, f) effects
compared with placebo (p,0.001 for all scales). Duloxetine significantly inhibited MDMA-induced elevations in all of these subjective effects (a–f)
(p,0.001 for all scales). Values are expressed as mean+SEM (n =16).
doi:10.1371/journal.pone.0036476.g002
Figure 3. Duloxetine prevented the acute emotional effects of MDMA in the Adjective Mood Rating Scale. MDMA produced a state of
well-being (a), emotional excitation (b), increased introversion at drug onset at 1.25 h (d), increased extroversion at 2 h (c), increased dreaminess (e),
and decreased performance-oriented activity (f) (*p,0.05, **p,0.01, ***p,0.001, vs. placebo-placebo). Duloxetine prevented MDMA-induced
elevations in well-being, emotional excitation, and extroversion (a-c) (###p,0.001, placebo-MDMA vs. duloxetine-MDMA). Values are expressed as
mean+SEM (n =16).
doi:10.1371/journal.pone.0036476.g003
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MDMA administration (Fig. 5), consistent with the inhibitory
effect of MDMA on duloxetine metabolism via CYP 2D6.
Interindividual differences in CYP 2D6 activity also affected the
PK of MDMA. Lower CYP 2D6 function (i.e., a lower
dextromethorphan:dextrorphan urine concentration ratio) was
associated with a longer t1/2 of MDMA (r =0.65, p,0.01).
PK-PD Relationship
Fig. 7 shows the mean PD effects of MDMA plotted against
simultaneous plasma concentrations at the different time points
(hysteresis loops). The increases in ‘‘any drug effect’’ (Fig. 7a) and
MAP (Fig. 7b) returned to baseline within 6 h when MDMA
concentrations were still high. This clockwise hysteresis indicates
that a smaller MDMA effect was seen at a given plasma
concentration later in time, indicating rapid acute pharmacody-
namic tolerance, which was similarly described for cocaine [33].
Duloxetine robustly reduced the physical and subjective response
to MDMA, but it increased exposure to MDMA, illustrated by the
downward and rightward shift of the MDMA hysteresis loops
(Fig. 7).
Adverse Effects
MDMA produced adverse effects, such as sweating, difficulty
concentrating, thirst, and lack of appetite, resulting in an increase
in total LC scores at both 3 and 24 h after drug administration
(Table 1). Duloxetine produced daytime somnolence and moder-
ate insomnia. No severe adverse events were observed.
In vitro Studies
MDMA-induced 5-HT and NE release studies in vitro. MDMA
was nonsignificantly more potent in releasing NE via NET than 5-
HT via SERT (IC50 = 0.55 and 1.69 mM, respectively; Fig. 8;
Table 3), consistent with earlier work that used human [3,34] and
rat [2] transporters. MDA similarly released monoamines with
EC50 values of 0.85 and 2.77 mM for NE and 5-HT, respectively
(Fig. 8; Table 3). Thus, both amphetamines were active
transporter-mediated monoamine releasers and exhibited slightly
higher potency at NET than SERT. Duloxetine potently inhibited
the ability of MDMA and MDA to induce 5-HT release from
SERT and NE release from NET cells (Fig. 8). Duloxetine
(0.1 mM) decreased the Emax by approximately 50% and shifted
the concentration-effect curves to the right, consistent with a
mixed competitive and noncompetitive mode of inhibition. A high
concentration of duloxetine (10 mM) completely blocked the effects
of MDMA and MDA (Fig. 8). We then compared the inhibitory
effect of duloxetine on MDMA-induced monoamine release to the
inhibitory effects of the selective SERT inhibitor citalopram and
selective NET inhibitor reboxetine, each of which have been
shown to attenuate some of the effects of MDMA in humans
[7,10]. The potencies of duloxetine and citalopram to inhibit
MDA- and MDMA-induced 5-HT release were similar (Fig. S1;
Table 3). The potencies of duloxetine and reboxetine to block
MDMA-induced NE release were also similar (Fig. S1; Table 3).
These in vitro data indicate that duloxetine inhibited both SERT
and NET similarly to citalopram and reboxetine, respectively.
PK-PD and in vitro-in vivo relationship. Duloxetine
mainly affected the Emax of MDMA in the in vivo PK-PD
relationship of MDMA (Fig. 9a) consistent with a primarily
Figure 4. Duloxetine prevented the acute effects of MDMA in the Altered States of Consciousness (ASC) scale. MDMA significantly
increased the ASC sum score, Oceanic Boundlessness (OB), Anxious Ego Dissolution (AED), and Visionary Restructuralization (VR) dimensions, and
most of the subscales (*p,0.05, **p,0.01, ***p,0.001, placebo-placebo vs. placebo-MDMA). Duloxetine significantly reduced the effect of MDMA in
all dimensions and subscales (#p,0.05, ##p,0.01, ###p,0.001, placebo-MDMA vs. duloxetine-MDMA). Values are expressed as mean+SEM
(n = 16).
doi:10.1371/journal.pone.0036476.g004
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noncompetitive mode of inhibition and similar to the effect of
duloxetine on monoamine release produced by MDMA in vitro.
Duloxetine decreased the Emax from 93.867.3% to 20.864% for
placebo-MDMA compared with duloxetine-MDMA, respectively.
The EC50 values were 92.567.6 ng/mL (0.48 mM) and
83.8625 ng/mL (0.43 mM) for placebo-MDMA and duloxetine-
MDMA, respectively. The EC50 of the PK-PD curve of placebo-
MDMA in humans was 74 ng/ml (0.38 mM), similar to the EC50
values of MDMA to release 5-HT and NE in vitro. The plasma
concentrations of duloxetine (Cmax =112 ng/ml or 0.38 mM) were
also in the range of the concentrations that reduced MDMA-induced
5-HT and NE release in vitro. To relate our in vitro data to the PD of
MDMA in humans, we linked the concentration-effect relationship of
the in vitro effect of MDMA on 5-HT and NE release to the individual
concentration-time curves of our subjects (Fig. 9b). The observed
effect-time curve for MDMA in humans was predicted well by the in
vitro NE release model, assuming similar concentrations in plasma
and brain and no time lag. The 5-HT release model fitted, but 2- to
10-fold higher MDMA concentrations in the brain than in plasma
would be needed to obtain similar pharmacodynamic effects as NE.
The higher potency of MDMA to release NE vs. 5-HT in vitro also
predicted that NE release occurred at lower MDMA plasma and
brain concentrations and therefore sooner after MDMA administra-
tion, playing a predominant role during the initial drug effect (i.e.,
rush, stimulant effect). 5-HT release becomes relatively more
important later in time and predominantly mediates ‘‘entactogenic’’
effects, including feelings of being open and closer to others, that
prevail later. The model predicted that the half-maximal effects
would be reached at 4062 min and 70614 min for NE and 5-HT
release, respectively (Fig. 9b). The observed half-maximal subjective
drug effect of MDMA was reached 4464 min after drug adminis-
tration. At that time, the models predicted 4 (3–6)-fold higher NE
release compared with 5-HT release, consistent with the view of a
primary role for NE in the early effects of MDMA.
Monoamine transporter binding in vitro. The binding of
MDMA and MDA to monoamine transporters was weak (Table 4)
compared with the high potency of MDMA to release 5-HT and
NE. The binding profile of MDMA was consistent with other
binding studies that used human transporters [3] but different
from studies that used rat transporters [17]. Duloxetine showed
more than 100-fold higher affinity for both SERT and NET
compared with the affinity of MDMA for these transporters in the
same assay, supporting our approach of using duloxetine to
prevent MDMA from interacting with SERT and NET (Table 4).
Monoamine uptake inhibition in vitro. MDMA inhibited
NET three-fold more potently than SERT, consistent with previous
studies that used human transporters [3,35] but in contrast to data
derived frommouse and rat transporters [17,35,36] (Table 5). MDA
was equally potent to MDMA in inhibiting NET and SERT. Both
MDMA andMDA showed low potency to inhibit DAT. Duloxetine
was more potent in inhibiting SERT than NET (Table 5), which
was expected [13]. Because the selective SERT inhibitor citalopram
and selective NET inhibitor reboxetine have previously been shown
to attenuate the psychological effects of MDMA [7,10], we
compared duloxetine with these inhibitors. Duloxetine exhibited
similar potency as citalopram to inhibit SERT but 2- to 5-fold lower
potency as reboxetine to inhibit NET (Table 5).
Ex vivo Binding Studies
The ability of duloxetine to block monoamine transporters in
our study was confirmed with an ex vivo assay, in which plasma
from duloxetine-treated subjects inhibited ex vivo radioligand
binding to SERT and NET but not DAT (Table 1). We also
found a 10-fold higher affinity for SERT compared with NET,
Figure 5. Duloxetine reduced the cardiostimulant response to
MDMA. Duloxetine reduced the elevations in mean arterial blood
pressure (a) and heart rate (b) in response to MDMA. Duloxetine also
nonsignificantly lowered the MDMA-induced increase in body temper-
ature (c). Values are expressed as mean+SEM of 16 subjects.
doi:10.1371/journal.pone.0036476.g005
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Figure 6. Duloxetine increased MDMA exposure. Pharmacokinetics of MDMA, MDA, HMMA, and duloxetine (a–d). Duloxetine was administered 16 h
and 4 h before MDMA, which was administered at the 0 h time point. Duloxetine increased the Cmax and AUC0–6 of MDMA (a), had no significant effect on
MDA exposure (b), and decreased the Cmax and AUC0–6 of HMMA (c). Plasma duloxetine concentrations were similar in the duloxetine-placebo and duloxetine-
MDMA groups before MDMA administration (at –4 h and 0 h). Duloxetine concentrations increased 1 h after MDMA administration in the duloxetine-MDMA
vs. duloxetine-placebo group (d). Values are expressed as mean6SEM of 16 subjects. MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-
methylenedioxyamphetamine; HMMA, 4-hydroxy-3-methoxymethamphetamine.
doi:10.1371/journal.pone.0036476.g006
Table 2. Pharmacokinetic parameters of MDMA, MDA, HMMA, and duloxetine.
Cmax (ng/ml) Tmax (h) T1/2 (h) AUC0-6 (ng/ml h) AUC(0-‘) (ng/ml h)
MDMA
Placebo-MDMA 221.31611.63 2.3460.19 8.1760.74 952.75645.89 2908.556275.64
Duloxetine-MDMA 253.63613.60** 2.6660.29 7.1460.40 1106.87657.22** 2915.286154.27
MDA
Placebo-MDMA 11.7560.70 5.5060.22 – 46.6063.02 –
Duloxetine-MDMA 10.6760.72 5.2560.30 – 41.9563.38 –
HMMA
Placebo-MDMA 3.3660.34 1.8460.17 – 13.5761.58 –
Duloxetine-MDMA 2.0060.38*** 1.8960.25 – 8.1461.45*** –
Duloxetine
Duloxetine-placebo 106.77610.25 5.1460.29 10.9761.04 799.88674.40 1960.186229.54
Duloxetine-MDMA 111.6967.06 5.9560.39 11.3761.43 814.31652.73 2189.456297.99
Cmax, maximum plasma concentration; Tmax, time from drug administration to maximum plasma concentration; AUC0-‘, area under concentration-time curve
extrapolated to infinity. HMMA, 4-hydroxy-3-methoxymethamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-methylenedioxyamphetamine.
**p,.01, ***p,.001, vs. Placebo-MDMA. Values are mean6SEM (n = 16).
doi:10.1371/journal.pone.0036476.t002
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which was previously shown [13] and consistent with the in vitro
profile of duloxetine. We calculated the duloxetine concentration
in the plasma samples using the Ki values of duloxetine for SERT
and NET binding (Table 2) and the IC50 values derived from the
ex vivo binding in the duloxetine-placebo group (Table 1). The
values (mean 6 SE) obtained were 388636 nM and 576644 nM
duloxetine using SERT and NET binding, respectively, which was
well in agreement with the duloxetine plasma concentrations
determined by LC-MS/MS (31462.5 nM). Plasma from MDMA-
treated subjects did not differ from placebo-treated subjects with
regard to ex vivo radioligand binding to monoamine transporters
(Table 1). This finding is consistent with the relatively low in vitro
binding affinity of MDMA, which does not reflect the high
pharmacological activity of the drug. Our assay assessed binding to
Figure 7. Pharmacokinetic-pharmacodynamic (PK-PD) relationship. MDMA effects are plotted against simultaneous MDMA plasma
concentrations (a, b). The time of sampling is noted next to each point in minutes or hours after MDMA administration. The clockwise hysteresis
indicates acute tolerance to the effects of MDMA. Duloxetine pretreatment markedly reduced physical and subjective responses to MDMA in the
hysteresis loops (a, b).
doi:10.1371/journal.pone.0036476.g007
Figure 8. Duloxetine blocked MDMA- and MDA-induced 5-HT and NE efflux. Duloxetine inhibited SERT-mediated 5-HT release by MDMA
(a) and MDA (b). Duloxetine also inhibited NET-mediated NE release by MDMA (c) and MDA (d). Values are expressed as mean 6 SEM (n = 3–6) of
retained radiolabeled substrate following incubation with various concentrations of MDMA and MDA.
doi:10.1371/journal.pone.0036476.g008
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the SERT and NET binding site for [3H]-citalopram and [3H]-
nisoxetine, respectively. A possible explanation for the low affinity
of MDMA in this assay could be a binding site for MDMA that is
different from citalopram and nisoxetine at SERT and NET,
respectively, consistent with the noncompetitive mode of inhibition
of the MDMA-induced 5-HT and NE release by duloxetine.
Discussion
The present study showed that the dual SERT and NET
inhibitor duloxetine markedly decreased the psychotropic and
cardiovascular responses to MDMA in human subjects, confirm-
ing and extending previous work with selective SERT [7,8,9] and
NET [10] inhibitors. The inhibition of the effect of MDMA by
duloxetine in humans was pronounced and primarily noncompet-
itive. In vitro, duloxetine similarly blocked the interactive effects of
MDMA with SERT and NET to release 5-HT and NE. The
present findings provide further support for a central role of SERT
and NET as targets of MDMA with regard to its acute effects in
humans. Previous clinical data indicated that 5-HT release
primarily mediates the MDMA-typical ‘‘empathogenic’’ mood
effects of MDMA [7], whereas NE release may be responsible for
the stimulant and cardiovascular effects of the drug [10]. In the
present study, dual inhibition of 5-HT and NE release robustly
blocked both aspects of the MDMA effect, consistent with the role
of both 5-HT and NE. The precise mode of interaction of
amphetamine derivatives, including MDMA, with monoamine
transporters remains to be elucidated and may involve the
exchange of amphetamine with the transmitter, channel-like
conformational changes of the transporter [37], or transporter
internalization [38,39,40], MDMA is structurally similar to 5-HT,
and a common binding site has been proposed in transmembrane
domain 6 of SERT [41]. A distinct binding site was found for
SERT inhibitors, including citalopram and fluoxetine, proximal to
the 5-HT binding site [42]. Some SERT inhibitors may therefore
allosterically inhibit the interaction between MDMA and SERT to
release 5-HT. Consistent with these molecular data, our study
showed that duloxetine inhibited MDMA-induced 5-HT release,
NE release, and the response to MDMA in humans possibly
according to a noncompetitive inhibition mode. Both our in vitro
and in vivo findings may indicate acute allosteric inhibition of the
effects of MDMA by duloxetine. Prior work with rat brain
synaptosomes showed that indatraline competitively inhibited
MDMA-induced 5-HT release [5]. However, later studies
indicated that many SERT inhibitors also decreased the Emax
for different monoamine releasers, suggesting unique transporter
Table 3. Inhibition of MDMA-induced 5-HT or NE release by different inhibitors.
SERT NET
EC50 (mM) (95% CI)
Emax, % retained,
(95% CI) EC50 (mM) (95% CI)
Emax, % retained,
(95% CI)
MDMA alone 1.69 (1.07–2.66) 48 (42–55) 0.55 (0.17–1.81) 78 (73–82)
MDMA plus 0.1 mM duloxetine 3.51 (0.46–27) 82 (75–90) 0.59 (0.02–19) 90 (84–97)
MDMA plus 0.1 mM citalopram 3.17 (1.89–5.31) 72 (68–77) na na
MDMA plus 0.1 mM reboxetine na Na 3.35 (0.63–179) 78 (56–102)
MDA alone 2.77 (1.78–4.30) 48 (41–54) 0.85 (0.29–2.55) 73 (67–79)
MDA plus 0.1 mM duloxetine 6.86 (0.5–100) 83 (77–89) 2.06 (0.35–12.12) 80 (73–87)
MDA plus 0.1 mM citalopram 5.0 (1.28–19.6) 59 (44–75) na na
95% CI, 95% confidence interval; na, not assessed.
doi:10.1371/journal.pone.0036476.t003
Figure 9. Pharmacokinetic-pharmacodynamic modeling. Duloxetine lowered Emax in the MDMA concentration-effect curve (a) with little
effect on EC50, similar to the effect of MDMA on monoamine release in vitro. Diamonds and circles represent concentration-effect data pairs for
ascending concentrations for placebo-MDMA and duloxetine-MDMA, respectively (a). The solid lines show the fit of a sigmoid Emax PD model to the
observed PK data (a). Dashed lines indicate the 95% confidence interval (CI) of the estimation error (a). NE release predicted the observed subjective
effect of MDMA in vivo (b). Predicted effects are shown as curves (mean695% CI) that represent the fit of the in vitro concentration-effect data to the
16 individual plasma concentration-time curves (b). Observed values are expressed as mean6SEM of 16 subjects (b). MDMA, 3,4-
methylenedioxymethamphetamine; NE, norepinephrine; 5-HT, serotonin.
doi:10.1371/journal.pone.0036476.g009
Duloxetine and MDMA
PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36476
interactions for different inhibitor-releaser combinations [6]. This
indicates that different SERT inhibitors may also more or less
effectively reduce the effects of psychostimulants in humans.
Nevertheless, several of the present findings indicate that the effect
of duloxetine on the MDMA response was likely attributable to the
dual inhibition of SERT and NET and not only the result of
potent SERT inhibition alone. First, duloxetine blocked MDMA-
induced NE release in vitro and MDMA-induced increases in
plasma NE in vivo, similar to the selective NET inhibitor reboxetine
[10]. Second, we documented, ex vivo, NET binding in plasma
from duloxetine-treated subjects, and duloxetine has previously
been shown to effectively inhibit NET in humans [13]. Third,
potent and selective inhibition of SERT alone using citalopram in
a single high dose [7], fluoxetine for 5 days [8], or paroxetine for
3 days [9] failed to block the effects of MDMA in humans to the
extent seen here with dual SERT and NET inhibition. Conversely,
selectively blocking NET alone also did not as effectively reduce
the effects of MDMA in humans [10] as blocking both SERT and
NET. The importance of NE as a modulator of the acute effects of
MDMA is also supported by the fact that NE plasma levels after
MDMA treatment in the present study correlated with the
subjective effects and increases in blood pressure. Furthermore, we
compared our in vitro 5-HT and NE release data to clinical data in
humans and showed that the NE release link model better
predicted the ascending subjective effects of MDMA in humans
than the 5-HT release link model. A full assessment of the relative
efficacy of SERT and NET inhibitors to prevent the effects of
MDMA would require administration of SERT and NET
inhibitors alone and in combination and dose-response studies.
However, such studies were not ethically feasible because we did
not want to expose our MDMA-naive subjects to more than two
doses of MDMA in a crossover design.
The role of DA in the reinforcing effects of psychostimulants is
well established, but unknown is whether DA is critical for the
acute effects of MDMA. We found that MDMA exhibited higher
affinity for DAT than NET or SERT in vitro. However, MDMA
functionally exhibited significantly higher inhibition potency of the
SERT and NET compared with DAT, respectively. MDMA is
also more potent in releasing 5-HT and NE compared with DA in
vitro [3], and the magnitude of 5-HT release exceeded DA release
in the nucleus accumbens, striatum, and prefrontal cortex, assessed
with in vivo microdialysis in rats [43]. DAT inhibition did not affect
the acute response to MDMA in rhesus monkeys [44]. Addition-
ally, the D2 dopamine receptor antagonist haloperidol only weakly
attenuated MDMA-induced euphoria in humans and only at doses
that produced significant dysphoria [45]. Whether DAT (NET)
inhibitors, such as bupropion or methylphenidate, inhibit the
effects of MDMA in humans remains to be tested. Duloxetine is a
potent SERT and NET inhibitor but also weak DAT inhibitor
[13,46], which was confirmed in the present in vitro study. We
cannot exclude the possibility that the relatively high dose of
duloxetine used in the present study also inhibited MDMA-
induced DA release. Notably, the present ex vivo binding studies
further showed that the plasma from the subjects treated with
duloxetine exhibited binding to SERT and NET but not DAT.
The transporter-independent vesicular release of monoamines
could theoretically contribute to the mechanism of action of
MDMA. We recently showed that this is not the case for NE
because clonidine, which blocks transporter-independent vesicular
NE release, did not alter the effects of MDMA in humans [12].
Additionally, MDMA did not directly stimulate the Ca2+-
dependent vesicular release of DA [47]. Nevertheless, MDMA
may indirectly stimulate the DA system and induce the vesicular
release of DA by downstream 5-HT-DA or NE-DA system
interactions. For example, 5-HT release by MDMA stimulates DA
release via 5-HT2 receptor activation [48], and this indirect effect
on the DA system is also prevented by SERT inhibition [49].
Thus, downstream DA system activation may be a contributing
factor to MDMA-induced euphoria and the mechanism of action
of psychostimulants in general, even when SERT and NET may
be considered the primary pharmacological targets.
Finally, it is also possible that duloxetine induced adaptive
effects on monoamine systems that reduced the response to
MDMA in vivo. For example, decreases in SERT but not in NET
Table 4. Binding affinities to human monoamine
transporters.
SERT NET DAT
MDMA 13.360.47 22.4614.6 6.5262.24
MDA 18.762.76 17.864.06 26.464.24
Duloxetine 0.00560.002 0.0760.05 0.7060.07
Reboxetine 0.2460.02 0.01560.01 16.264.91
Citalopram 0.00560.001 5.0663.00 21.4610.5
Indatraline 0.0260.008 0.0360.02 0.0160.01
Paroxetine 0.00460.001 0.4260.17 0.7760.18
Values are mean6SD of Ki (mM) (n$3). Radioligands were 3[H]citalopram,
3[H]nisoxetine, and 3[H]-WIN35,428 for SERT, NET, and DAT, respectively.
doi:10.1371/journal.pone.0036476.t004
Table 5. Monoamine transport inhibition.
SERT NET DAT
Ki (mM) (95% CI) Ki (mM) (95% CI) Ki (mM) (95% CI)
MDMA* 1.40 (1.00–1.96) 0.470 (0.334–0.598) 16.7 (11.5–24)
MDA* 2.41 (1.49–3.92) 0.341 (0.253–0.461) 11 (7.5–17)
Duloxetine 0.050 (0.04–0.07)* 0.126 (0.099–0.161)* 2.26 (0.7–3.8)#
Reboxetine 2.07 (1.4–2.6)# 0.036 (0.030–0.044)* 16.4 (11.5–25.2)#
Citalopram* 0.045 (0.037–0.057) .20 .20
Indatraline# 0.09 (0.06–0.12) 0.043 (0.03–0.06) 0.025 (0.01–0.04)
Paroxetine# 0.014 (0.01–0.02) 1.12 (0.03–1.7) 4.83 (2.4–7.3)
*method A; #method B; 95% CI, 95% confidence interval; values are significantly different (p,0.05) if 95% CI do not operlap.
doi:10.1371/journal.pone.0036476.t005
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binding sites were documented following chronic administration of
duloxetine in rats [50].
In conclusion, the present study adds to a better understanding
of the mechanism of action of MDMA in humans. The data
support the roles of both NE and 5-HT in the acute effects of
MDMA. The robust and almost complete prevention of the effects
of MDMA by duloxetine suggests that dual transporter inhibitors
may be useful in the prevention of the acute and long-term
consequences of MDMA and potentially other psychostimulants in
addicted subjects.
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Figure S1 Potency and efficacy of MDMA- and MDA-
induced 5-HT and NE release inhibition by duloxetine,
citalopram, and reboxetine. Both duloxetine and citalopram
inhibited MDMA-induced (a, c) and MDA-induced (b, d) 5-HT
release in vitro with approximately similar potency and efficacy.
The potency of duloxetine to block MDMA-induced NE release
was also similar to the selective NET inhibitor reboxetine (e, f).
EC50 and Emax values are shown in Table 3. Data points represent
mean 6 SEM.
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Sex Differences in the Effects of MDMA (Ecstasy) on
Plasma Copeptin in Healthy Subjects
Linda D. Simmler, Ce´dric M. Hysek, and Matthias E. Liechti
Psychopharmacology Research Group, Division of Clinical Pharmacology and Toxicology, Department of
Biomedicine and Department of Internal Medicine, University Hospital and University of Basel, CH-4031
Basel, Switzerland
Background: 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) misuse is associated with
hyponatremia particularly in women. Hyponatremia is possibly due to inappropriate secretion of
plasma arginine vasopressin (AVP).
Objective: To assess whether MDMA increases plasma AVP and copeptin in healthy male and
female subjects and whether effects depend on MDMA-induced release of serotonin and norepi-
nephrine. Copeptin, theC-terminal part of theAVPprecursorpreprovasopressin, is cosecretedwith
AVP and can be determined more reliably.
Methods:We used a randomized placebo-controlled crossover design. Plasma and urine osmola-
lities as well as AVP and copeptin levels were measured in 16 healthy subjects (eight female, eight
male) at baseline and afterMDMA (125mg) administration. In addition,we testedwhether effects
ofMDMAonAVPandcopeptin secretioncanbepreventedbypretreatmentwith the serotoninand
norepinephrine transporter inhibitor duloxetine (120 mg), which blocks MDMA-induced trans-
porter-mediated release of serotonin and norepinephrine.
Results:MDMA significantly elevated plasma copeptin levels at 60 min and at 120 min compared
with placebo inwomenbut not inmen. The copeptin response toMDMA inwomenwas prevented
by duloxetine. MDMA also nonsignificantly increased plasma AVP levels in women, and the effect
was prevented by duloxetine. Although subjects drank more water after MDMA compared with
placebo administration, MDMA tended to increase urine sodium levels and urine osmolality com-
pared with placebo, indicating increased renal water retention.
Conclusion:MDMA increased plasma copeptin, a marker for AVP secretion, in women but not
in men. This sex difference in MDMA-induced AVP secretion may explain why hyponatremia is
typically reported in female ecstasy users. The copeptin response to MDMA is likely mediated
via MDMA-induced release of serotonin and/or norepinephrine because it was prevented by
duloxetine, which blocks the interaction of MDMA with the serotonergic and noradrenergic
system. (J Clin Endocrinol Metab 96: 0000–0000, 2011)
Abuseof3,4-methylenedioxymethamphetamine (MDMA,ecstasy) has been associated with the syndrome of
inappropriate secretion of antidiuretic hormone (SIADH)
(1, 2) and symptomatic hyponatremia particularly in
women (3, 4). Specifically, a case series of ecstasy-associ-
ated hyponatremia included 18 cases, of which 17 were
women (4). Another larger retrospective series of ecstasy
exposures reported to a poison center found hyponatre-
mia (Na!130mmol/liter) in 73 (38.8%) of 188 cases (3).
Of the 73 cases with hyponatremia, 55 (75.3%) were
women and 18 (24.7%) men (3). Thus, female sex was
significantly associated with increased odds of hypona-
tremiaand increasedoddsof associated comaamong these
cases (3). A small nonblinded laboratory study showed
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that MDMA significantly increased plasma concentra-
tions of arginine vasopressin (AVP) at 1–4 h after con-
trolled MDMA administration in eight healthy male
volunteers (5, 6). This study provides evidence for a stim-
ulatory effect of MDMA on AVP secretion. However, no
female subjects were included. We assessed MDMA ef-
fects on AVP system activation and associated changes in
plasma and urine osmolality as well as sodium levels in
resting healthy subjects with ad libitum water intake in a
controlled laboratory setting.
MDMA is a substrate of both the serotonin and nor-
epinephrine transporter (7). It enters presynaptic nerve
terminals andpotently releases serotonin andnorepineph-
rine through the transporter (7). AVP secretion is thought
to be regulated by serotonergic (8) and noradrenergic (9)
pathways, and these monoamines could act as mediators
for the effects ofMDMAon theAVPsystem.TheMDMA-
induced carrier-mediated release of serotonin and norepi-
nephrine can be reduced by serotonin and norepinephrine
transporter inhibitors, respectively (10, 11). We therefore
assessed whether blockade of both the serotonin and nor-
epinephrine transporter with duloxetine would prevent
potential effects of MDMA on AVP secretion in the pres-
ent study.
The reliable determination of plasma AVP is problem-
atic. We therefore measured copeptin in addition to AVP
levels. Copeptin is the C-terminal part of the AVP precur-
sor preprovasopressin. Copeptin is produced together
with AVP in equimolar ratio and exhibits similar kinetics
in response to osmotic changes (12–14). In contrast to
AVP, copeptin levels remain stable in serum or plasma
samples and can easily and reliably be measured (12).
Wehypothesized thatMDMAwould increaseAVPand
copeptin levels, particularly in women, and that pretreat-
ment with the serotonin-norepinephrine transport inhib-
itor duloxetine would prevent this effect.
Subjects and Methods
Study subjects
The study was performed in 16 healthy subjects (eight
women, eightmen).Womenwere (mean" SD) 29.0" 7.1 yr old.
Body weight was 59.0 " 6.9 kg. Men were 23.3 " 3.1 yr old.
Body weight was 79.5" 9.8 kg. Exclusion criteria included age
under 18 or over 45 yr, pregnancy (urine pregnancy test before
each test session), bodymass index below18.5 or over 25 kg/m2,
personal or family (first-degree relatives) history of psychiatric
disorder, regular use of medications, chronic or acute physical
illness (normal physical exam, normal electrocardiogram, and
standard hematological and chemical blood analyses), smoking,
lifetime prevalence of illicit drug use over five times (except for
tetrahydrocannabinol), illicit drug use within the last 2 months,
and illicit drug use during the study (urine tests before test ses-
sions). Subjects were asked to abstain from excessive alcohol
consumptionbetween test sessions and inparticular to limit their
use to one glass on the day before the test sessions. Subjects
abstained from caffeinated beverages on the test days. Female
subjects were investigated during the follicular phase (d 2–14) of
their menstrual cycle when the reactivity to amphetamines (15)
andosmotic sensitivity (16) are expected to be similar tomen.All
subjects gave theirwritten informed consent before participating
in the study, and subjects were paid for participation.
Study procedures
The study was conducted in accordance with the Declaration
of Helsinki and was approved by the Ethics Committee of Basel,
Switzerland. The use of MDMA in healthy subjects was autho-
rized by the Swiss Federal Office of Public Health, Bern, Swit-
zerland. The study was registered at www.clinicaltrials.gov
(number NCT00990067) with neuroendocrine measures as a
secondary outcome. We used a randomized placebo-controlled
crossover design with four conditions (placebo-MDMA, place-
bo-duloxetine, duloxetine-MDMA, and placebo-placebo) in
balanced order.Washout periods between sessions lasted 10–14
d. Duloxetine (120 mg) or placebo was administered twice 16
and 4 h before MDMA (125 mg) or placebo, respectively. We
assessed plasma and urine osmolality aswell as plasma and urine
sodium 4 h before and 120 min after MDMA/placebo adminis-
tration. Plasma levels of copeptinwere assessed 4 h before and at
60 and 120 min after MDMA/placebo. Plasma levels of AVP
were assessed 4 h before and 120 min after MDMA/placebo.
Subjects were not engaged in any physical activity andwere rest-
ing in hospital beds during the test session. Subjects had a small
standardizedbreakfast at thebeginningof each test session. Fluid
consumption was not restricted up to a total intake of 2000 ml
water during the session andwas recorded from4hbefore to120
min after MDMA/placebo administration when the last hor-
mone measurement was performed. In addition, saline was ad-
ministered via an iv catheter to keep catheters open for blood
sampling at a rate of 100 ml/h from 0–120 min after MDMA/
placebo administration. The study design also included addi-
tional assessments of subjective and cardiovascular effects,
blood drawings for pharmacokinetics, and monitoring of ad-
verse events for 6 h afterMDMA/placebo administration as will
bedescribedelsewhere (Simmler,L.D.,C.M.Hysek, J.Huwyler,
M. E. Liechti, unpublished data).
Measurements
Measurementswere done in duplicates in a blinded fashion in
a single batch. AVP was assessed in EDTA plasma using a RIA
(Direct Vasopressin RIA; Bu¨hlmann Laboratories AG, Scho¨nen-
buch/Basel, Switzerland). The lower detection limit was 0.82
pmol/liter, and the intraassay precisionwas 6.0%.Copeptin lev-
els were assessed using an immunoassay (LIA CT-proAVP;
B.R.A.H.M.S./ThermoFisher Scientific, Hennigsdorf/Berlin, Ger-
many) as described previously (12) and modified as described
previously (14).The lowerdetection limitwas0.4pmol/liter, and
the intraassay coefficient of variation was less than 5%. Sodium
concentrations were measured by indirect potentiometry (Hita-
chi 917; RocheDiagnostics, Rotkreuz, Switzerland).Osmolality
was measured by cryoscopy (Micro Osmometer; Advances In-
struments for Switzerland Instruments, Zurich, Switzerland).
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Study drugs
(")MDMA hydrochloride (Lipomed AG, Arlesheim, Swit-
zerland) was obtained from the Swiss Federal Office of Public
Health and prepared as gelatin capsules (100 and 25 mg). Iden-
tical placebo (lactose) capsules were prepared. MDMA was ad-
ministered in a single absolute dose of 125 mg. This dose of
MDMA corresponds to a typical recreational dose of ecstasy,
and comparable doses of MDMA have previously been used in
controlled settings. Because MDMA was dosed in an absolute
dose of 125 mg, differences in body weight resulted in different
weight-adjusted relative MDMA doses of 1.6 " 0.23 mg/kg
(range, 1.4–2.1 mg/kg) in men and 2.1 " 0.25 mg/kg (range,
1.8–2.5 mg/kg) in women. Duloxetine (Cymbalta; Eli Lilly SA,
Vernier, Switzerland) was prepared as 60-mg gelatin capsules,
and identically looking placebo (lactose) capsules were similarly
prepared.
Statistical analysis
Repeated-measures ANOVAwith the factors drug (placebo-
placebo, duloxetine-placebo, placebo-MDMA, and duloxetine-
MDMA) and time (baseline, 60 min, and 120 min) stratified for
sex and followed by pairwise Tukey post hoc tests was used to
assess differences in the effects of the different drugs. Nonnor-
mally distributed variables were log nor-
malized before the ANOVA. Correlation
analyses were performed using Spearman’s
rankcorrelationsusing the total of all values
(n# 128). All tests were two tailed, and the
significance level was set to P # 0.05.
Results
ANOVA on plasma copeptin levels
yielded a significant drug $ time $ sex
interaction [F(6,84)# 3.93; P# 0.0017].
MDMAsignificantlyelevatedplasmaco-
peptin levels at60min (P!0.001)andat
120 min (P! 0.01) compared with pla-
cebo in women (Fig. 1A) but not in men
(Fig. 1B). The MDMA-induced increase
in plasma copeptin in women was pre-
vented by duloxetine pretreatment
bothat 60min (P!0.001) and120min
(P ! 0.01) (Fig. 1A). A similar trend
was observed for AVP levels but drug
effects did not reach significance (Fig.
1, C and D). Oral liquid intake varied
across drug treatments, but there
were no sex differences [main effect of
drug: F(3,42) # 8.62; P ! 0.001, no
drug $ sex interaction]. Oral liquid
intake (mean" SEM) was 612" 50 ml
after placebo-placebo, 1267" 118ml
after duloxetine-placebo (P ! 0.001
vs. placebo-placebo), 1198 " 130 ml
after placebo-MDMA (P # 0.001 vs.
placebo-placebo), and 807 " 83 ml after duloxetine-
MDMA (P # 0.02 vs. duloxetine-placebo, and P #
0.051 vs. placebo-MDMA). Urine osmolality decreased
significantly over time [main effect of time: F(1,14) #
62.69; P! 0.001]. Urine osmolality tended to be higher
after placebo-MDMAor duloxetine-MDMA compared
with placebo-placebo or duloxetine-placebo as evi-
denced by a near-significant drug $ time interaction in
the ANOVA [F(3,42) # 2.70; P # 0.058] (Fig. 2, A and
B). A similar trend was observed for urine sodium levels
[drug$ time interaction: F(3,42)# 2.33;P# 0.088] (Fig.
2, C and D). There were no significant drug effects on
plasma sodium levels or plasma osmolality (Fig. 2,
E–H). Circulating copeptin levels correlated with AVP
levels (all: rs# 0.34, P! 0.001; women: rs# 0.53, P!
0.001; men: rs # 0.28, P ! 0.05]. Copeptin levels were
also correlated with plasma and urine osmolality [rs #
0.22; P ! 0.05 and rs # 0.68; P ! 0.001, respectively]
as well as with plasma and urine sodium [rs # 0.18; P !
A              B              
C              D
FIG. 1. Mean values " SEM for plasma levels of copeptin and AVP in eight female and eight
male healthy subjects 4 h before (PRE) and 60 and 120 min after MDMA (125 mg) or placebo.
A, MDMA significantly increased copeptin levels in women at 60 and 120 min after drug
administration compared with placebo. Duloxetine pretreatment prevented the MDMA-
induced elevation in circulating copeptin in women. B, MDMA did not alter copeptin levels in
men. C, Similar to its effects on MDMA-induced copeptin increases, duloxetine also prevented
the nonsignificant increase in AVP at 120 min after MDMA administration in women. D,
There were no drug effects on AVP levels in men. **, P ! 0.01; ***, P ! 0.001 vs. placebo-
placebo; ##, P ! 0.01; ###, P ! 0.001 vs. placebo-MDMA.
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0.05 and rs # 0.28; P ! 0.01, respectively]. Baseline co-
peptin levels were significantly lower in women than men
[F(1,14) # 8.38; P # 0.012]. The relative dose of MDMA
(inmilligrams per kilogrambodyweight) did not correlate
with the MDMA-induced increase in plasma copeptin
within the two sex groups. In the present study, MDMA
also producedmarked subjective and cardiovascular stim-
ulant effects aswill be reported separately elsewhere (Sim-
mler, L. D., C. M. Hysek, J. Huwyler, M. E. Liechti, un-
published data).
Discussion
We found that MDMA increased circulating copeptin, a
marker for AVP secretion, in women but not in men. This
sex difference inMDMA-induced AVP secretion is in line
with the clinical observation that ecstasy-associated hy-
ponatremia is typically reported in female users (3, 4).
Other sex differences in the response toMDMAor ecstasy
have previously been reported and include increased sub-
jective effects in women compared with men to equal
weight-adjusted doses of MDMA (18), more pronounced
depression after ecstasy use (19), and a potential increase
in serotonergic neurotoxicty in associationwith long-term
useof ecstasy inwomen (20).Thepresent findings indicate
that women may be at increased risk for developing hy-
ponatremia and associated neurotoxicity due to their sex-
specific stronger AVP response to MDMA. In addition,
the threshold levels of plasma sodium at which neurolog-
ical complications occur appear to be higher in women
than men (21, 22), and woman are more likely than men
to die from hyponatremic encephalopathy after surgery
(21, 23). Seizures and coma were also more frequently
reported in female cases of ecstasy-associated hypona-
tremia compared with men (3). However, ecstasy-asso-
ciated hyponatremia may have multiple causes, and
MDMA-induced AVP secretion may be only one of sev-
eral contributing factors. Dry mouth and physical ex-
ertion with sweating followed by hyperhydration with
electrolyte-free water may all contribute to the devel-
opment of hyponatremic states in recreational ecstasy
users. Even loss of sodium into the gastrointestinal tract
has been discussed (24).
The AVP system is activated by factors typically asso-
ciated with MDMA consumption in a party setting in-
A
E F G H
B C D
FIG. 2. Mean values " SEM for sodium and osmolality in urine and plasma in eight female and eight male healthy subjects 4 h before (PRE) and
120 min after MDMA (125 mg) or placebo. The two treatment conditions including MDMA (placebo-MDMA and duloxetine-MDMA) tended to
increase both urine osmolality (A and B) and urine sodium levels (C and D) in both sexes. There were no treatment effects on plasma osmolality or
plasma sodium levels (E–H).
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cluding dehydration (12–14), heat (25), and physical ac-
tivity (12, 26), all of which are potentially increasing the
risk of SIADH. Our results indicate that direct activation
of the AVP system by MDMA may play a crucial facili-
tating role in the development of ecstasy-associated
SIADH, in particular in women, because we controlled
carefully for confounding factors that may increase AVP.
Subjects werewell hydrated orally and iv and resting com-
fortably in hospital beds in a temperature-controlled re-
search environment. Of note, our subjects drank more
water after MDMA than after placebo administration
possibly due to a dry mouth and increased thirst after
MDMAadministration (18). Fluid consumptionwouldbe
expected to decrease copeptin secretion (13), counteract-
ing the effects of MDMA. However, copeptin levels were
actually increased during the MDMA condition, which
further supports the concept that MDMA activated the
AVP system via pharmacological stimulation, although
we cannot exclude an indirect effect via increased thirst
perception (14). Furthermore, urine osmolality and urine
sodium levels tended to be higher afterMDMA compared
with placebo administration despite the increase in oral
fluid intake. This finding indicates thatMDMA increased
renal fluid retention, which is consistent with an elevated
secretion of AVP.
The AVP response to MDMA in women was blocked
by duloxetine pretreatment. Duloxetine prevents the
transporter-mediated release of serotonin and norepi-
nephrine by MDMA. Thus, MDMA-induced AVP secre-
tion appears to bemediated by serotonin and norepineph-
rine. This clinical finding is in line with preclinical studies
indicating a role for central serotonin (8) and norepineph-
rine (9) systems in AVP secretion. The mediating role of
the serotonin system in AVP regulation is also supported
by the fact that several serotonergic medications are typ-
ically associatedwithan increased riskof SIADH(22).The
precise mechanism of the serotonin/norepinephrine-AVP
system interaction is not known. AVP and copeptin are
also hypothalamic stress hormones (27, 28), andMDMA
is a pharmacological stressor. MDMA activates the hy-
pothalamo-pituitary-adrenal axis and increases plasma
corticotropin and cortisol (29, 30). In addition, MDMA
increases aldosterone secretion in rats. Cortisol and min-
eralocorticoids also influence the electrolyte and body
fluid balance. We did not assess the role of steroids in the
present study. However, steroids increase renal sodium
reabsorption and would thereby antagonize AVP effects
on plasma osmolality.
In our study, MDMA (125 mg) had no effect on AVP
or copeptin plasma levels in male subjects, whereas an
earlier study showed an increase inAVP after a lower dose
of MDMA (47.5 mg) in eight healthy men (5, 6). This
discrepancy is likely due to differences in the study design
and setting. Importantly, subjects were free to drink as
much as they wanted in our study, and fluid consumption
was higher after MDMA than after placebo which could
have counteracted any MDMA effects on AVP secretion
and even abolished any MDMA effects in men. In addi-
tion, our subjectswere resting inhospital beds, eliminating
any contributing effects of physical activity on AVP se-
cretion. Nevertheless, it is surprising that our compara-
tively high dose ofMDMAdid not affect AVP or copeptin
secretion despite pronounced subjective and cardiovascu-
lar stimulant effects of MDMA in the same subjects (Sim-
mler, L. D., C. M. Hysek, J. Huwyler, M. E. Liechti, un-
published data). Interestingly, similar inconsistencies are
seen in the clinical reports on ecstasy-associated hypona-
tremia. Hyponatremia was found in 55 (52.4%) of 105
women and 18 (21.7%) of 83 men in ecstasy exposures
reported to the California Poison Control System (3).
However, other reports indicate that hyponatremia is a
relatively rare complication of ecstasy use. Ecstasy-asso-
ciated hyponatremiawas observed in only two (5%) of 40
monointoxications (31) or was not reported (32) accord-
ing to other poison center studies. Hyponatremiawas also
a rare medical complication according to a series of in-
toxication cases presenting to emergency rooms (17, 33,
34). Taken together, the available data point toward an
important role of additional contributing personal (sex,
menstrual phase, and genetic factors) and/or environmen-
tal (heat and hydration) factors that may contribute and
modulate the effects of MDMA on AVP secretion and
osmotic regulation.
Our studyhas several limitations.The study sample size
is relatively small. Only single doses of MDMA and du-
loxetine were used. However, the doses were selected in
the upper dose range and produced pronounced effects on
a variety of outcomes. Importantly, the absolute dose of
MDMAwas the same in both sexes and was not adjusted
for body weight, resulting in higher relative doses of
MDMAper kilogramof bodyweight inwomen compared
with men. Thus, we cannot exclude that the observed sex
difference was in fact a dose effect with women receiving
higher relative doses of MDMA than men. However, rel-
ative MDMA doses did not correlate with MDMA-in-
duced changes in copeptin levels within the male and fe-
male groups, supporting the view that our finding
represents a true sex difference and not a dose effect. Fur-
thermore, fluid consumption was different across treat-
ment conditions, which may have counteracted effects of
MDMA on AVP secretion because subjects consumed
more liquids after MDMA than after placebo administra-
tion. Finally, urine osmolality and associated AVP system
activationwas higher inmen thanwomen at the beginning
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of the study, which may have differentially affected the
response to MDMA.
With regard to the validity of theoutcomemeasures,we
documented a correlation of plasma AVP and copeptin,
confirmingprevious studies (12, 14). In addition, copeptin
plasma concentrations also weakly correlated with
plasma and urine osmolalities as expected based on os-
moregulation and as previously documented in hypo-,
iso-, and hyperosmolar states in healthy subjects (14). We
also confirmed the previously reported sex differences in
basal plasma copeptin concentration (12, 13).
In conclusion, we found thatMDMA increased copep-
tin plasma levels reflecting AVP system stimulation in
women but not in men. The finding is consistent with an
increased risk for the development of hyponatremia and
associated complications after recreational ecstasy use in
women compared with men. AVP system activation by
MDMAis likelydue to the serotonin- andnorepinephrine-
releasing properties of MDMA.
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Abstract
Rationale 3,4-Methylenedioxymethamphetamine (MDMA,
ecstasy) increases sociability. The prosocial effects of MDMA
may result from the release of the “social hormone” oxytocin
and associated alterations in the processing of socioemotional
stimuli.
Materials and methods We investigated the effects ofMDMA
(125 mg) on the ability to infer the mental states of others from
social cues of the eye region in the Reading the Mind in the
Eyes Test. The study included 48 healthy volunteers (24 men,
24 women) and used a double-blind, placebo-controlled,
within-subjects design. A choice reaction time test was used
to exclude impairments in psychomotor function. We also
measured circulating oxytocin and cortisol levels and subjec-
tive drug effects.
Results MDMA differentially affected mind reading depend-
ing on the emotional valence of the stimuli. MDMA enhanced
the accuracy of mental state decoding for positive stimuli (e.g.,
friendly), impaired mind reading for negative stimuli (e.g.,
hostile), and had no effect on mind reading for neutral stimuli
(e.g., reflective). MDMA did not affect psychomotor perfor-
mance, increased circulating oxytocin and cortisol levels, and
produced subjective prosocial effects, including feelings of
being more open, talkative, and closer to others.
Conclusions The shift in the ability to correctly read socio-
emotional information toward stimuli associated with positive
emotional valence, together with the prosocial feelings elicited
by MDMA, may enhance social approach behavior and so-
ciability when MDMA is used recreationally and facilitate
therapeutic relationships in MDMA-assisted psychotherapeu-
tic settings.
Keywords Emotion .MDMA . Oxytocin . Cortisol . Social
cognition . Face recognition
Introduction
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)
increases empathic feelings and sociability (Bedi et al. 2009,
2010; Dumont et al. 2009). The prosocial effects of MDMA
could result from the emotional interoceptive effects of the
drug but also from the altered perception or processing of
social signals. For example, acute administration of MDMA
in ecstasy users decreased the accuracy of facial fear recogni-
tion (Bedi et al. 2010), attenuated responses to threatening
faces in the amygdala (Bedi et al. 2009), and enhanced
responses to happy expressions in the ventral striatum (Bedi
et al. 2009). Thus, MDMAmay increase sociability by reduc-
ing recognition and responses to threatening social stimuli and
enhancing responses to rewarding stimuli. Here, we evaluated
whether MDMA also alters the ability to identify more com-
plex emotions assessed with the Reading the Mind in the Eyes
Test (RMET).
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The neurochemical mechanisms that underlie the social
effects of MDMA are largely unexplored. The social neuro-
peptide oxytocin is a key regulator of emotional and social
behavior (Meyer-Lindenberg et al. 2011; Neumann 2008) and
may mediate the social effects of MDMA. In fact, in rats,
MDMA has been shown to activate oxytocin-containing neu-
rons in the hypothalamus (Thompson et al. 2007), release
oxytocin from the hypothalamus (Forsling et al. 2002), and
increase plasma levels of oxytocin (Thompson et al. 2007).
MDMA increased social interaction in male rats (Thompson
et al. 2007, 2009), an effect blocked by intraventricular admin-
istration of an oxytocin receptor antagonist (Thompson et al.
2007). MDMA also elevated plasma concentrations of oxyto-
cin in humans (Dumont et al. 2009; Wolff et al. 2006).
Oxytocin has been shown to improve mind reading in the
RMET (Domes et al. 2007b; Guastella et al. 2010). MDMA
releases oxytocin and may similarly improve performance in
the RMET. However, in other tests, oxytocin selectively im-
proved the recognition of happy facial expressions but impaired
the decoding of negative facial expressions (Di Simplicio et al.
2009; Marsh et al. 2010). We therefore explored whether
MDMA differentially interferes with the ability to decode com-
plex emotions in the RMET depending on the emotional va-
lence of the stimuli.
MDMA releases norepinephrine, serotonin, and dopa-
mine from nerve terminals via their corresponding mono-
amine transporter (Rothman et al. 2001). To explore the
mechanism of action of MDMA, we investigated the effects
of three pretreatments on the response to MDMA. We used
the norepinephrine transporter inhibitor reboxetine to block
the MDMA-induced release of norepinephrine (Hysek et al.
2011). The dual serotonin and norepinephrine transporter
inhibitor duloxetine was used to block the MDMA-induced
release of both serotonin and norepinephrine (Simmler et al.
2011a). Clonidine was used to block any MDMA-induced
transporter-independent vesicular release of norepinephrine
(Hysek et al. 2012).
Materials and methods
Study design
This was a prospectively designed pooled analysis of three
double-blind, placebo-controlled, randomized, within-subjects
studies (Hysek et al. 2011, 2012; Simmler et al. 2011a, b). The
pre-specified primary endpoint of the pooled analysis was to
demonstrate an effect of MDMA on RMET performance
compared with placebo in 48 subjects. All subjects included
in the three studies received MDMA, placebo, one of three
different pretreatments prior to MDMA, or the pretreatment
alone (Fig. 1). Thus, the four experiential conditions for all
subjects were placebo-placebo, pretreatment-placebo, placebo-
MDMA, and pretreatment-MDMA in balanced order. Of
the 48 subjects, 16 (eight male, eight female) received the
serotonin-norepinephrine transport inhibitor duloxetine as pre-
treatment, 16 (eight male, eight female) received the norepi-
nephrine transport inhibitor reboxetine as pretreatment, and 16
(eight male, eight female) received the α2 adrenergic receptor
agonist clonidine as pretreatment. The random allocation se-
quence was developed by a clinical pharmacist and concealed
from all individuals involved in study management. The wash-
out periods between sessions were ≥10 days. The studies were
conducted in accordance with the Declaration of Helsinki and
the International Conference on Harmonization Guidelines on
Good Clinical Practice and approved by the Ethics Committee
of the Canton of Basel, Switzerland. The use of MDMA in
healthy subjects was authorized by the Swiss Federal Office of
Public Health, Bern, Switzerland. The studies were registered
at ClinicalTrials.gov (NCT00886886, NCT00990067, and
NCT01136278). Target sample size of the pooled study was
based on the effects of oxytocin in the RMET in previous
studies (Domes et al. 2007b; Guastella et al. 2010). The sample
size of the individual studies was based on power analyses
indicating that 13 subjects would be needed to detect a reduc-
tion of 20% in the subjective effects of MDMA (the primary
outcome) by the pretreatments with more than 80% power
using a within-subjects study design. Test sessions took place
in a quiet hospital research ward with no more than two
research subjects present per session.
Volunteers
Forty-eight healthy subjects (24 men, 24 women) aged 18 to
44 years (mean ± SD, 26 ± 5 years) and with a body weight
of 68 ± 11 kg were recruited on the university campus.
The exclusion criteria included the following: (1) age <18
or >45 years, pregnancy determined by a urine test before each
test session; (2) body mass index <18.5 or >25 kg/m2; (3)
personal or family (first-degree relative) history of psychiatric
disorder (determined by the structured clinical interview for
axis I and axis II disorders according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (Wittchen
et al. 1997) supplemented by the SCL-90-R Symptom Check-
list (Derogatis et al. 1976; Schmitz et al. 2000), Freiburg
Personality Inventory (Fahrenberg et al. 1984), and Trait Scale
of the State-Trait Anxiety Inventory (Spielberger et al. 1970);
(4) the regular use of medications; (5) chronic or acute physical
illness assessed by physical examination, electrocardiogram,
standard hematology, and chemical blood analyses; (6) smok-
ing more than 10 cigarettes per day; (7) a lifetime history of
using illicit drugs more than five times, with the exception of
cannabis; (8) illicit drug use within the last 2 months; and (9)
illicit drug use during the study determined by urine tests
conducted before the test sessions using TRIAGE 8 (Biosite,
San Diego, CA, USA). The subjects were asked to abstain from
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excessive alcohol consumption between test sessions and limit
alcohol use to one glass on the day before each test session. All
of the subjects were nonsmokers. Thirty-six subjects had pre-
viously used cannabis. Fourteen subjects reported using illicit
drugs (one to four times). Four subjects had tried ecstasy, two
had tried lysergic acid diethylamide, seven had tried psilocybin,
four had tried cocaine, and one had tried amphetamine. Impor-
tantly, 44 subjects were MDMA-naive. Female subjects were
investigated during the follicular phase (days 2–14) of their
menstrual cycle to account for the potential confounding effects
of sex hormones and cyclic changes in the reactivity to amphet-
amines (White et al. 2002). All of the subjects provided their
written informed consent before participating in the study, and
they were paid for their participation.
Measures
Reading the Mind in the Eyes Test (RMET)
The RMET (Baron-Cohen et al. 2001) was used to assess
the identification of complex emotions 90 min after the
administration of 125 mg MDMA or identical placebo.
The RMET was originally developed to assess the social
cognitive abilities of high functioning individuals with au-
tism spectrum disorder (Baron-Cohen et al. 2001). In the
RMET, 36 pictures of the eye region of faces are presented
on a computer screen, and participants are asked to decide
which of four words best describes what the person in the
picture is thinking or feeling (Baron-Cohen et al. 2001).
RMET scores are calculated as the total number of correct
discriminations of all 36 items. Additionally, subscores in the
present study were computed for positive (eight items), neg-
ative (12 items), and neutral (16 items) emotional valence as
previously described (Harkness et al. 2005) and used by others
(Fertuck et al. 2009).
Choice reaction time task (CRTT)
We used an adaptive five CRTT to assess potential drug
effects on sustained attention and executive motor function
(Schachinger et al. 2003). In this test, the subjects had to
respond to the presentation of five different colored lights by
pressing the button with the corresponding color as quickly
and accurately as possible (Schachinger et al. 2003). A
training run was performed before the first baseline assess-
ment and data were analyzed as drug-induced changes from
baseline to correct for training effects (Haschke et al. 2010).
The CRTT was performed before and 120 min after admin-
istration of MDMA or placebo in 32 subjects. The task is
sensitive to benzodiazepine administration (Haschke et al.
2010).
Endocrine measures
Blood samples for the determination of plasma oxytocin and
cortisol levels were collected in 32 and 48 subjects before and
120 min after drug administration, respectively. Plasma oxyto-
cin concentrations were determined using a radioimmunoassay
Assessed for 
eligibility (n=56)
Prescreening
Excluded (n=8)
•Refused to participate (n=2)
•Medical reason (n=6)
Randomized (n=48) assignment of order of 
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Placebo-Placebo
(n=48)
Placebo-MDMA
(n=48)
Reboxetine-Placebo
(n=16)
Reboxetine-MDMA
(n=16)
All participants completed the study (n=48) Drop outs (n=0)
Data analyzed (n=48)
Duloxetine-Placebo
(n=16)
Clonidine-Placebo
(n=16)
Duloxetine-MDMA
(n=16)
Clonidine-MDMA
(n=16)
Fig. 1 Study diagram
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in the Neurobiology Department (Inga D. Neumann),
University of Regensburg, Germany, as previously described
(Landgraf et al. 1995). Plasma cortisol concentrations were
determined using an automated solid-phase chemilumines-
cence immunoassay (Immulite 2000 Cortisol, Siemens Med-
ical Solutions Diagnostics, Los Angeles, CA, USA).
Subjective effects
Subjective effects were assessed using the Addiction Re-
search Center Inventory (ARCI) (Martin et al. 1971) and
visual analog scales (VASs) (Hysek et al. 2011). The ARCI
is a true–false questionnaire with five empirically derived
scales (Martin et al. 1971). The Amphetamine scale is
sensitive to the effects of d-amphetamine, the Benzedrine
Group scale is a stimulant scale consisting mainly of items
relating to intellectual efficiency and energy, the Morphine-
Benzedrine Group scale is a measure of euphoria, the
Pentobarbital-Chlorpromazine-Alcohol Group scale is a mea-
sure of sedation, and the Lysergic Acid Diethylamine Group
scale is a measure of dysphoria and somatic symptoms. The
ARCI has previously been shown to be sensitive to the effects
ofMDMA (Farre et al. 2007; Tancer and Johanson 2007). The
ARCI was used in its validated German version (Bopp et al.
2005) before and 2.5 and 5 h after drug administration. Visual
analog scores were used to assess “any drug effects” and
prosocial effects, including “closeness to others,” “open,”
and “talkative.” VASs were presented as 100 mm horizontal
lines marked from “not at all” on the left to “extremely” on the
right. VASs assessing prosocial feelings were bidirectional
(±50 mm). VAS scores were assessed before and 0,
0.33, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 h after drug
administration. The study included additional pharmacody-
namic and pharmacokinetic outcomes as reported elsewhere
(Hysek et al. 2011, 2012; Simmler et al. 2011a, b). All out-
come measures were assessed identically and at the same time
points following MDMA or placebo administration across
all three studies.
Drugs
(±) MDMA hydrochloride (Lipomed AG, Arlesheim,
Switzerland) was obtained from the Swiss Federal Office of
Public Health and prepared as gelatin capsules (100 and
25 mg). Identical placebo (lactose) capsules were prepared.
MDMA was administered in a single absolute oral dose of
125 mg. This dose of MDMA corresponds to a typical recre-
ational dose or the dose of MDMA used as an adjunct to
psychotherapy (Mithoefer et al. 2010). In the reboxetine-
MDMA study, reboxetine (8 mg, Edronax; Pfizer, Zurich,
Switzerland) or identical placebo (lactose) was administered
at 20:00 hours the day before the test session and again at 7:00
hours on the test day. MDMA or placebo was administered at
8:00 hours, 1 and 12 h after reboxetine. In the duloxetine-
MDMA study, duloxetine (120 mg, Cymbalta, Eli Lilly,
Vernier, Switzerland) or identical placebo (lactose) was ad-
ministered at 20:00 hours the day before the test session and
again at 8:00 hours on the test day. MDMA or placebo was
administered at 12:00 hours, 4 and 16 h after duloxetine.
Reboxetine and duloxetine were administered twice in high
doses to obtain plasma concentrations similar to those reached
with chronic daily administrations of the drugs and as previ-
ously used to manipulate the norepinephrine function in
healthy subjects (Roelands et al. 2008). In the clonidine-
MDMA study, clonidine (150 μg, Catapresan; Boeringer
Ingelheim, Basel, Switzerland) or identical placebo (lactose)
was administered at 8:00 hours, 1 h before MDMA or
placebo (9:00 hours). Clonidine has previously been
shown to produce sympatholytic effects in this dose in healthy
subjects (Anavekar et al. 1982; Nieuwenhuis et al. 2007). The
pretreatment times used for the three drugs resulted in maxi-
mal plasma concentrations of the pretreatments at the time of
the maximal effect of MDMA (Hysek et al. 2011, 2012). On
the test days, oral drug administration was supervised by study
personnel. Compliance with the first administration of rebox-
etine and duloxetine in the evening prior to the test day was
confirmed analytically in plasma (Hysek et al. 2011; Simmler
et al. 2011a).
Statistical analyses
For the statistical analyses, data from the three studies were
pooled, and endocrine measures and reaction times were
transformed to differences from baseline. Peak effects
(Emax) were determined for repeated measures. Emax values
and RMET scores were compared using one-way General
Linear Model repeated-measures analysis of variance
(ANOVA) with drug (MDMA vs. placebo) as a factor using
STATISTICA 6.0 (StatSoft, Tulsa, OK, USA). Data from
the three substudies on all four treatment conditions were
assessed using ANOVAs, with drug (placebo-placebo,
placebo-MDMA, pretreatment-placebo, and pretreatment-
MDMA) as a factor, followed by the Tukey post hoc test.
Sequence effects were tested by including treatment order as a
factor. Potential associations between MDMA-induced endo-
crine changes and subjective effects or RMET accuracy were
assessed using Spearman’s rank correlations. The criterion for
significance was p<0.05.
Results
RMET
As shown in Fig. 2, MDMA improved mind reading perfor-
mance in the RMET for stimuli with a positive emotional
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valence (F1, 4705.13, p<0.05) and impaired performance for
stimuli with a negative emotional valence (F1, 4707.05, p<
0.01). Improvements in reading positive emotions were seen
in 40 of the 48 participants, and impairments in reading
negative emotions were seen in 38 of the 48 participants.
MDMA had no effect on the accuracy of mind reading for
emotionally neutral stimuli or the total performance score.
There were no sex differences. No statistically significant
main effects of sequence and no sequence×drug interaction
were found, excluding sequence effects of treatment on test
performance. Drug effects on the RMET in each of the three
studies are shown in Tables 2, 3, and 4. MDMA consistently
exerted similar effects on mind reading in each of the three
studies as in the pooled analysis, but the effects did not reach
statistical significance. Duloxetine nonsignificantly attenuated
the effects of MDMA on RMET performance. Similar weak
and nonsignificant reductions of the MDMA effect were also
observed for reboxetine and clonidine.
CRTT
MDMA did not alter reaction time in the CRTT (Table 1)
or the RMET (F1, 4701.8, p0NS). In the individual
studies, none of the drugs altered reaction time in the CRTT
(Tables 2, 3 and 4).
Endocrine effects
MDMA increased plasma levels of oxytocin (F1, 3108.00, p<
0.01) and cortisol (F1, 470110, p<0.001) compared with
placebo (Table 1). In the duloxetine-MDMA study sample,
duloxetine reduced the MDMA-induced increase in plasma
levels of oxytocin and cortisol (Table 3). Neither reboxetine
nor clonidine significantly affected the endocrine effects of
MDMA (Tables 2 and 4).
Subjective effects
MDMA increased scores on the Amphetamine Group, Ben-
zedrine Group, Morphine-Benzedrine Group, Pentobarbital-
Chlorpromazine-Alcohol Group, and LSDGroup scales of the
ARCI compared with placebo (F1, 47036.4, 5.1, 44.7, 36.4,
and 15.2, respectively; all p<0.001, with the exception of the
Benzedrine Group [p<0.05]; Table 1). MDMA also increased
VAS scores for “any drug effect,” “closeness,” “open,” and
“talkative” (F1, 4701183, 98.0, 105, and 105, respectively; all
p<0.001; Table 1). The endocrine effects of MDMAwere not
associated with the subjective effects of MDMA or perfor-
mance on the RMET (all rs<0.28, all p>0.1). Duloxetine
reducedMDMA-induced increases in all VAS scores (Table 3).
Duloxetine also reduced the effect of MDMA on the
Amphetamine and Morphine-Benzedrine Group scales,
which were the only scales that showed significant
effects of MDMA in the ARCI in the duloxetine-MDMA
study (Table 3). In the reboxetine-MDMA study, reboxetine
loweredMDMA-induced increases in the VAS scores for “any
drug effects” and “closeness” (Table 2). The effects of
MDMA on all subscales of the ARCI were nonsignificantly
lower after reboxetine administration. In contrast, clonidine
had no effect on the subjective response to MDMA in the
clonidine-MDMA study (Table 4). No severe adverse effects
were reported.
Discussion
The main finding of the present study was that MDMA
improved performance on the RMET for positive stimuli
and impaired performance for negative stimuli, indicating that
MDMA differentially affected the ability to correctly decode
social facial stimuli depending on the emotional valence of the
Fig. 2 MDMA had differential effects on performance in the Reading
the Mind in the Eyes Test (RMET) depending on the emotional valence
of the stimuli. MDMA increased the ability in affective mind reading
for expressions with a positive emotional valence (positive items, *p<
0.05) and impaired mind reading for negative items (**p<0.01) com-
pared to placebo. MDMA did not alter performance for neutral items or
the total score (all items). Values are mean ± SEM accuracy (percentage
of correct items) in 48 subjects
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stimulus. In a party setting, the use of MDMA may therefore
improve the correct reading of positive facial expressions and,
combined with elevated mood and extroversion, may lead to
higher approach behavior and sociability. In contrast, the
misreading of negative social information as being more neu-
tral or positive may result in higher social risk behavior. When
Table 1 Mean ± SEM
values for endocrine,
psychomotor, and subjective
effects of MDMA (n048)
*p<0.05, **p<0.01,
***p<0.001 compared
to placebo
Placebo MDMA
Hormones
Oxytocin (Δ pg/mL) 5.0±3.9 28.1±4.0**
Cortisol (Δ nmol/L) −262.0±27.1 174.5±29.8***
Choice reaction time test (CRTT)
Reaction time (Δ ms) 4.6±3.7 −1.7±6.1
Addiction Research Inventory (ARCI)
Amphetamine −0.1±0.1 2.4±0.4***
Benzedrine Group 0.6±0.18 1.3±0.3*
Morphine-Benzedrine Group 0.2±0.2 5.5±0.8***
Pentobarbital-Chlorpromazine-Alcohol Group 0.2±0.2 3.0±0.5***
LSD Group 0.5±0.2 2.1±0.4***
Visual analog scales
Any drug effect 2.2±1.3 87.2±2.4***
Closeness 0.2±0.2 28.2±2.8***
Open 0.8±0.4 30.9±2.4***
Talkative 0.6±0.3 26.7±2.6***
Table 2 Mean ± SEM values and statistics for the reboxetine-MDMA study (n016)
Placebo-Placebo Reboxetine-Placebo Placebo-MDMA Reboxetine-MDMA F3, 45 0 p <
Hormones
Oxytocin (Δ pg/mL) NA NA NA NA
Cortisol (Δ nmol/L) −203±46 −230±60### 245±47*** 144±60*** 21.86 0.001
Reading the Mind in the Eyes Test
Total score 0.679±0.03 0.679±0.03 0.649±0.03 0.684±0.03 0.99 NS
Positive items 0.719±0.04 0.688±0.04 0.734±0.06 0.727±0.04 0.46 NS
Negative items 0.630±0.06 0.599±0.05 0.552±0.05 0.615±0.04 1.44 NS
Neutral items 0.695±0.04 0.734±0.04 0.680±0.04 0.715±0.04 1.19 NS
Choice reaction time task
Mean reaction time (ms) 4.5±5.7 16.1±8.5 0.42±13.3 21.9±10.1 1.23 NS
Addiction Research Center Inventory
Amphetamine 0.2±0.1 0.4±0.3## 4.1±0.9*** 3.3±0.6** 12.04 0.001
Benzedrine Group 1.1±0.4 0.7±0.3# 2.5±0.4 1.7±0.5 5.74 0.05
Morphine-Benzedrine Group 0.4±0.2 0.7±0.5### 8.4±1.3*** 5.4±1.1** 19.33 0.001
Pentobarbital-Chlorpromazine-
Alcohol Group
0.6±0.2 1.4±0.6## 4.4±0.9*** 3.1±0.7** 9.18 0.001
LSD Group 0.7±0.2 0.9±0.3### 4.3±0.8*** 2.8±0.6* 10.4 0.001
Visual analog scales
Any drug effect 1.9±1.3 8.0±3.4 85±4.8*** 68±6.2***,## 120.40 0.001
Closeness 0.3±0.2 0.0±0.0### 34±5.9*** 21±4.5***,# 22.66 0.001
Open 1.0±0.8 4.2±2.2### 30±3.1*** 23±4.9 22.73 0.001
Talkative 0.5±0.4 2.2±1.3### 26±4.3*** 20±5.1 18.56 0.001
NA not assessed, NS not significant
*p<0.05, **p<0.01, ***p<0.001, compared with Placebo-Placebo; # p<0.05, ## p<0.01, ### p<0.001, compared with Placebo-MDMA
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MDMA is administered during psychotherapy to treat post-
traumatic stress disorder (Mithoefer et al. 2010), the MDMA-
induced shift in accuracy toward a better perception of posi-
tive emotional stimuli may facilitate the therapeutic alliance
(Johansen and Krebs 2009).
MDMA did not affect total RMET score or the decoding of
stimuli with neutral emotional valence. Thus, MDMA did not
improve mind reading overall. Our finding in mostly non-
ecstasy-experienced volunteers is consistent with a previous
work, in which MDMA did not alter performance on the
RMET in 21 ecstasy users (Bedi et al. 2010). The latter study
did not evaluate whether emotional valence modulates the
effect of MDMA on the RMET. However, in another test in
the same study, MDMA differentially reduced the accurate
identification of negative, threat-related facial signals but did
not affect the identification of neutral or positive emotions
(Bedi et al. 2010). The emotion-specific effect of MDMA on
the decoding of facial expressions suggests that MDMA may
differentially affect brain areas involved in the processing of
emotional information. Indeed, functional magnetic resonance
imaging showed that MDMA attenuated the response to angry
faces in the amygdala, a structure activated by negative social
signals and fear (Zald 2003), and enhanced the response to
happy faces in the ventral striatum (Bedi et al. 2009), a structure
activated by reward expectation (Knutson and Cooper 2005).
Altogether, the data indicate that MDMA lowers reactivity to
negative social stimuli, such as threat, and enhances responding
to positive social stimuli, such as a smile.
We found that MDMA increased plasma levels of oxyto-
cin, confirming a placebo-controlled MDMA study (Dumont
et al. 2009) and observations in clubbers following the use of
ecstasy pills (Wolff et al. 2006). Oxytocin is a candidate for
the mediation of the empathic and social effects of MDMA
(Thompson et al. 2007). For example, MDMA increased
social interaction in rats that interacted for the first time,
predominantly reflected by an increase in adjacent lying be-
havior. This effect of MDMA was reduced by pretreatment
with an oxytocin antagonist (Thompson et al. 2007). Similar
to MDMA, oxytocin also reduced activation of the amygdala
in response to threatening social stimuli (Kirsch et al. 2005),
although other work showed that oxytocin reduced amygdala
responses regardless of the emotional valence of the facial
stimuli (Domes et al. 2007a) in men and enhanced amygdala
responses to fearful stimuli in women (Domes et al. 2010),
suggesting both sex differences and more complex effects of
oxytocin on emotion processing. Particularly relevant for the
present study, intranasal oxytocin administration improved
performance on the RMET in healthy male subjects (Domes
Table 3 Mean ± SEM values and statistics for the duloxetine-MDMA study (n016)
Placebo-Placebo Duloxetine-Placebo Placebo-MDMA Duloxetine-MDMA F3, 45 0 p <
Hormones
Oxytocin (Δ pg/mL) 1.4±7.1 1.6±4.7 22.2±9.1* 1.8±5.9# 4.56 0.01
Cortisol (Δ nmol/L) −354±46 −241±30### 157±62*** −181±29*,### 25.65 0.001
Reading the Mind in the Eyes Test
Total score 0.665±0.02 0.661±0.02 0.656±0.02 0.689±0.02 1.28 NS
Positive items 0.656±0.05 0.680±0.04 0.750±0.05 0.711±0.04 1.71 NS
Negative items 0.630±0.02 0.661±0.03 0.578±0.04 0.667±0.03 2.26 NS
Neutral items 0.695±0.02 0.641±0.04 0.668±0.05 0.695±0.04 0.70 NS
Choice reaction time task
Mean reaction time (ms) 4.7±7.1 3.4±32 −3.8±30 4.5±30 0.28 NS
Addiction Research Center Inventory
Amphetamine −0.1±0.2 −0.3±0.2 4.6±0.5*** 0.9±0.5### 35.13 0.001
Benzedrine Group 0.6±0.2 −0.1±0.3 1.4±0.4 −0.2±0.5# 4.07 0.05
Morphine-Benzedrine Group 0.5±0.5 0.6±0.2 8.4±0.9*** 2.3±0.8### 41.74 0.001
Pentobarbital-Chlorpromazine-
Alcohol Group
0.1±0.4 1.9±0.5 3.1±0.8 2.3±0.9 3.92 0.05
LSD Group 0.8±0.2 0.1±0.3 0.6±0.5 0.9±0.5 0.84 NS
Visual analog scales
Any drug effect 3.8±3.6 6.0±2.5 86.7±3.6*** 33±8***,### 74.47 0.001
Closeness 0.0±0.0 0.0±0.0 27.3±3.9*** 4.6±2.5### 37.32 0.001
Open 1.4±0.9 0.4±0.4 32.2±4.3*** 6.0±3.3### 36.88 0.001
Talkative 1.2±0.8 0.3±0.3 28.8±5.1*** 10.7±3.7### 21.13 0.001
NA not assessed, NS not significant
*p<0.05, **p<0.01, ***p<0.001, compared with Placebo-Placebo; # p<0.05, ## p<0.01, ### p<0.001, compared with Placebo-MDMA
Psychopharmacology
et al. 2007b) or male subjects with autism spectrum disorders
(Guastella et al. 2010). The effect of MDMA on the decoding
of positive emotional information in the present study might
therefore be explained by the oxytocinergic properties of
MDMA. Notably, oxytocin selectively improved the recogni-
tion of specific emotions in previous studies, similar to
MDMA in the present study. Specifically, oxytocin selectively
enhanced the recognition of happy facial expressions (Marsh
et al. 2010; Schulze et al. 2011), reduced misclassifications of
positive or ambiguous emotions as negative emotions (Di
Simplicio et al. 2009), increased the memory for positive faces
(Guastella et al. 2008), and slowed reaction times dur-
ing the recognition of negative fearful facial expressions
(Di Simplicio et al. 2009). Altogether, these data support the
hypothesis that the effects of MDMA on mind reading are
very similar to those of oxytocin and are potentially mediated
by this neuropeptide. MDMA-induced increases in the plasma
concentration of oxytocin were not correlated with RMET
performance in our study. However, plasma samples were
not available for all subjects of the study and it is also unclear
whether plasma concentrations of oxytocin reflect brain con-
centrations of this neuropeptide.
The administration of oxytocin in humans does not pro-
duce subjective mood effects. However, a drug discrimination
study showed that rats trained to respond for MDMA also
responded if MDMAwas substituted by the oxytocin receptor
agonist carbetocin, and responding for MDMA was reduced
by administration of the oxytocin receptor antagonist atosiban
(Broadbear et al. 2011). Oxytocin may therefore contribute to
the interoceptive subjective effects of MDMA. Whether the
subjective state of positive feelings and closeness to others
elicited by MDMA in humans is also associated with in-
creased emotional empathy (i.e., the sharing of experiences
of emotional states perceived in others) remains to be tested.
The finding that MDMA did not improve overall perfor-
mance on the RMET in the present study and a previous
study (Bedi et al. 2010) and the lack of improved face or
vocal affect recognition (Bedi et al. 2010) suggest that
MDMA does not improve cognitive empathy overall (i.e., the
recognition of emotional states in others). Oxytocin has
recently been shown to increase emotional but not cog-
nitive empathy in healthy male volunteers (Hurlemann
et al. 2010). We did not assess the effects of MDMA on
emotional empathy. Studies on the effects of MDMA on
different measures of emotional and cognitive empathy are
needed.
In the present study, MDMA also increased plasma levels
of cortisol, consistent with previous studies (Harris et al.
Table 4 Mean ± SEM values and statistics for the clonidine-MDMA study (n016)
Placebo-Placebo Clonidine-Placebo Placebo-MDMA Clonidine-MDMA F3, 45 0 p <
Hormones
Oxytocin (Δ pg/mL) 9.2±6.3 12.1±12.4 33.9±3.4* 20.2±5.5 3.32 0.05
Cortisol (Δ nmol/L) −229±42 −241±43 122±42 190±36*** 37.02 0.001
Reading the Mind in the Eyes Test
Total score 0.69±0.03 0.698±0.02 0.684±0.03 0.698±0.03 0.16 NS
Positive items 0.62±0.05 0.641±0.04 0.695±0.05 0.656±0.05 0.88 NS
Negative items 0.69±0.04 0.641±0.04 0.620±0.05 0.661±0.04 1.12 NS
Neutral items 0.73±0.04 0.770±0.02 0.727±0.04 0.746±0.03 0.54 NS
Choice reaction time task
Mean reaction time (ms) NA NA NA NA
Addiction Research Center Inventory
Amphetamine −0.4±0.2 −0.5±0.3### 3.3±0.4*** 3.3±0.5*** 37.11 0.001
Benzedrine Group 0.1±0.2 −1.5±0.5## 0.7±0.6 0.5±0.4 5.36 0.01
Morphine-Benzedrine Group −0.4±0.4 −0.9±0.5### 7.7±1.0*** 7.4±1.0*** 46.12 0.001
Pentobarbital-Chlorpromazine-
Alcohol Group
0.1±0.4 2.7±0.7 4.6±0.7*** 4.0±0.8*** 11.08 0.001
LSD Group 0.1±0.2 0.6±0.2 1.4±0.7 1.7±0.4* 3.84 0.05
Visual analog scales
Any drug effect 0.9±0.9 16.8±6.2### 89.6±4.0*** 81.6±6.9*** 87.55 0.001
Closeness 0.4±0.4 0.0±0.0### 23.4±4.6*** 24.1±4.7*** 20.35 0.001
Open 0.0±0.0 0.0±0.0### 30.3±4.4*** 30.2±5.0*** 33.71 0.001
Talkative 0.0±0.0 0.0±0.0### 24.8±4.4*** 24.7±4.5*** 24.26 0.001
NA not assessed, NS not significant
*p<0.05, **p<0.01, ***p<0.001, compared with Placebo-Placebo; # p<0.05, ## p<0.01, ### p<0.001, compared with Placebo-MDMA
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2002; Mas et al. 1999). We did not observe any association
between cortisol levels and RMET performance, and high
stress- compared with low stress-induced cortisol elevations
in healthy subjects did not alter RMETscores in another study
(Smeets et al. 2009).
In the ARCI, MDMA produced moderate amphetamine-
type effects with only slight stimulation, pronounced euphoria,
as well as moderate alcohol-like and moderate hallucinogen-
like effects similar to earlier works (Farre et al. 2007; Tancer
and Johanson 2007). In the VAS, MDMA produced its
MDMA-typical “entactogenic” effects including closeness to
others, openness, and talkativeness as described earlier (Hysek
et al. 2011; Liechti et al. 2001). We also assessed the effects of
different pretreatments on the response toMDMA.Duloxetine,
which inhibits MDMA-induced monoamine transporter-
dependent serotonin and norepinephrine release (Simmler
et al. 2011a, b), reduced all the amphetamine-type and euphori-
genic psychotropic effects of MDMA in the ARCI, the
entactogen-like aspects of the MDMA response in all the
VAS, and also endocrine effects of MDMA. Duloxetine also
tended to attenuate the effects of MDMA on RMET, although
these trends were not statistically significant. Reboxetine,
which inhibitsMDMA-induced norepinephrine release (Hysek
et al. 2011), reduced some of the psychotropic effects in the
VAS but not the endocrine effects of MDMA. Clonidine,
which inhibits any MDMA-induced transporter-independent
vesicular release of norepinephrine (Hysek et al. 2012), had
no effect on either the subjective or endocrine response to
MDMA. The finding that inhibition of the MDMA-induced
serotonin and norepinephrine release by duloxetine was more
effective in reducing the acute MDMA effects in humans than
inhibition of the release of norepinephrine alone by reboxetine
or clonidine suggests that serotonin may be primarily respon-
sible for the acute effects of MDMA in humans. This view is
also consistent with earlier mechanistic studies in humans
(Farre et al. 2007; Liechti et al. 2000; Liechti and Vollenweider
2000; Tancer and Johanson 2007). The data also indicate a
primary role for serotonin in the effects ofMDMA on oxytocin
release, emotion identification, and MDMA’s potential proso-
cial effects.
In conclusion, the MDMA-induced shift in the ability to
detect socioemotional information, together with the proso-
cial feelings elicited by MDMA, is likely to enhance social
approach behavior and sociability when MDMA is used
recreationally. The change in the processing of emotional
information may also facilitate therapeutic relationships in
MDMA-assisted psychotherapy.
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Abstract
Rationale Pupillometry can be used to characterize auto-
nomic drug effects.
Objective This study was conducted to determine the auto-
nomic effects of 3,4-methylenedioxymethamphetamine
(MDMA, ecstasy), administered alone and after pretreat-
ment with reboxetine, duloxetine, clonidine, carvedilol,
and doxazosin, on pupillary function.
Methods Infrared pupillometry was performed in five
placebo-controlled randomized studies. Each study included
16 healthy subjects (eight men, eight women) who received
placebo–MDMA (125 mg), placebo–placebo, pretreatment–
placebo, or pretreatment–MDMA using a crossover design.
Results MDMA produced mydriasis, prolonged the latency,
reduced the response to light, and shortened the recovery
time. The impaired reflex response was associated with
subjective, cardiostimulant, and hyperthermic drug effects
and returned to normal within 6 h after MDMA administra-
tion when plasma MDMA levels were still high. Mydriasis
was associated with changes in plasma MDMA concentra-
tion over time and longer-lasting. Both reboxetine and
duloxetine interacted with the effects of MDMA on pupil-
lary function. Clonidine did not significantly reduce the
mydriatic effects of MDMA, although it produced miosis
when administered alone. Carvedilol and doxazosin did not
alter the effects of MDMA on pupillary function.
Conclusions The MDMA-induced prolongation of the la-
tency to and reduction of light-induced miosis indicate
indirect central parasympathetic inhibition, and the faster
recovery time reflects an increased sympathomimetic action.
Both norepinephrine and serotonin mediate the effects of
MDMA on pupillary function. Although mydriasis is lasting
and mirrors the plasma concentration–time curve of
MDMA, the impairment in the reaction to light is associated
with the subjective and other autonomic effects of MDMA
and exhibits acute tolerance.
Keywords Pupil .Pupillary reflex .Pupillometry .MDMA .
Norepinephrine . Serotonin
Introduction
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)
induces the transporter-mediated release of serotonin and
norepinephrine (Liechti and Vollenweider 2001; Rothman
et al. 2001; Verrico et al. 2007) and produces cardiostimu-
lant and psychostimulant effects in humans (Hysek et al.
2011). The autonomic sympathomimetic effects of MDMA
in humans include increases in blood pressure, heart rate,
body temperature, and pupil diameter (Farre et al. 2004,
2007; Hysek et al. 2012c; Kolbrich et al. 2008; Liechti et
al. 2001; Mas et al. 1999). Pupil size and the response to a
flashlight stimulus are typically assessed in the evaluation of
intoxicated patients. Mydriasis is a clinical hallmark of
sympathomimetic toxicity in cases of ecstasy or cocaine
use. Laboratory studies have also shown an increase in pupil
diameter after MDMA administration (Farre et al. 2004,
2007; Kolbrich et al. 2008; Mas et al. 1999). However,
whether MDMA alters the pupillary light reflex response
and how pupillary changes are linked to MDMA exposure
and other pharmacodynamic effects of the drug are unknown.
Additionally, the pharmacological mechanism by which
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MDMA produces mydriasis and the potential changes in
pupillary function are unclear. Mydriasis and alterations in
the pupillary light reflex may result from increased sympa-
thetic activity, the release of norepinephrine, and α1-adrener-
gic receptor stimulation directly in the iris or from a decrease
in parasympathetic activity (Loewenfeld 1999). At the level of
the iris, the latency to the light reflex and miotic response to
light are thought to reflect parasympathetic activation (Heller
et al. 1990; Loewenfeld 1999), whereas redilation is consid-
ered to mainly reflect sympathetic activation (Loewenfeld
1999; Morley et al. 1991). Notably, the parasympathetic input
to the pupil may also be inhibited centrally via α2-adrenergic
receptors in the Edinger–Westphal nucleus by an increase in
sympathetic activity (Phillips et al. 2000a; Siepmann et al.
2007; Szabadi and Bradshaw 1996). Furthermore, the seroto-
nin system has been shown to indirectly influence pupillary
function, possibly by enhancing sympathetic activity (Prow et
al. 1996). Therefore, the MDMA-induced release of norepi-
nephrine in the periphery may stimulate α1-adrenergic recep-
tors in the iris or inhibit parasympathetic activity via central
α2-adrenergic receptors in the Edinger–Westphal nucleus. The
adrenergic mechanismsmay be further enhanced by the potent
MDMA-induced release of serotonin. To explore the mecha-
nism of action of MDMA on pupillary function, we investi-
gated the effects of five pretreatments on the response to
MDMA. We used the norepinephrine transporter inhibitor
reboxetine to block the transporter-mediated, MDMA-
induced release of norepinephrine (Hysek et al. 2011; i.e.,
the indirect sympathomimetic effect of MDMA). The seroto-
nin and norepinephrine transporter inhibitor duloxetine was
similarly used to block the MDMA-induced, transporter-
mediated release of both serotonin and norepinephrine
(Simmler et al. 2011). The α2-adrenergic agonist clonidine
was used as a sympathicolytic to inhibit the transporter-
independent vesicular release of norepinephrine (Hysek et
al. 2012a). Carvedilol and doxazosin were used to block
postsynaptic α1β1–3- and α1-adrenergic receptors, respective-
ly (Hysek et al. 2012c; i.e., to directly antagonize the effects of
norepinephrine in the iris, on the cardiovascular system, and
on body temperature). The series of studies included addition-
al outcome measures presented elsewhere (Hysek et al. 2011,
2012a, b, d; Simmler et al. 2011).
Material and methods
Study design
This was a pooled analysis of five double-blind, double-
dummy, placebo-controlled, randomized, crossover studies
(Hysek et al. 2011, 2012a, b, d; Simmler et al. 2011). The
primary aim of the pooled analysis was to assess the effects
of MDMA on pupil size and pupillary light reflex compared
with placebo in all 80 subjects and to explore associations with
the pharmacokinetics of MDMA and other pharmacodynamic
measures. All of the subjects included in the five studies
received MDMA, placebo, one of five different pretreatments
prior to MDMA, or the pretreatment alone (Fig. 1). Thus, the
four experiential conditions for all of the subjects were place-
bo–placebo, pretreatment–placebo, placebo–MDMA, and pre-
treatment–MDMA in a balanced order. Each of the five studies
included 16 subjects (eight male, eight female). The pretreat-
ments used in the five studies were reboxetine, duloxetine,
clonidine, carvedilol, and doxazosin. The random allocation
sequencewas developed by a clinical pharmacist and concealed
from all of the individuals involved in the study management.
The washout periods between sessions were ≥10 days. The
studies were conducted in accordance with the Declaration of
Helsinki and International Conference on Harmonization
Guidelines on Good Clinical Practice and approved by the
Ethics Committee of the Canton of Basel, Switzerland. The
use of MDMA in healthy subjects was authorized by the Swiss
Federal Office of Public Health, Bern, Switzerland. The studies
were registered at ClinicalTrials.gov (NCT00886886,
NCT00990067, NCT01136278, NCT01270672, and
NCT01386177).
Participants
Eighty healthy subjects (40 men and 40 women) aged 18
to 44 years (mean ± SD, 25±5 years) were recruited on
the university campus. The exclusion criteria included the
following: (1) age <18 or >45 years, (2) pregnancy
determined by a urine test before each test session, (3)
body mass index <18.5 or >25 kg/m2, (4) personal or
family (first-degree relative) history of psychiatric disor-
der [determined by the structured clinical interview for
axis I and axis II disorders according to the Diagnostic
and Statistical Manual of Mental Disorders, 4th edition
(Wittchen et al. 1997), supplemented by the SCL-90-R
Symptom Checklist (Derogatis et al. 1976; Schmitz et al.
2000)], (5) the regular use of medications, (6) chronic or
acute physical illness assessed by physical examination,
electrocardiogram, standard hematology, and chemical
blood analyses, (7) smoking more than 10 cigarettes per
day, (8) a lifetime history of using illicit drugs more than
five times, with the exception of cannabis, (9) illicit drug
use within the last 2 months, and (10) illicit drug use
during the study determined by urine tests conducted
before the test sessions using TRIAGE 8 (Biosite, San
Diego, CA, USA). The subjects were asked to abstain
from excessive alcohol consumption between test ses-
sions and limit alcohol use to one drink on the day
before each test session. Eight of the 80 subjects had
previously tried ecstasy (one to two times). Female sub-
jects were investigated during the follicular phase (day
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2–14) of their menstrual cycle to account for the poten-
tial confounding effects of sex hormones and cyclic
changes in the reactivity to amphetamines (White et al.
2002). All of the subjects provided their written informed
consent before participating in the study, and they were
paid for their participation.
Measures
Pupillometry
Pupillometry was performed 1 h before and 0, 0.33, 0.66, 1,
1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo
administration. Pupil function was measured under stan-
dardized dark–light conditions of 5.7±0.8 lx assessed by a
Voltcraft MS-1300 lux meter (Voltcraft, Hirschau, Germany)
following a dark adaption time of 1 min. Pupillometry was
performed using a handheld PRL-200 infrared pupillometer
(NeurOptics, Irvine, CA, USA; Taylor et al. 2003). The
subjects were instructed to focus on a black dot on a white
wall at a distance of 4 m. After a 10-s focusing period,
measurements were taken for 5 s. During this time frame,
the following parameters were assessed: dark-adapted pupil
diameter (MAX), minimal pupil diameter after a light
stimulus (MIN), and latency to the pupillary light reflex
(Fig. 2). The constriction amplitude was calculated as
MAX−MIN. The time taken by the pupil to recover 75 %
of the initial resting pupil size after it reached constriction
Assessed for eligibility (n=92)
Screening
Excluded (n=12)
•Refused to participate (n=3)
•Medical reason (n=8)
•noncompliance (n=1)
Randomized (n=80) assignment of order of 
4 drug conditions for each subject
Placebo-Placebo 
(n=80)
Placebo-MDMA
(n=80)
Reboxetine-Placebo
(n=16)
Reboxetine-MDMA
(n=16)
All participants completed the study (n=80) Drop outs (n=0)
Data analyzed (n=80)
Duloxetine-Placebo
(n=16)
Clonidine-Placebo
(n=16)
Duloxetine-MDMA
(n=16)
Clonidine-MDMA
(n=16)
Carvedilol-Placebo
(n=16)
Carvedilol-MDMA
(n=16)
Doxazosin-Placebo
(n=16)
Doxazosin-MDMA
(n=16)
Fig. 1 Study diagram
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Fig. 2 Schematic drawing of the light reflex response.MAX represents
the dark-adapted resting pupil size before the light stimulus. Latency
represents the time of the onset of constriction. MIN represents the
minimal pupil size after the light stimulus. The constriction amplitude
was calculated as MAX−MIN. The 75 % recovery time is the time to
recover 75 % of the initial resting pupil size after reaching MIN
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was also assessed. The dynamic pupil measurements
were triggered by a light impulse of 180 μW intensity
and duration of 167 ms. Measurements were performed
on both eyes, and the average values were used for
further analyses.
Subjective drug effect
Subjective drug effects were assessed using visual analog
scales (VAS) reported in detail elsewhere (Hysek et al. 2011,
2012a). In the present report, we included only the VAS
rating of “any subjective drug effects,” measured using a
1000mm horizontal line marked “not at all” on the left and
“extremely” on the right. The VAS was repeatedly admin-
istered 1 h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, and
6 h after MDMA or placebo administration. The scale is
very sensitive to the overall psychotropic effects of MDMA
(Farre et al. 2007; Hysek et al. 2011). The comprehensive
assessments of different aspects of the psychotropic re-
sponse to MDMA have been presented in the reports of
the individual studies (Hysek et al. 2011, 2012a, b, d).
Blood pressure, heart rate, and body temperature
Blood pressure and heart rate were assessed repeatedly
before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h
after MDMA or placebo administration using an
OMRON M7 monitor (Omron Healthcare Europe,
Hoofddorp, The Netherlands) in the dominant arm and
after a resting time of 5 min. Measures were taken
twice per time point with an interval of 1 min, and
the average was used for analysis. Mean arterial pres-
sure (MAP) was calculated from diastolic and systolic
blood pressure using the formula MAP 0 diastolic blood
pressure + (systolic blood pressure−diastolic blood pres-
sure)/3. Core (tympanic) temperature was assessed using
a GENIUS 2 ear thermometer (Tyco Healthcare Group,
Watertown, NY, USA).
Pharmacokinetics of MDMA
Blood samples were collected before and 0, 0.33, 0.66, 1,
1.5, 2, 2.5, 3, 4, and 6 h after MDMA or placebo adminis-
tration, and plasma MDMA levels were determined as pre-
viously described (Hysek et al. 2012a). The data for the
plasma concentrations of MDMAwere analyzed using non-
compartmental methods. Maximal plasma concentration and
the time to maximal plasma concentration were obtained
directly from the concentration–time curves of the observed
values. Plasma concentrations were only determined up to
6 h after MDMA administration because the aim of the
study was to assess plasma exposure only during the time
of the pharmacodynamic effects of MDMA.
Drugs
(±)-MDMA hydrochloride (Lipomed AG, Arlesheim, Swit-
zerland) was prepared as gelatin capsules (100 and 25 mg).
Identical placebo (mannitol) capsules were prepared. MDMA
was administered in a single absolute oral dose of 125 mg.
This dose of MDMA corresponds to a typical recreational
dose or the dose of MDMA used as an adjunct to psychother-
apy (Mithoefer et al. 2010). In the reboxetine–MDMA study,
reboxetine (Edronax; 8 mg; Pfizer, Zurich, Switzerland) or
identical placebo was administered at 8:00 p.m. on the day
before the test session and again at 7:00 a.m. on the test day.
MDMA or placebo was administered at 8:00 a.m., 1 and 12 h
after reboxetine. In the duloxetine–MDMA study, duloxetine
(Cymbalta; 120 mg; Eli Lilly, Vernier, Switzerland) or identi-
cal placebo was administered at 8:00 p.m. on the day before
the test session and again at 8:00 a.m. on the test day. MDMA
or placebo was administered at 12:00 p.m., 4 and 16 h after
duloxetine. Reboxetine and duloxetine were administered
twice at high doses to obtain peak plasma concentrations of
(mean ± SD) 372±34 and 107±10 ng/ml, respectively, similar
to the concentrations reached with chronic daily administra-
tion of 4 and 60 mg of the drugs, respectively (Hysek et al.
2011; Simmler et al. 2011), and as previously used to manip-
ulate noradrenergic function in healthy subjects (Roelands et
al. 2008). Compliance with the first administration of rebox-
etine and duloxetine on the evening prior to the test day was
confirmed analytically in plasma (Hysek et al. 2011, 2012d).
In the clonidine–MDMA study, clonidine (Catapresan;
150 μg; Boehringer Ingelheim, Basel, Switzerland) or identi-
cal placebo was administered at 8:00 a.m., 1 h before MDMA
or placebo (9:00 a.m.; Hysek et al. 2012a). Clonidine has
previously been shown to produce sympatholytic effects at
this dose in healthy subjects (Anavekar et al. 1982; Bitsios et
al. 1996; Nieuwenhuis et al. 2007) and was expected to
produce peak plasma concentrations in the range of 0.6–
0.7 ng/ml (Anavekar et al. 1982; Keranen et al. 1978). In the
carvedilol–MDMA study, carvedilol (Dilatrend; 50 mg;
Roche, Basel, Switzerland) or identical placebo was adminis-
tered at 8:00 a.m., 1 h before MDMA or placebo (9:00 a.m.;
Hysek et al. 2012c). The same dose of carvedilol has previ-
ously been shown to attenuate the smoked cocaine-induced
increases in heart rate and blood pressure in humans (Sofuoglu
et al. 2000) and was expected to produce peak plasma con-
centrations in the range of 120–180 mg/ml (Henderson et al.
2006; Morgan 1994). At this dose, carvedilol is expected to
inhibit both α1- and β-adrenergic receptors (Sofuoglu et al.
2000; Tham et al. 1995), with fivefold to tenfold higher
activity at β receptors (Tomlinson et al. 1988, 1992). In the
doxazosin–MDMA study, continued-release doxazosin (Car-
dura; 4 mg; Pfizer, Zurich, Switzerland) or identical placebo
was used. A first dose of 4 mg of doxazosin was administered
3 days before MDMA or placebo (−64 h) at 5:00 p.m., a
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second dose of 8 mg was administered 2 days before MDMA
or placebo (−40 h) at 5:00 p.m., and a third dose of 8 mg was
administered the day before MDMA or placebo administra-
tion (−16 h) at 5:00 p.m. The subjects were reminded by a
phone call or phone text message to ingest the capsules, and
medication containers were checked to confirm that the first
two doses of doxazosin were administered. The last adminis-
tration was supervised by study personnel at the research
facility. This administration schedule accounted for the long
tmax of 8–10 h of the continuous-release formulation of dox-
azosin and reduced the risk of hypotension (Chung et al.
1999). Based on similar dosing regimes in healthy subjects
(Chung et al. 1999; Shirai et al. 2010), the mean estimated
peak plasma concentration of doxazosin was 30±5 ng/ml,
similar to the concentration with steady-state dosing of 4 mg
(Chung et al. 1999). The pretreatment times for the adminis-
tration of the five pretreatments resulted in maximal plasma
concentrations of the pretreatments at the time of or shortly
before the maximal effect of MDMA, based on our analytical
results (Hysek et al. 2011, 2012a, c, d) or published data
(Anavekar et al. 1982; Chung et al. 1999; Henderson et al.
2006; Keranen et al. 1978; Morgan 1994; Shirai et al. 2010).
Oral drug administration on the test days was supervised by
study personnel.
Statistical analyses
Maximal effect values (Emax), minimal effect values
(Emin; only for clonidine), and areas under the effect–
time curves were determined with repeated measures.
Values from the five studies were separately compared
using two-way factorial general linear models repeated-
measures analysis of variance (ANOVA), with the factors
MDMA (MDMA vs. placebo) and pretreatment (pretreat-
ment vs. placebo), using STATISTICA 6.0 software (Stat-
Soft, Tulsa, OK, USA). Additionally, MDMA and
placebo values from all of the studies were pooled and
analyzed with MDMA as a single within-subjects factor.
Tukey post hoc comparisons were performed based on
significant main effects or interactions in the ANOVA.
Analyses of the area under the effect–time curve data
yielded identical results to those of the maximal values
and are, therefore, not shown. Associations between the
pharmacodynamic changes and plasma concentration of
MDMA were analyzed using Spearman’s rank correla-
tions. This first correlation analysis assessed the associa-
tions of the parameters between subjects (n080) for each
time point. The mean pharmacodynamic changes after
MDMA administration for each time point were then
plotted against the respective mean plasma concentrations
of MDMA and graphed as hysteresis curves. Correlations
between the pharmacodynamic–pharmacokinetic data
pairs over time (n09 time points) were then analyzed
using Spearman’s rank correlation. Associations between
pupillary function parameters and cardiovascular or sub-
jective effects were similarly analyzed (n010 time
points). This second correlation analysis assessed the
associations of mean parameter changes from baseline
over time within the 16 subjects (n09 or 10). The
criterion for significance was p<0.05.
Results
Parameters of pupillary function (placebo condition)
Pupillary function parameters were measured 10 times in 80
subjects after placebo administration. Mean ± SEM values
were as follows: pupil size06.23±0.09 mm, pupil size after
light04.34±0.08 mm, constriction amplitude01.90±
0.01 mm, and recovery time02.46±0.06 s. Maximal values
are shown in Table 1. The diameter of the light-stimulated
pupil correlated with the resting pupil size prior to the light
stimulus (Rs00.94, p<0.001, n080).
Effects of MDMA on pupillary function
MDMA increased pupil size both at rest and after the
light stimulus and lowered the constriction amplitude
compared with placebo (Fig. 3; Table 1). The effect of
MDMA on pupil size peaked (mean ± SEM) 2.3±0.2 h
after drug administration at the time of the maximal
plasma concentration of MDMA and remained high over
6 h in parallel with plasma levels that also remained high
over 6 h (Fig. 3a). The effect of MDMA on the con-
striction amplitude was maximal 1.7±0.1 h after drug
administration and decreased to baseline levels over 6 h
(Fig. 3b) despite high plasma levels of MDMA. MDMA
also prolonged the latency to the pupillary light reflex
and shortened the recovery time of the pupillary light
reflex response (Table 1).
Subjective effects of MDMA
MDMA produced significant subjective drug effects com-
pared with placebo (Table 1). The peak effect was
reached 1.5±0.1 h after MDMA administration (Fig. 3c).
The subjective effects of MDMA completely reverted to
baseline within 6 h, although the plasma levels of
MDMA remained high (Fig. 3c). The effects of the pre-
treatments on the subjective response to MDMA are
reported in detail elsewhere (Hysek et al. 2011, 2012a,
b, d). Briefly, reboxetine and duloxetine reduced the
subjective effects of MDMA, whereas the other pretreat-
ments overall had no effect on the subjective response to
MDMA (Hysek et al. 2012c).
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Table 1 Effects of MDMA
n080 (values from all five stud-
ies were pooled)
Placebo
(mean ± SEM)
MDMA
(mean ± SEM)
F1,79 p value
Pupil size (mm) Emax 6.60±0.09 7.58±0.07 288.1 <0.001
Pupil size after light (mm) Emax 4.76±0.09 6.86±0.09 646.9 <0.001
Constriction amplitude (mm) Emax 1.76±0.06 0.81±0.12 328.0 <0.001
Latency (s) Emax 0.25±0.00 0.33±0.02 16.2 <0.001
Recovery time (s) Emax 1.74±0.06 1.17±0.07 57.3 <0.001
Subjective drug effect (percent maximum) Emax 3.5±1.7 81.0±2.8 901.2 <0.001
Mean arterial pressure (mmHg) Emax 95.0±1.0 114.5±1.2 339.7 <0.001
Heart rate (bpm) Emax 76.0±1.2 96.2±1.9 138.1 <0.001
Body temperature (°C) Emax 37.3±0.1 37.6±0.1 26.2 <0.001
Placebo MDMA MDMA plasma levels
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Fig. 3 Acute effects of MDMA on pupil function. Values are
expressed as the mean ± SEM of 80 subjects. MDMA increased resting
pupil size compared with placebo (a). The mydriatic effect of MDMA
remained high in parallel with the plasma concentration of MDMA.
MDMA reduced the pupil constriction amplitude compared with
placebo and this effect decreased more rapidly than the plasma con-
centration of MDMA (b). The subjective (c), cardiovascular (d, e), and
thermogenic (f) effects of MDMA also disappeared within 6 h when
the plasma concentrations of MDMA were still high
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Effects of MDMA on blood pressure, heart rate, and body
temperature
MDMA significantly increased blood pressure, heart rate,
and body temperature compared with placebo (Table 1;
Fig. 3d–f). Similar to the subjective effects, MDMA-
induced increases in blood pressure and heart rate were
short-lasting.
Pharmacokinetics of MDMA
Plasma MDMA concentrations are shown in Fig. 3. The
peak plasma MDMA concentration was (mean ± SEM)
243±6 ng/ml. The time to maximum plasma concentra-
tion was 2.5±0.1 h.
Pharmacokinetic–pharmacodynamic and
pharmacodynamic–pharmacodynamic associations
The relationships between the concentration of MDMA and
its pharmacodynamic effects are shown in Fig. 4a–c. The
average group pupil size was correlated with the average
plasma levels of MDMA over time (Rs00.77, p<0.01, n09),
with moderate clockwise hysteresis (Fig. 4a). In contrast, the
MDMA-induced reduction in constriction amplitude was not
significantly associated with the plasma concentrations of
MDMA (Rs00.43, p00.24, n09), attributable to pronounced
clockwise hysteresis (Fig. 4b). There was a similar marked
hysteresis in the relationship between the concentration of
MDMA and the subjective drug effects (Fig. 4c) and no
correlation between the two (Rs00.48, p00.17, n09). The
association between the average subjective effect and pupil
size over time was relatively strong (Rs00.77, p<0.01, n010),
but hysteresis was observed in the relationship between sub-
jective effects and pupil size over time (Fig. 4d), indicating
that the subjective effects decreased more rapidly than the
mydriasis associated with MDMA. In contrast, little or no
hysteresis was observed in the plot of the relationship of
subjective effects with constriction amplitude (Fig. 4e), indi-
cating a closer association and more congruent subjective and
dynamic pupillary effects of MDMA, also demonstrated by a
very strong correlation between the means of these two effects
over time (Rs00.96, p<0.001, n010; Fig. 4e). There were
similar strong associations between MDMA-induced reduc-
tions in constriction amplitude and changes in MAP, heart
rate, and body temperature (Rs00.98, 0.92, 0.87; all p<0.001,
n010). Between-subjects correlations further showed that
subjective effects were strongly correlated with reductions in
the light reflex but not with pupil size (Table 2). MDMA-
induced increases in blood pressure and heart rate did not
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Fig. 4 Pharmacokinetic–pharmacodynamic relationship. MDMA
effects plotted against the plasma concentrations of MDMA (a–c).
The values are expressed as the means of 80 subjects, with SEM
omitted for clarity. The times of pupillometry and blood sampling are
noted next to each point in minutes or hours after MDMA administra-
tion. While pupil size (a) remained high, constriction amplitude (b) and
subjective effect (c) returned to baseline within 6 h when MDMA
concentrations remained high. This clockwise hysteresis was moderate
for the mydriatic effect of MDMA, reflecting well the plasma concen-
tration of MDMA (a), but pronounced for the impairment in the
pupillary reflex response (b) and subjective effect of MDMA (c). The
subjective effect of MDMA returned to baseline faster than the myd-
riatic response to MDMA (d). In contrast, the time course of the
subjective effect of MDMA was more congruent with the time course
of the MDMA-induced impairment in constriction amplitude (e)
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correlate with the plasma concentrations ofMDMAover time,
consistent with the reduced effect over time despite high
plasma concentrations of MDMA (Fig. 3d, e).
The findings from the between-subjects analyses of the
correlations between the plasma levels of MDMA and phar-
macodynamic effects of MDMA for each time point (n080)
are shown in Table 3. The MDMA-induced reductions in the
constriction amplitude, the pupil size after light, the increase in
MAP, and the subjective effects were significantly and strongly
associated with the plasma levels of MDMA (Table 3).Weaker
correlations were also found between plasma levels of MDMA
and the pupil diameter, latency, or heart rate (Table 3). How-
ever, these associations were only observed at the beginning of
the MDMA effect. Recovery time and body temperature after
MDMA administration were not or only weakly and inconsis-
tently associated with plasma MDMA levels (Table 3).
The MDMA-induced reduction in pupil constriction am-
plitude was significantly greater in subjects with greater
MDMA-induced increases in MAP (Rs00.56, p<0.001,
n080) or more pronounced increases in heart rate (Rs00.30,
p<0.01, n080) as measured 1 h after MDMA administration.
In contrast, MDMA-induced changes in the pupil size were
not or only poorly associated with other autonomic changes
across subjects.
Pupillary effects of reboxetine, duloxetine, clonidine,
carvedilol, and doxazosin alone and on the pupillary
response to MDMA
The peak effects of the pretreatments are shown in Table 4.
The drug effects on pupil size over time for all five studies
are shown in Fig. 5. Both reboxetine and duloxetine in-
creased resting pupil size and pupil size after the light
stimulus. Duloxetine also lowered the constriction ampli-
tude (Table 4). The effect of the two monoamine uptake
inhibitors on the static pupil diameter was similar in mag-
nitude to the effect of MDMA (Table 4; Fig. 5a, b). In
contrast, the effect of MDMA on the constriction amplitude
was more pronounced. When duloxetine was administered
together with MDMA, the drug effects on all static and
dynamic parameters were nonadditive and showed negative
synergism, reflected by a significant pretreatment ×MDMA
interaction in the factorial ANOVA. Thus, duloxetine pre-
vented the effect of MDMA on pupil function, reflected by
the absence of a mydriatic effect of MDMA compared with
baseline in the duloxetine–MDMA condition and compared
with the duloxetine–placebo condition (Fig. 5b). Duloxetine
also prevented the MDMA-induced impairment in the pu-
pillary light reflex, although it had a similar effect when
Table 2 Correlations between MDMA-induced changes in pupillary function and subjective drug effects
t00 t020 min t040 min t01 h t01.5 h t02 h t02.5 h t03 h t04 h t06 h
Pupil size (mm) NS NS 0.31 0.27 NS NS NS NS NS NS
Pupil size after light (mm) NS NS 0.62 0.51 0.42 0.26 0.27 NS NS NS
Constriction amplitude (mm) NS NS −0.74 −0.61 −0.41 −0.28 −0.28 −0.28 −0.23 NS
Latency (s) NS NS 0.46 0.29 NS NS NS NS NS NS
Recovery time (s) NS NS −0.42 −0.31 −0.32 −0.22 −0.38 −0.23 −0.28 −0.32
Values are Spearman correlation coefficients for significant correlations (p<0.05; p<0.001 in italics); n080
NS not significant
Table 3 Correlations between the effects of MDMA and plasma concentrations of MDMA
t00 t020 min t040 min t01 h t01.5 h t02 h t02.5 h t03 h t04 h t06 h
Pupil size (mm) NS 0.46 0.45 0.35 0.27 NS NS NS NS NS
Pupil size after light (mm) NS 0.50 0.64 0.57 0.54 0.53 0.49 0.47 0.34 NS
Constriction amplitude (mm) NS −0.28 −0.40 −0.55 −0.53 −0.60 −0.55 −0.65 −0.48 −0.28
Latency (s) NS 0.23 0.46 0.33 0.35 NS 0.25 0.25 NS 0.25
Recovery time (s) NS NS −0.32 NS −0.26 NS −0.37 −0.26 −0.26 NS
Subjective drug effect NS NS 0.68 0.56 0.37 0.31 0.44 0.34 0.46 0.31
Mean arterial pressure (mmHg) NS 0.22 0.69 0.60 0.47 0.35 0.33 0.29 0.39 NS
Heart rate (bpm) NS NS 0.61 0.47 0.46 0.32 NS NS NS NS
Body temperature (°C) NS −0.24 NS NS NS NS NS NS NS NS
Values are Spearman correlation coefficients for significant correlations (p<0.05; p<0.001 in italics) between MDMA-induced pharmacodynamic
changes and plasma levels of MDMA; n080
NS not significant
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administered alone compared with placebo. The effects
of reboxetine and MDMA on pupil size were also
nonadditive (Table 4; Fig. 5b). However, resting pupil
size and pupil size after the light stimulus were signif-
icantly larger after reboxetine plus MDMA compared
with MDMA alone. Reboxetine also failed to prevent
the effect of MDMA on the pupillary light reflex. In the
present study, reboxetine also reduced the cardiostimu-
lant and psychostimulant effects of MDMA (Hysek et
al. 2011), and duloxetine nearly completely prevented
the cardiovascular, psychotropic, and neuroendocrine
effects of MDMA as reported elsewhere (Hysek et al.
2012b, d; Simmler et al. 2011). Clonidine reduced rest-
ing pupil size and size after the light stimulus (Table 4;
Fig. 5c). This effect of clonidine was antagonistic and
overall additive with the effect of MDMA (Fig. 5c).
Specifically, clonidine did not significantly reduce the
effects of MDMA on any parameter of pupillary func-
tion, although it had significant effects alone and re-
duced the cardiovascular response to MDMA (Hysek et
al. 2012a). Clonidine did not significantly reduce the
mydriatic effects of MDMA, although it produced sig-
nificant miosis. Clonidine also had no effects on the
psychotropic response to MDMA as previously reported
(Hysek et al. 2012a). Carvedilol did not alter the effects
of MDMA on pupillary function. In contrast, carvedilol
decreased the cardiostimulant and thermogenic effects of
MDMA in the same subjects as reported elsewhere
(Hysek et al. 2012c). Carvedilol alone decreased pupil
size, reflected by a significant main effect of pretreat-
ment in the ANOVA, but the reduction in pupil size
after carvedilol–placebo treatment compared with the
placebo–placebo condition (Fig. 5d) was not significant
in the post hoc test. Doxazosin alone had no effect on
Reboxetine-MDMA
5
6
7
8
9
pre 0 1 2 3 4 5 6
Time (h)
Pu
pi
l s
ize
 
(m
m
)
Duloxetine-MDMA
5
6
7
8
9
pre 0 1 2 3 4 5 6
Time (h)
Pu
pi
l s
ize
 
(m
m
)
Clonidine-MDMA
5
6
7
8
9
pre 0 1 2 3 4 5 6
Time (h)
Pu
pi
l s
ize
 
(m
m
)
Carvedilol-MDMA
5
6
7
8
9
pre 0 1 2 3 4 5 6
Time (h)
Pu
pi
l s
ize
 
(m
m
)
Doxazosin-MDMA
5
6
7
8
9
pre 0 1 2 3 4 5 6
Time (h)
Pu
pi
l s
ize
 
(m
m
)
BA
DC
E
Pretreatment-MDMA
Placebo-MDMA
Pretreatment-placebo
Placebo-placebo
Fig. 5 Drug effects on pupil
size over time.MDMA increased
pupil size compared with
placebo (a–e). The pretreatment
with reboxetine increased pupil
size to a similar extent as
MDMA alone (a). The effect of
MDMA on pupil diameter after
reboxetine pretreatment
compared with reboxetine was
significantly smaller than the
effect of MDMA compared with
placebo (a). Duloxetine
increased pupil size similar to
reboxetine and MDMA (b).
Duloxetine pretreatment
prevented the further increase in
pupil size induced by MDMA
administration (b). Clonidine
significantly reduced pupil
diameter (c). The effects of
clonidine and MDMA on pupil
size were additive (c). Carvedilol
nonsignificantly decreased pupil
size (d). Similar to the effects of
clonidine and MDMA, the
effects of carvedilol and MDMA
on pupil size were additive (d).
Doxazosin alone had no effect on
pupil size compared with
placebo, but it tended to
nonsignificantly attenuate the
mydriatic effect of MDMA (e).
The data are expressed as the
mean ± SEM values in 16
subjects per study
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pupil size compared with placebo but slightly and non-
significantly reduced the MDMA-induced increase in
pupil size (Fig. 5e).
Discussion
In the present study, we showed that MDMA impaired the
pupillary reflex response to light, including inducing a lon-
ger latency, reducing the constriction amplitude, and reduc-
ing the recovery time. MDMA produced mydriasis as
previously documented using nonautomated techniques
(Farre et al. 2004, 2007; Kolbrich et al. 2008; Mas et al.
1999). MDMA also increased blood pressure, heart rate, and
body temperature and produced positive mood effects as
described in more detail elsewhere (Hysek et al. 2011,
2012a, b, d).
The analyses of the effects of MDMA over time showed
a very strong correlation between the MDMA-induced re-
duction in constriction amplitude and other autonomic or
subjective effects of the drug. The MDMA-induced reduc-
tion in the pupillary light reflex normalized over 6 h, similar
to the cardiostimulant and subjective drug effects that also
largely disappeared over 6 h, although the plasma levels of
MDMA remained high. Thus, the reduced reactivity of the
pupil to light is relatively short-lasting and subject to acute
pharmacological tolerance, similar to the subjective and
cardiostimulant effects of MDMA.
Clinical examination of pupil function in cases of drug
intoxication typically includes both an estimation of static
pupil size and an assessment of the reactivity to a flashlight
stimulus. With regard to MDMA intoxication, our findings
suggest that the impaired reactivity to light indicates
MDMA exposure within the past 1–4 h and is a marker
for the acute subjective and autonomic effects of the drug. In
contrast, mydriasis lasts at least 6–10 h (Farre et al. 2007;
Mas et al. 1999), correlates best with the plasma MDMA
concentration changes over time, and shows only moderate
pharmacological tolerance. The mydriatic responses to two
successive doses of MDMA separated by 24 h were similar,
although the peak concentration after the second dose of
MDMA increased by 29 %, indicating some degree of
tolerance (Farre et al. 2004). Although the mean group
changes in pupil size over time reflected the concentra-
tion–time curve of MDMA, pupil size did not correlate well
with the plasma concentrations of MDMA across subjects at
various time points in our study or with MDMA plasma
levels 1.25 h after drug administration in a previous study
(Kolbrich et al. 2008). This is not surprising because the
effects of MDMA on pupil size were maximal at single
doses of 75 mg and did not further increase at 125 mg
(Mas et al. 1999). Thus, the lack of an association is likely
attributable to a ceiling effect of the plasma MDMA
concentration–effect curve. In contrast, dynamic impair-
ments of the pupil light reflex response were significantly
associated with plasma MDMA levels or the cardiostimulant
effects of MDMA across subjects. Evaluating the dynamic
pupillary response to light may, therefore, be a better esti-
mation of the time and amount of exposure to MDMA than
static pupil size.
Both sympathetic and parasympathetic innervations con-
tribute to the regulation of pupil size and the reflex response
(Loewenfeld 1999). At the level of the iris, the latency to
and amplitude of the reflex response are mainly determined
by parasympathetic activity (Heller et al. 1990), whereas
redilation is controlled by sympathetic inputs (Loewenfeld
1999; Morley et al. 1991). Additionally, parasympathetic
function is under tonic noradrenergic inhibition centrally at
the level of the Edinger–Westphal nucleus where the sym-
pathetic stimulation of α2-adrenergic receptors may lower
parasympathetic output, resulting in “pseudoanticholiner-
gic” mydriasis (Phillips et al. 2000a; Siepmann et al. 2007;
Szabadi and Bradshaw 1996). Furthermore, the serotonin
system is implicated in pupillary function, possibly via 5-
HT1A-mediated stimulation of the release of norepinephrine
and consequent activation of α2-adrenergic receptors (Prow
et al. 1996). MDMA mainly releases serotonin and norepi-
nephrine (Liechti and Vollenweider 2001; Rothman et al.
2001; Verrico et al. 2007). Because MDMA affected both
the parasympathetic and sympathetic aspects of the pupil-
lary reflex response, all of the aforementioned mechanisms
may be involved in the effects of MDMA on pupillary
function.
The norepinephrine transporter inhibitor reboxetine sig-
nificantly increased pupil diameter at rest and after light,
consistent with previous studies (Theofilopoulos et al.
1995). Reboxetine did not reduce the mydriatic response
to MDMA, but the effects of the two drugs on pupil size
were subadditive, indicating that MDMA produces part of
its effects on pupil size through the transporter-mediated
release of norepinephrine, which is inhibited by reboxetine
(Hysek et al. 2011). This finding is consistent with the
attenuation of the cardiostimulant and psychostimulant
effects of MDMA by reboxetine (Hysek et al. 2011) and
supports the view that norepinephrine is involved in the
stimulant effects of MDMA.
The α1-adrenergic receptor inhibitor doxazosin did not
affect pupillary function when administered alone but non-
significantly reduced the mydriatic response to MDMA.
Prazosin did not antagonize mydriasis induced by norepi-
nephrine or phenylephrine in anesthetized cats (Hey et al.
1988; Koss et al. 1988). The data suggest that α1-adrenergic
receptors in the iris may only minimally contribute to my-
driasis induced by systemically administered sympathomi-
metic drugs and that central parasympathetic inhibition may
be more relevant.
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The α1β-adrenergic receptor inhibitor carvedilol had no
significant effect on pupil size compared to placebo, consis-
tent with earlier work (Hirohashi et al. 1990) and the ab-
sence of effects of the β-adrenergic receptor blocker
propranolol on pupillary function (Koudas et al. 2009).
Carvedilol did not affect the mydriatic response to MDMA,
but it reduced other autonomic effects of MDMA, including
increases in blood pressure and body temperature (Hysek et
al. 2012c).
Clonidine decreased pupil diameter and enhanced the pu-
pillary reflex, consistent with its known sympatholytic effects
(Clifford et al. 1982; Morley et al. 1991; Phillips et al. 2000b,
c). Clonidine also lowered the plasma concentrations of nor-
epinephrine and blood pressure in the subjects of the present
study (Hysek et al. 2012a). The effect of clonidine on pupil
function is thought to involve the stimulation of α2-adrenergic
receptors on central noradrenergic neurons, leading to de-
creased sympathetic outflow to the iris. The enhancement of
the parasympathetic light reflex is consistent with clonidine-
induced disinhibition of the noradrenergic central control of
parasympathetic outflow (Phillips et al. 2000b). Despite its
significant sympathicolytic effects (Hysek et al. 2012a), clo-
nidine failed to significantly reduce the effects of MDMA on
pupillary function. Moreover, clonidine did not reduce the
MDMA-induced increase in norepinephrine or blood pressure
to the same extent as it reduced these parameters when admin-
istered alone (Hysek et al. 2012a). Thus, the sympatholytic
effects of clonidine and sympathomimetic effects of MDMA
were antagonistic in an additive manner, without evidence of
interactive effects of the two drugs. The findings indicate that
α2-adrenergic receptors and the vesicular release of norepi-
nephrine are not critically involved in the pharmacological
effects of MDMA.
The dual serotonin and norepinephrine transporter inhib-
itor duloxetine increased resting pupil diameter, prolonged
the latency to the light reflex, and reduced the reaction to
light. Identical effects on pupillary function have been
reported for the serotonin and norepinephrine transporter
inhibitor venlafaxine (Bitsios et al. 1999; Siepmann et al.
2007). Serotonin releasers, including fenfluramine (Kramer
et al. 1973), meta-chlorophenylpiperazine (Benjamin et al.
1997), and MDMA, and serotonin transporter inhibitors
(Nielsen et al. 2010; Noehr-Jensen et al. 2009; Schmitt et
al. 2002) also cause mydriasis. Citalopram and paroxetine
have also been shown to reduce the constriction amplitude
(Nielsen et al. 2010; Noehr-Jensen et al. 2009), similar to
previous observations with duloxetine. Duloxetine may,
therefore, exert its effects on pupillary function via both
noradrenergic and serotonergic mechanisms. Although both
duloxetine and MDMA produced mydriasis, pupil size did
not further increase after the administration of both drugs,
suggesting interactive effects of the two drugs. Moreover,
duloxetine almost completely prevented the effects of
MDMA on the light reflex. Duloxetine also markedly
inhibited the cardiostimulant, psychotropic, and neuroendo-
crine responses to MDMA in the same subjects (Hysek et al.
2012b, d; Simmler et al. 2011). Selective serotonin trans-
porter inhibitors including citalopram, fluoxetine, and
paroxetine have previously been shown to attenuate the
physiological and psychological effects of MDMA in
humans (Farre et al. 2007; Liechti et al. 2000; Liechti and
Vollenweider 2000; Tancer and Johanson 2007). Notably,
paroxetine also prevented the mydriatic effects of MDMA
(Farre et al. 2007). Together with the interactive effects of
duloxetine and MDMA in the present work, the findings
provide strong support for a role of serotonin in the mech-
anism of action of MDMA. The reduction of the effects of
MDMA on the pupil light reflex by duloxetine but not
reboxetine supports a central modulatory role of serotonin
in the effects of MDMA on pupillary function, possibly
involving central serotonergic potentiation of noradrenergic
outflow (Prow et al. 1996).
In the present study, we assessed pupillary function under
dark–light conditions, similar to other studies of the autonom-
ic effects of pharmaceuticals (Bitsios et al. 1999; Nielsen et al.
2010; Noehr-Jensen et al. 2009; Phillips et al. 2000c). The
values of the latency to the light reflex and constriction am-
plitude obtained in the present study were similar to those
measured under daylight conditions with the same pupillom-
eter (Taylor et al. 2003), indicating that these parameters may
not be critically affected by the light conditions. Overall, our
data indicate that the constriction of the pupil represents a
measure that is sensitive to pharmacological interventions and
may be relatively insensitive to changes in light conditions
compared with measures of pupil size.
In summary, MDMA increased pupil size and reduced
the response to light. The MDMA-induced prolongation of
the latency to the light reflex and reduction in light-induced
miosis indicate indirect central parasympathetic inhibition.
The faster recovery reflects increased direct sympathomi-
metic action. Both reboxetine and duloxetine interacted with
the effects of MDMA on static and dynamic measures of
pupillary function, supporting a role for both norepinephrine
and serotonin in the effects of MDMA on pupillary function.
MDMA-induced mydriasis was associated with the plasma
concentration–time curve of MDMA. The reduced miotic
response to light was highly correlated with the cardiosti-
mulant and subjective effects of MDMA and demonstrated
acute pharmacological tolerance.
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In this project we demonstrated a crucial role for NE in the mechanism of action of 
MDMA in humans. The study findings are reported and discussed in detail in the published 
papers presented above. This is a brief discussion of the overall work. 
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Clinical data indicates that 5-HT plays a major role in the mediation of the acute 
emotional effects of MDMA in humans.12,68,69 Pretreatment with citalopram attenuated most 
of the subjective effects induced by MDMA, including positive mood, derealization, and 
thought disorder.68  In this project we now describe that also the inhibition of the NE 
transporter leads to a reduction of a substantial range of MDMA-induced effects in healthy 
subjects.99,100 The selective NE transporter blocker reboxetine reduced MDMA-induced 
subjective effects such as drug high, stimulation, emotional excitation, and anxiety.  Similarly, 
the inhibition of the NE transported also reduced the psychostimulant response to 
D-amphetamine.92 These findings are consistent with a role of the NE transporter in the 
mediation of the sympathomimetic stimulant-like aspects of the MDMA effect and are in line 
with the preclinical data of the strong NE releasing potency of MDMA.60,78,100  The dual 5-HT 
and NE transporter blocker duloxetine robustly and almost completely prevented the 
emotional effects produced by MDMA.100  The blocking effect of duloxetine on the response 
to MDMA was more pronounced than that of a selective 5-HT or NE inhibitor supporting to 
conclusion that both 5-HT and NE contribute to the acute effects of MDMA in humans.  
This project also describes that subjective effects induced by MDMA are mainly 
mediated via a release of the monoamines through the presynaptic transporter site. The !2 
agonist clonidine, which inhibits the vesicular release of NE, did not affect the acute response 
to MDMA in humans.101 Taken together, the pronounced effects of duloxetine as well as the 
effects of citalopram or reboxetine implicate that monoamine transporters are the primary 
targets of MDMA and physiological impulse-dependent vesicular release of monoamines 
does not seem to play a critical role for the psychotropic effects of MDMA in humans. 
Finally, the !1 adrenergic receptor might be one of the post-synaptic adrenergic 
receptors, which is critically involved in psychotropic effects produced by MDMA. We 
selectively inhibited the !1 adrenergic receptor with doxazosin and attenuated the heightened 
mood effects produced by MDMA. Similarly, doxazosin has been shown to reduce subjective 
liking of the acute effects of cocaine.102 These findings indicate a possible role for the !1 
adrenergic receptors in the mediation of the mood-enhancing and stimulating effects of 
psychostimulants and of MDMA in humans.  
 %&'()''&*+#
!"@#
-./0#.1#2.304520463520#52#760#:A3;5.BA8:</A3#0110:78#43.;<:0;#=9#>%>?#
NE also plays a substantial role in the mediation of the MDMA-induced somatic effects. 
MDMA highly affects markers for sympathetic system activation, such as increased blood 
pressure, heart rate, and peripheral NE plasma levels.99,101,103 We demonstrated that a 
pretreatment with reboxetine significantly reduced the MDMA-induced increases in NE 
circulating plasma levels, blood pressure and heart rate99 and confirmed hereby that the 
transporter-mediated release of NE plays a crucial role in the cardiovascular response to 
MDMA. A pretreatment with the post-synaptic ! adrenergic receptor antagonist pindolol 
reduced the heart rate response to MDMA but lead to an enhanced blood pressure reaction.104 
Opposite to the effects of pindolol on the cardiostimulant effects of MDMA, the post-synaptic 
!1 adrenergic receptor blocker doxazosin lowered hypertension but enhanced the heart rate 
response to MDMA. Finally, the combined !1 and ! adrenergic receptor blocker carvedilol 
prevented both the heart rate and the blood pressure responses to MDMA.105 Together our 
findings confirm a central role for ! adrenergic receptors in the regulation of stimulant-
induced tachycardia and for !1 adrenergic receptors in the regulation of stimulant-associated 
hypertension.  
The dual inhibition of both the 5-HT and the NE transporter produced an almost 
complete reduction of the cardiovascular effects produced by MDMA.103 Thus, in addition to 
NE, 5-HT release may also contribute to the cardiostimulant effects of MDMA possibly 
through activation of 5-HT2 receptors.  
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We showed that !1 adrenergic inhibition with doxazosin partly attenuated the MDMA-
induced increase in body temperature. Additionally, we found that carvedilol, a combined !1 
and !1,2,3 adrenergic receptor blocker, significantly reduced the hyperthermic response to 
MDMA in humans.105 These findings are consistent with the preclinical which indicate that 
the MDMA-induced increase in body temperature involves !1 adrenergic receptor-mediated 
peripheral cutaneous vasoconstriction with impaired heat dissipation106 and !3 adrenergic 
receptors-mediated heat generation by mitochondrial uncoupling.106,107 and Interestingly, 
reboxetine and duloxetine only tended to reduce the MDMA-induced increase in body 
temperature.99,100  Thus, a post-synaptic receptor inhibition appears to be more effective than 
the inhibition of the transporter-mediated monoamine release.  
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We showed that MDMA increased plasma levels of copeptin, a marker for arginine 
vasopressin (AVP) secretion, in women but not in men.108 This sex-difference in MDMA-
induced AVP secretion may explain why hyponatremia is typically reported in female ecstasy 
users.28 29 The copeptin response to MDMA is likely mediated via MDMA-induced release of 
5-HT and/or NE because it was prevented by duloxetine.108  
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There is evidence that MDMA leads to alterations in the processing of socioemotional 
information.109 We illustrated that MDMA enhanced the capacity to read positive emotional 
cues and impaired to capacity to identify negative emotions from the eye region.110 MDMA 
also produced strong subjective pro-social effects, including feelings of being more open, 
talkative, and closer to others. In addition, MDMA increased in plasma levels of oxytocin, a 
neuro-peptide, which is thought to mediate interpersonal bonding and to increase 
empathy.111,112 Conclusively, the shift in the ability to correctly read socio-emotional 
information, together with the pro-social feelings produced by MDMA, may enhance social 
approach behavior and sociability when MDMA is used recreationally and facilitate 
therapeutic relationships in MDMA-assisted therapy.  
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MDMA increased the pupil size consistent with its sympathomimetic properties. We 
found that the MDMA-induced increase in pupil size was lasting and reflected the plasma 
concentration-time curve of MDMA. In contrast, we observed that the impairment in the 
reaction to a light reflex was associated with the subjective and other autonomic effects 
produced by MDMA and exhibited acute tolerance. These findings will aid in the clinical 
assessment of pupillary changes associated with intoxications with MDMA.  
(.2:/<85.2#H#*<7/..I#
Our findings extend the understanding of the mechanism of action of MDMA in 
humans. We conclude that NE is primarily involved in the mediation of the acute 
psychostimulant and cardiostimulant aspects of the effects of MDMA in humans. The acute 
effects evoked by MDMA seem mainly to be mediated via the presynaptic uptake transporters 
and not by an impulse-dependent vesicular release of monoamines.  
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Our findings suggest that NE and 5-HT transporter inhibitors and !1-adrenergic receptor 
antagonists could be useful in the treatment of stimulant dependence. In cases of 
sympathomimetic toxicity associated with psychostimulants, combined ! and ! adrenergic 
receptor blockers should be used, whereas selective !1 or ! blockers should be withheld due 
to the risk of enhanced tachycardia or hypertension, respectively.  
There are still various research questions to address about the mechanism of action of 
MDMA. In addition, to the 5-HT and NE transporter, MDMA also binds to the DA 
transporter where it inhibits the uptake and releases DA from the presynaptic cell.60,61 DA has 
been well documented to mediate drug reinforcement and the addictive properties of drugs of 
abuse but its role in psychostimulant-induced acute emotional effects in humans is still 
unclear. An interesting target of investigation is the DA transporter which is currently being 
tested in a similar design as used in the present studies. Further, there is evidence that the 
genetic background may affect the response to MDMA and other psychostimulants.113 The 
role of the genes will also be explored in the present study sample once additional studies 
have been completed and on the basis of a sufficiently large pooled data sample allowing for 
pharmacogenetic analyses. Sexual hormones such as testosterone or progesterone have shown 
to play a role in the mediation of emotions114 or trust.115 However, to which extend these 
hormones play a role in the emotional effects including those induced by MDMA is still 
unclear. Additionally there are also clinical studies underway investigating the effect of 
MDMA in the treatment of psychiatric disorders such as PTSD or end-stage cancer 
(clinicaltrials.gov identifier: NCT01211405, NCT00252174).  
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